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A b s t r a c t
HIV Proteinase (HIV PR) has proved to be an excellent target for the 
development of anti-AIDS drugs. Four inhibitors of this enzyme are now approved for 
clinical use but they, like others, suffer from shortcomings associated with their size and 
the fact they are peptides. In this thesis the development of small non-peptidic cyclic 
compounds is described. They were designed to inhibit HIV PR principally by targeting its 
unique structural features rather than by mimicking its natural substrates.
The designed compounds all contained the borinic acid functional group which 
it was anticipated would interact with the two critical aspartic acid residues of HIV PR. A 
heteroatom incorporated into these compounds was positioned in such a way that a water 
molecule which plays a pivotal role in the binding of the enzyme's substrates was 
displaced. Finally, two benzyl groups were incorporated; these were designed to mimic 
the side-chains of phenylalanine and tyrosine frequently found in the substrates of HIV PR.
The borinic acid functional group has not previously been incorporated into 
HIV PR inhibitors. Therefore, an analogous series of five 2,6-dibenzylated-4- 
heterocyclohexanols, where the borinic acid group had been replaced by a hydroxyl group, 
were prepared and evaluated against the enzyme. These were prepared through bis aldol 
condensations followed by reduction of the carbonyl group in the èwenones that resulted 
from dehydration. Although low solubility prevented the analysis of three of these 
compounds and thereby their effectiveness, two of them were found to be moderately 
active. Having validated the design of the heterocyclic template, attempts were then made 
to synthesise borinic acid-containing analogues of these 4-heterocyclohexanols.
The attempted syntheses of a directly comparable series of compounds, through 
application of both èwmetallation and ^whydroboration strategies, was unsuccessful. 
Instead, two acyclic diphenyl borinic acids were synthesised. Additionally, several related 
cyclic borinic acids and acyclic borinic and boronic acids consistent with the design strategy 
were prepared, from diphenyl sulfone, 2-bromodiphenyl ether and 2-bromodiphenyl 
sulfide, through the appropriate lithiated species formed by either lithium-hydrogen or 
lithium-halogen exchange. During the attempted syntheses of a cyclic borinic acid by 
selective oxidative cleavage of an organoborane derived from diphenyl sulfone, two highly 
novel borane-amine adducts were synthesised.
None of the boron-containing compounds assayed against HIV PR were found 
to be inhibitors of the enzyme. This is thought to be as a result of the phenyl groups being 
directly attached to the boron atom, rather than being present in benzyl substituents as had 
been originally planned.
m
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C h a p t e r  o n e  
I n t r o d u c t io n
Introduction
1.1  The Realities of AIDS Today
The human immunodeficiency virus (HIV) that has been shown to cause 
AIDS,h2 is one of the principal threats to human life and well being today. The Global 
AIDS Policy Coalition estimated that the number of people infected worldwide at the end of 
1987 was around 7 million.^ Ten years later, estimates suggest that 25 million people are 
infected with the virus and that 6 million people have died from AIDS-related diseases A 
The number of cases of HIV infection expected to have occurred by the year 2000 range 
from 40-110 million. ^
It is now 16 years since AIDS sprang into medical and public awareness as a 
fatal disease of the immune system. -^® HIV is the most intensively studied virus in history. 
Despite this, many aspects of HIV infection and its pathogenesis remain unclear. Whilst 
treatments exist to control HIV in the body (these will be discussed through this chapter), 
there is no cure. It is true that there are other alarming diseases; 40% of the world's 
population are exposed to malaria and 2 million people die from it each year."^  However, 
the rapid spread of HIV and lack of any vaccine to prevent AIDS make it particularly 
alarming. Although therapies will help to control the pandemic, HIV resistance to these 
treatments continues to increase and has been extensively examined.8.9 Also, it is 
important to emphasise in this context that 90% of people with HIV infection live in 
societies without the financial resources to afford such treatments.lo The unprecedented 
effort in the search for a cure will therefore continue.
1 .2  General Introduction to HIV
After the identification of HIV as the primary aetiological agent for A I D S , h 2  
remarkable progress has been made in elucidating many of the aspects of the biological 
structure of HIV. It is a member of a large group of viruses known as the retroviridae or
retroviruses^ ^  Retroviruses {retro and virus, respectively, are Latin for "backwards" and 
"poison") are defined as viruses with RNA genomes, the replication of which takes place 
by a DNA intermediate. Within this family HIV is classed as a lentivirus {lentus is Latin 
for "slow"); infection is followed by a subclinical latent phase which can last for several 
years. Such a delay in the pathogenesis enables HIV to survive in nature; as the major 
modes of transmission of HIV are either vertical or by intimate contact, it is paramount that 
it should not kill its host before it replicates otherwise it will not survive.
Two genetically distinct but related HIV strains have been identified. The first, 
HIV-1,h2 is highly virulent and is primarily responsible for the pandemic throughout 
Europe, the USA, Africa, India and Asia. The second strain, HIV-2 , v i r t u a l l y  
confined to regions of West Africa and is less pathogenic than HIV-l.^^ Within these two 
strains, however, there are many different subtypes. For example, ten discrete strains 
constitute the group M (major) of HIV-1 viruses. The base sequences that comprise their 
genomes vary by 21-31% but each strain is know to contain a plethora of variants, whose 
genomes' base sequences vary by an average of 11%. 15 Whilst the organisations of the 
genomes of HIV-1 and HIV-2 are very similar, they differ by more than 55% in their 
primary nucleotide s e q u e n c e s . I n  fact, HIV-2 is more closely related to simian 
immunodeficiency virus (SIV), which infects African monkeys with no pathological 
consequences, than it is to H I V - 1 . A s  HIV-1 is the pathogen of greater consequence, 
the remainder of this discussion will focus on this strain.
1.2 .1  Description of an HIV-1 Virion
Electron microscopy reveals HIV-1 (Fig. 1.1) to be a roughly spherical particle 
with a diameter of 110 nm.548 Its surface is covered in a lipid bilayer similar to and taken 
from the membranes surrounding human cells. Protruding from this layer are 72 spikes. 
These spikes are composed of multimers (probably containing four each) of two viral 
glycoproteins: surface protein (SU) gp l20 and transmembrane protein (TM) gp41. 
Noncovalently linked to gp41, gpl20 is displayed at the surface of the virus where it
recognises cells which display an appropriate receptor. [Genetic nomenclature used in this 
text is according to Leis et al. (for example the denotation of surface protein gpl20 as 
SU)].19
Beneath the lipid bilayer is a sphere of matrix protein (MA) p i7. Beneath MA 
is a bullet-shaped core enclosed by a further layer of protein, the capsid (CA) p24. It 
measures 100 nm by 50 nm tapering to 40 nm.
G P41
QP120
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P 2 4  CAPSID
Figure 1.1: A Single Virion of HIV-1 (reproduced from Scientific American^ with the 
kind permission of the artist, Mr Kirk Moldojf)
Contained within CA are the components required for replicating HIV,20 as follows:
• two identical strands of the RNA genome (see section 1.2.2). This consists of 
9,800 nucleotides which code for the entire structure and replication processes 
of HIV. Associated with the RNA are two further proteins, the nucleocapsid 
(NC) proteins p9 and p6,
• two cellular transfer RNAs captured during the budding process (see section 
1.3.2.2)
• three virally encoded enzymes called reverse transcriptase (RT), integrase (IN) 
and proteinase (PR). The roles of these will be discussed later (section 1.3.2)
1 . 2 .2  The Genome of HIV-1
tev’"■0.
Ivpu
rev
tatvpr
env LTR
LTR net
pol
Figure 1.2; The HIV-l Genome^^
Despite its relatively small size (it is 100,000 times smaller than the human 
genome), sequencing of the HIV-1 genome revealed it to be astonishingly complex. It 
exhibits the same basic organisation as all retroviruses (5'-LTR-gag-poZ-mv-LTR-3'),^^ 
but additionally carries ORFs for several regulatory proteins. As can be seen from Fig. 1.2 
several of these genes overlap. This means that not all the proteins are encoded in the same 
ORF. However, all the viral proteins found in the intact virus described earlier are derived 
from just three genes ( o v e r le a f ) ; 2 0 » 2 i ,2 3 ,2 4
gag • this encodes the structural proteins MA, CA and NC
pol * this encodes the viral enzymes required for replication: PR, RT and IN
env • this encodes the glycoproteins SU and TM
The remaining genes encode the regulatory p r o t e i n s . ^0,21 ,23-25  Two of these, 
tat (transactivator) and rev (regulator of virion expression) play essential roles in the 
replication cycle of HIV.3.25 ypy  (viral protein R), vpu (viral protein U), vif (viral 
infectivity factor) and so-called nef (negative factor) are frequently referred to as non- 
essential or accessory proteins. This is because early studies,25 suggested that these genes 
were dispensable for virus growth in vitro although important in vivo functions may remain 
to be elucidated. The remaining tev gene encodes a protein that appears to have both tat and 
rev activities, although its actual regulatory role is u n k n o w n . A t  the termini of the 
genome are LTRs. Signals provided within the LTRs, which are unique to r e t r o v i r u s e s ,  
stimulate and sometimes regulate the activity of the cellular transcription system.^
1 .3  HIV Infection and Disease
The infection of humans with HIV is characterised by three phases. Within 
several weeks of infection there is an acute phase. This is typified by extensive viraemia 
and large numbers of CD4-bearing T cells in the blood (see section 1 .3 . 1 ) . 2 6  The onset of 
the immune response causes the amount of circulating virus to decline sharply, by a factor 
of 100 or more.^^ There then follows a clinically latent steady-state chronic phase when 
cells are infected (see section 1.3.2) and die in large numbers and at a high rate; during this 
time the total number of infected cells remains small but c o n s t a n t . 28 .29  This phase lasts for 
about 10 years after which the number of CD4 cells have greatly declined (from an initial 
concentration of 1000 to less than 100 per mm^).^ The symptoms of ADDS (the final stage 
of HIV infection) then appear, coincident with sharply increasing viraemia and numbers of 
infected cells in circulation. At this point the immune system has been so badly damaged 
that the infected patient is prone to opportunistic infections such as pneumonia
{Pneumocystis carinii);^ in the absence of an adequate defence mechanism, death usually 
results.
Many aspects of the progression of HIV-1 infection are extremely complex and 
poorly understood. The exact role that viral latency plays in HIV d i s e a s e , 2 6 , 2 8  the 
mechanisms by which HIV-1 infection actually causes cell death and other aspects of HIV 
infection and disease are not understood fully.303i However, much is known about the 
propagation of HIV-1 and this is discussed in section 1.3.2.
1 .3 .1  The Biological Targets of HIV-1
A major consequence of HIV-1 infection is the selective depletion of CD4- 
bearing T-lymphocytes (T4 cells),^*32 the white blood cells that play a central role in 
regulating the immune system (CD4 is a 55 kD glycoprotein). Different cell types that 
display CD4 have also been shown to be in f e c t e d .^ ^  However, other cells that display 
either low numbers of CD4 or none at all have also been shown to become infected,24 
suggesting that a second component, thought to be the "chemokine" receptor,34 is required 
for binding events in the infection process. The mechanism of entry of HIV-1 is not clearly 
understood. It is a pH-independent process mediated by gp41,35 in which the virion enters 
the cell by either endocytosis or cell fusion,36 after initial recognition of (probably) CD4 by 
gpl20.
1 . 3 .2  The Replication Cycle of HIV
Once the virion is inside the host cell, the replication cycle may be divided into 
two sets of processes. The pre-integration phase, shown on the left of Fig. 1.3, consists 
of work performed almost exclusively by the enzymes contained within and encoded by the 
infecting virion. Collectively these processes result in the formation of the provirus, the 
term used to describe the virus once its two strands of DNA have been incorporated 
(integrated) into the chromosomes of the host. Thereafter, the enzymes and proteins of the
host cell perform the bulk of the work, shown on the right of Fig. 1.3. These processes 
comprise the post-integration phase.
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Figure 1.3: The Replication Cycle o f HIV-l
1.3 .2 .1  The Pre-Integration Phase
Once the virion has entered the cytoplasm of a susceptible cell, it is "uncoated" 
by proteolysis. There is evidence both f o r ,3 7 - 3 9  and a g a i n s t , the viral proteinase 
playing a role in this uncoating. The viral RNA is then transcribed to a DNA copy in a 
reaction catalysed by RT. RT is closely associated with the viral RNA nucleocapsid protein 
and is activated within 6 h of i n f e c t i o n . 4 2 .4 3  initiation of transcription requires a host cell 
transfer RNA molecule, captured during the budding process (see section 1. 3 .2.2 ) . 20 The 
role of RT is to synthesise a double stranded DNA genome which contains all the 
information originally held on the RNA genome. As part of a nucleoprotein complex 
comprising the MA, IN and perhaps other regulatory proteins, the proviral DNA is 
transported into the cell n u c l e u s . On c e  inside the nucleus, IN catalyses the insertion of 
the proviral genome into random regions of the host cell's chromatin. Because there is no
evidence to suggest that an integrated HIV provirus is ever excised from the host DNA, it is 
believed that infection is permanent from this point.
I . 3 . 2 . 2  The Post-Integration Phase
The post-integration phase occurs when the provirus is expressed. Both 
transcription and translation are subject to complex regulation by both host cell proteins and 
by viral proteins such as tat and rev.23,24 The initial task of the cell's replication apparatus 
is to transcribe RNA from the proviral DNA. This is done using cellular RNA polymerase
II. Some of the RNA formed serves as the genetic material for the assembly of new virions 
and some is translated into viral "precursor" polyproteins, as is typical in the translation of 
viral g e n o m e s .4 4  The actual viral proteins are synthesised during subsequent processing of 
these poly proteins. The significance of this delay shall be explained later.
The gag gene is translated to produce a polyprotein called Pr55g®g. Independent 
translation of the pol gene, however, is not known; its translation has only been observed 
in conjunction with gag, to form a fusion polyprotein called Prl60g^S"Po*.45 As gag and 
pol are in different ORFs, such a translation may occur only by way of a ribosomal 
frameshift (when translation moves to a different ORF) to the pol ORF. The gag stop 
codon is, therefore, not read and translation continues until the pol stop codon is 
encountered. This frameshift occurs infrequently (11% of the time) and ensures that the 
structural proteins coded by gag are synthesised in an 8:1 excess to the enzymes coded by 
polf^  The env gene is translated as an 88 kD polyprotein containing the proteins necessary 
for both gp41 and gpl20. The translation of the regulatory and accessory genes is complex 
and will not be discussed here.
The above polyproteins next undergo a series of post-translational 
modifications. The env-associated polyprotein is glycosylated before it is cleaved into 
gp41 and gpl20 by a cellular proteinase.46 These two glycoproteins are then transported to 
the cell membrane. Post-translational modification of both Pr55g®g and Prl60§^§-po  ^ is 
subtly regulated. The N-terminal amino acid, glycine, of both these polyproteins is the
same. This amino acid is recognised by a cellular acylase which adds a myristoyl 
(tetradecanoyl) unit to its amino group, an addition which directs both polyproteins to the
cell membrane.47.48
The penultimate stage of the replication cycle is the assembly of viral 
components into particles and their budding from the cell. It appears that this is a self- 
assembly process in which the lipophilic N-myristoylated Pr55s^g and PrlbOe^g-Po* are 
directed to and are anchored into the cytoplasmic side of the host cell m e m b r a n e .4 8  Strands 
of Pr55g^g then bind both viral RNA and cellular transfer RNA and a small portion of the 
cellular membrane evaginates to form an immature viral particle.
The immature progeny virus is not infectious at this point.49 Maturity and thus 
the ability to infect is conferred on the virus particle by the action of PR.49 However, PR 
is active only as a homodimer (discussed in detail below in sections 1.5.2 and 1.5.3).5^ 
Each strand of Prl60g®g‘P°^  only contains "half" a PR and must therefore associate with 
another for an active PR to be generated. Such association is achieved during the budding 
process when the polyproteins are forced together.^^-^^ Firstly, the anchoring of N- 
myristoylated Pr55g^g and Prl608^s-P°i to the membrane increases the local concentration 
of PR monomer (contained within P rl6 0 gag-poi). Secondly, as the linear membrane buds 
into a spherical particle, the concentrations of Pr55sag and Prl60g®g"Poi increase still 
further. At some point, two PR monomers contained within two separate strands of 
P r l 6 0 sag-poi are forced so close to one another that an active dimer is formed and PR 
catalyses its own release. This is thought to proceed in an m?ermolecular manner; two 
domains of PR fold and associate to form an active dimer which acts on a processing site at 
the PR region in a third strand of Prl60g^g‘P°^  (see section 1.5.3).^^ Once free the dimer 
performs the cascade of proteolytic cleavages discussed below, thereby effecting the 
maturation of the virion and the completion of the replication cycle. Maturation may be 
observed under an electron microscope: the doughnut-like centre of the immature virus is 
transformed to the diagnostic bullet shape of CA.48
It is not possible to overemphasise the critical nature and consequential timing 
of proteinase self-activation. Delay in the proteolysis of the viral polyproteins containing
the structural and enzymatic proteins ensures that they are all packaged into the budding 
virus particle. If PR was active before budding, proteolysis of Pr55g^g and Prl60g^g-P°  ^
would occur in the cytoplasm of the host cell. This would leave only the N-terminal 
protein (MA, Fig. 1.6) of both Pr55§^g and Prl60g^g-P°i with an attached myristoyl group. 
Only it would, therefore, concentrate at the cell membrane; the other proteins would have 
no driving force for doing so. The consequences of premature proteolysis have been 
demonstrated by K r a u s s l i c h , ^ ^  who transfected a gene encoding a tethered dimer of HIV-l 
PR into a provirus. Expression of the linked dimer (two copies of the PR region linked by 
a structurally flexible hinge region) as a component of Prl60g^g"P°* by in vitro translation 
causes rapid autocatalytic processing. This phenomenon had previously been reported by a 
second g r o u p . W h a t  Krausslich showed was that this premature processing prevented 
virion formation and, therefore, the ability to infect. This contrasts directly with the 
behaviour of the wild-type polyprotein which was stable after prolonged incubation.
1 .4  Molecular Targets for Antiviral Chemotherapies
The challenges involved in the development of a prophylactic vaccine against 
HIV in the near future are considerable; they, and the disappointments experienced so far, 
have been extensively d o c u m e n t e d .^ 6 - 6 2  j^gt one of the many problems is the presence of 
a seemingly limitless number of strains of HIV-l (see section 1.2).^^ This is a direct 
consequence of two apparent flaws of RT: it is highly error-prone and has no "proof­
reading" abilities. This means that when it synthesises DNA, it fails to correct any 
mistakes that it makes. Unfortunately, it has been estimated that it makes an error of up to 
1 base in 1,700, and as a consequence, each cycle of replication causes an average of up to 
five erroneous bases to be incorporated into the transcribed DNA.^^ Because of this, 
individuals tend to be infected with a viral inoculum composed of a variety of strains. It 
has therefore proved difficult to find an invariant region of gpl20 on which to design a 
vaccine. As a cure has been impossible to find so far, a great deal of work has been
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undertaken to develop effective treatments as independent as possible from the 
heterogeneity imparted by RT.
Knowledge of the array of molecular processes that occur in the replication 
cycle of HIV-l (see section 1.3.2) has enabled the identification of numerous vims-specific 
processes, each of which is a potential target for antiviral chemotherapy. In principle, each 
stage of the replicative cycle can be envisaged as a viable target. To categorise broadly, 
these are adsorption, fusion, uncoating, reverse transcription, integration, transcription, 
translation, assembly and maturation.^
Up until the end of 1995, the only available treatments for AIDS were directed 
against the reverse transcriptase enzyme. As reverse transcription is unique to retroviruses, 
it was hoped that inhibitors of RT would not interfere with enzymes present naturally in the 
body. Azidothymidine (1, AZT) was approved by the Food and Drug Administration of 
the USA for the treatment of AIDS in March 1987. It and a number of drugs approved 
subsequently act against RT by being processed as alternative substrates (nucleoside 
analogues). They are incorporated by the enzyme into the growing DNA chain but do not 
permit any further elongation of it. The principal drawbacks of AZT are its toxicity (caused 
by interaction with other enzymes) and resistance, a problem frequently encountered with 
HIV therapies.8,9 Resistant strains of HIV are rapidly found to most drugs as a 
consequence of the infidelity of RT. These mutants that evolve naturally by base 
mismatching survive by natural selection because they are drug-resistant. The extremely 
rapid evolution of HIV (it has recently been estimated that up to 10 billion HIV-l virions 
may be produced d a i l y ) , 2 8 . 2 9  compounds the problem of natural selection of its drug- 
resistant strains. Consequently, the benefits of drugs that inadvertently stimulate the 
evolutionary selection of resistant mutants are only temporary.
As a result of the toxicity of some of the nucleoside analogues, non-substrate 
analogues have been in v e s t i g a t e d .^ ^  One such inhibitor that has recently been licensed for 
clinical use, nevirapine (2)f^ is more active than any nucleoside analogue but results in a 
greater problem with the emergence of resistant mutants than do any of the nucleoside 
analogues.9
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The majority of clinical trials to date have involved drugs targeted against RT 
and PR. Because of its relevance here, HIV-l PR is considered separately (see below), but 
space does not permit the inclusion of the many others enzymes and processes that have 
been studied. The reader is referred to an excellent review concerning the broad range of 
strategies that have been and are being investigated.^^ In particular much work has 
focused on the role and control of the regulatory proteins.
1 .5 The HIV -l Proteinase
1 . 5 .1  HIV-l PR as a Target for Antiviral Intervention
HIV-l PR was proposed as a target for therapeutic intervention in the treatment 
of AIDS as early as 1 9 8 6 . As has been discussed earlier, PR is essential for the 
production of infectious virions. This was first proved in 1988 when uninfectious virions 
were produced following site-directed mutagenesis of a single base in the PR-coding region 
of poL^^ The role of PR in the post-translational maturation step presents an immediate 
advantage in its inhibition over that of RT. Because RT plays only a pre-translational role, 
inhibitors of it have no effect against cells already infected.
A second, pre-integrational role of PR, (alluded to in section 1 .3 .2 .l),37-38 is 
thought to be the uncoating of the virion after it is brought into the cell. Inhibition of PR 
may therefore be effective in both infected and uninfected cells. Furthermore, cleavages 
mediated by HIV-l PR are not mediated by cellular proteinases (see b e l o w ) . 4 4 .6 8  This 
suggests that HIV-l PR is sufficiently different from cellular proteinases to allow its 
preferential inhibition.
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Finally, very early in the investigation of the enzyme there existed some 
practical advantages in this approach. Firstly, important technical advances came quickly 
on the s c e n e : a  sufficient and safe source of the enzyme was provided through the 
application of recombinant DNA technology and convenient in vitro assays applicable to the 
mass screening of potential inhibitors were developed. Secondly, a vast bank of 
knowledge to help in the design of inhibitors already existed. HIV-1 PR turned out to be in 
many ways related to renin (an enzyme involved in blood pressure regulation), pepsin (a 
digestive enzyme) and other extensively studied non-viral proteinases.”^® This greatly sped 
up initial investigations into the design of inhibitors for the enzyme; indeed, some renin 
inhibitors were found to inhibit HIV-1 PR.71
1 .5 .2  Classification and Structure of HIV-1 PR
The first task in the study of the proteinase was to determine its class: whether it 
was a cysteine, serine, métallo- or aspartic acid proteinase. This was achieved in a number 
of laboratories towards the end of the 1980s. After sequencing the entire genome of 
HIV-1, Ratner et al. postulated that the pal ORF encoded a proteinase similar to those 
found in other retroviruses.^^ However, the classes of all of these were unclear. It was 
subsequently observed that all those regions of retroviral genes thought to encode the 
proteinase contained the well conserved sequence Asp-Thr(Ser)-Gly. This triad was 
known to be characteristic of the aspartic acid proteinases (so-called because of two highly 
conserved aspartic acid residues in the active site) such as renin and p e p s i n , 73 and it was 
proposed that the retroviral proteinases were of this c la s s .7 2
At the time, the known aspartic acid proteinases were two-domain enzymes 
more than 300 residues in length and contained two Asp-Thr(Ser)-Gly sequences. The 
retroviral proteinases whose sequences had been determined contained no more than 130 
residues. Furthermore, they had only one Asp-Thr(Ser)-Gly sequence. It was proposed 
that they must act in dimeric f o r m s  .74
Three types of investigation confirmed both the mechanistic classification and 
the dimeric nature of the enzyme. Firstly, the enzyme was inhibited by pepstatin A (3) ,7i
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a known pentapeptide inhibitor of aspartic acid proteinases and inactivated by l,2-epoxy-3- 
(4-nitrophenoxy)propane (4, EPNP),30 which had previously been shown to esterify one 
or both of the active site aspartic acid residues of pepsin. Secondly, the experiment 
described in section 1.5.2 showed that the replacement of Asp25 with Asn produced 
inactive PR.49 Finally, determination of the crystal structures of both native P R ,7 5 -7 7  and 
P R  complexed with inhibitor HIV-1 proteinase,78 confirmed both its mechanistic class and 
its homodimeric architecture, with each monomer related to the other by a C2 axis of 
symmetry (see Fig. 1.4), associated through non-covalent interactions.
3, pepstatin A 4, EPNP
1 . 5 .3  Structural Features of HIV-1 PR
From the crystal structures obtained of the homodimeric HIV-1 PR, its overall 
molecular architecture and active site have been shown to be remarkably similar to the 
classical monomeric aspartic acid proteinases, yet they are encoded by only half the genetic 
information. In fact, it has been proposed that HIV-1 PR and the other viral aspartic acid 
proteinases are genetic "fossils". It had long been postulated that the primordial form of 
aspartic acid proteinases was a homodimer which had evolved into a heterodimer by gene 
duplication and fu s io n .7 3  This is supported by the internal twofold symmetry exhibited by 
the secondary and tertiary structures of the current monomeric bilobal aspartic acid 
proteinases. Each lobe of the current monomeric proteinases contributes one Asp- 
Thr(Ser)-Gly sequence to the active site. In an entirely analogous manner, each 99-amino 
acid, 11 kD subunit of HIV-1 PR does the same (see Fig. 1.4).
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Figure 1.4: Ribbon drawing of the a-carbon backbone o f HIV-1 PR showing its C2 
tertiary structure, the catalytic aspartic acids, 25 and 25' and the isoleucine 
residues, 50 and 50', present in the flaps (see text)
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The N- and C- termini of both monomers are arranged in an interdigitating 
network of four antiparallel |3-sheets which serve to hold the dimer together through 
hydrogen bonds .79 These rigidly held terminal strands are (a) remote from the active site 
and (b) by virtue of being at the end of the protein chain, form two separate halves of a 
cleavage site acted on by PR, Consideration of these facts led to the proposal that the 
autoprocessing of PR was intermolecular (see section 1.3.2.2), involving three (or 
possibly more) but not two PR domains. 3^
The similarity of HIV-1 PR to the monomeric aspartic acid proteinases is further 
exemplified by the manner in which it embraces its substrates. HIV-1 PR contains two 
identical glycine-rich ^-hairpin loops (flaps) which open to let substrate in, then close to 
form a binding pocket around it. This binding pocket is large enough to accommodate six 
or seven residues of the substrate. Once the cleavage is complete, products are released by 
the opening of the flaps, which move by up to 7 Â during the processing of an inhibitor.78 
The presence of such flaps is reminiscent of the single flap of the monomeric aspartic acid 
proteinases.
Unlike these monomeric aspartic acid proteinases however, there exists in most 
inhibitor complexes a water molecule (henceforth called the flap water molecule) which 
links the enzyme flaps to the inhibitor (or substrate during proteolysis) through hydrogen 
bonding interactions (Fig. 1.5). Normally located within 0.2 Â of the C2 axis of the 
enzyme, it exhibits approximately tetrahedral coordination by bridging the amide hydrogen 
atoms of Ile50 and Ile50' [prime (') is employed to distinguish the two chains] and the P2 
and Pi' carbonyl oxygen atoms of the inhibitor. (The Pn, Pn' terminology of Schechter and 
Berger,80 is adopted here. It prescribes that amino acids are numbered P%, P2 ,....from the 
scissile bond to the N-terminus and Pi>, P2 ,....from the scissile bond to the C-terminus. 
Furthermore, the pocket into which the Pn residue fits is known as Sn). A schematic 
diagram of the active site is shown overleaf, illustrating the terminology of Schechter and 
Berger, the hydrogen bonding network around the tetrahedral water molecule, viz. the 
catalytic aspartic acid residues and the scissile bond (boxed).
16
S i'Gly 27' S3.
Gly 27 Asp 25 Asp 25*
Asp 29* sAsp 29'
Gly 48 =  Gly 48
P3
Gly 48'
N N
lie 50 He 50'
Figure 1.5: Scheme of the hydrogen bonding between HIV-PR and a putative substrate
It has been proposed that the flaps serve roles in both binding and catalysis 
(discussed in section 1.5.5 below). Overall, HIV-1 PR is a very hydrophobic enzyme and 
its substrates (see Fig. 1.7, page 18) are in general also hydrophobic. The flaps cover four 
substrate clefts (S2 -S2 -), increasing the hydrophobic environment around the active site; 
this is consistent with the hydrophobic nature of Pi and Pi*. It is thought that, in addition 
to binding the substrate through hydrogen bonding interactions with a water molecule, the 
side chains of Ile50 and Ile50' "capture" the hydrophobic side chains of the Pi and Pi- 
residues, thereby adding a further distinctive feature to the specificity of the cleavage 
positions.^ ^
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1 . 5 .3  Function HIV-1 PR
When processing the viral polyproteins Pr55g^g and Prl60g^g“P°^ , the enzyme 
has been shown to perform eight specific cleavages (Figs. 1.6 and 1 .7 ) . ^ 3  The scissile 
bonds of the cleavage sites are henceforth indicated with asterisks.
gag
it it
p17 p24 P1 p9 p6
MA CA NC NC pol
p11 p51 p66 p32
PR RT RT IN
Figure 1.6: The overlapping gag andpo\ ORFs o f HIV-1 showing the proteolyses 
performed by HlV-1 PR once translation to Pr55^^s and Prl60s>^ s-po^  has 
occurred. The gag protein between CA and NC (p9) consists of 14 amino 
acids and is designatedpl.^^
(P4-P1) (P1-P4O
1. Ser-Gln-Asn-Tyr * Pro-Ile-Val-Gln
2. Ala-Arg-V al-Leu * Ala-Glu-Ala-Met
3. Ala-Thr-He-Met * Met-Gln-Arg-Gly
4. Pro-Gly-Asn-Phe * Leu-Gln-Ser-Arg
5. Ser-Phe-Asn-Phe * Pro-Gln-Ile-Thr
6. Thr-Leu-Asn-Phe * Pro-Ile-Ser-Pro
7. Ala-Glu-Thr-Phe * Tyr-V al-Asp-Gly
8. Arg-Lys-Ile-Leu * Phe-Leu-Asp-Gly
Figure 1.7: The Cleavage Sites ofHlV-1 PR
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At first sight, there is no obvious similarity between these sequences (shown in 
Fig. 1.7) suggesting that the primary sequence is not the dominant feature behind the 
specificity towards these particular substrates. In fact there is an apparent dichotomy 
between the adaptability of PR to tolerate the considerable variability in P4 -P4 ’ and the 
selective cleavages that it performs. On closer inspection however, some similarities in the 
sequences can be identified; for example, in sites 1, 5 and 6  the similar sequence Ser/Thr- 
Xaa-Yaa-Phe/Tyr*Pro-Zaa (X/Y/Zaa represent any amino acid) appears. This sequence 
has been observed in some other retroviral Gag-Pol polyproteins and at the present time has 
only been found in retroviruses (no known mammalian or proteinase can hydrolyse 
P h e / T y r * P r o ) . ^ 4  The other residues show an overall hydrophobicity, particularly in the Pi 
and Pi positions. In studies aimed at probing the specificities of the subsites with artificial 
substrates, it was shown that seven residues were required to bind in the enzyme in order 
for cleavage to occur. Smaller peptides were not processed.^^-^7 Recognising these trends 
was important, and the information gleaned was invaluable in the design of inhibitors.
1 . 5 .5  Mechanism of HIV-1 PR
There is a high degree of sequence homology and a similarity in the structural 
configurations of the catalytic aspartic acid residues that occupy the active site in the 
aspartic acid proteinases. This and their sensitivity to generic inhibitors such as pepstatin A 
implies that they might proceed by the same mechanism. Numerous mechanisms which 
fall into two broad categories, general acid-general base catalysis and catalysis by means of 
a covalently bound intermediate, have been proposed. Aspartic acid-catalysed proteolysis 
was long thought most likely to proceed through direct nucleophilic attack by one of the 
two aspartates, followed by subsequent hydrolysis of the covalent intermediate.^^ So far 
there has been no experimental evidence to support this. Furthermore, investigations into 
the mechanism of the cleavage of four oligopeptide substrates performed in the presence of 
i^O-labelled water gave products (and reformed substrate) with H2 ^ ^ 0  incorporation; this 
would not have been possible had the reaction proceeded by direct attack with aspartate.89
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Schem e 1,1 : Alternative general acid-general base catalytic mechanisms proposed for 
HTV-1 PR, illustrating neutral (a) and zwitterionic (b) intermediates
The consensual verdict of many recent kinetic and theoretical studies directed at 
HIV-1 PR is that the most likely mechanism involves general acid-general base catalysis, 
with either a neutral or zwitterionic intermediate (Scheme 1.1). These mechanisms require 
a water molecule (the lytic water molecule) to take part directly in the reaction. Implicit in 
the general acid-general base mechanism is that only one of the two aspartic acid residues is 
protonated. This is in agreement with studies of the pH dependence of the reaction rate.90 
In further studies with oligopeptides, plots of log (V/K) vs pH were bell-shaped,90 
indicating that (a) these two acids have remarkably different pKg values (3.4 - 3.7 and 5.5 - 
6 .5 ) and (b) for catalysis to occur, it is required that one acid is protonated and one is not. 
However, because of their proximity and ability to share a hydrogen atom, it is has been 
proposed that the proton transfer between Asp25 and Asp25' is facile.91
2 0
In mechanism a of Scheme 1.1, Asp25 acts as a general base activating the lytic 
water molecule which then attacks the amide carbonyl group. Asp25', which is 
protonated, stabilises the negative charge built up on the oxygen atom of the carbonyl 
group and then protonates the oxygen atom. In the second step, Asp25 and Asp25' reverse 
roles; Asp25 protonates the scissile nitrogen atom and Asp25' abstracts a proton from the 
diol. In mechanism b depicted in Scheme 1.1, Asp25' provides a proton to the nitrogen 
atom leaving a zwitterion which undergoes internal collapse to form the products. In both 
of these mechanisms, the nucleophilic attack and proton transfer processes may be 
concerted or occur in separate steps, resulting in reaction intermediates with slightly 
different structures.
Although the flap water molecule is thought to play a part in the catalytic 
process because it is located near the active site in many crystal stmctures, its precise role is 
unclear. Its importance is thought to be in stabilising the transition state and in aiding the 
straining of the peptide linkage away from coplanarity, thereby weakening the bond and 
promoting cleavage.91 However, it has been suggested that the flap water and lytic water 
molecules are one and the same. If the two are different, it has been proposed that an 
appropriately designed inhibitor would enable the detection of a lytic water in its crystal 
structure with the enzyme, in addition to the flap water molecule.88
Recently, a number of NMR and crystallographic studies have attempted to 
clarify the exact nature of the mechanism, in particular to establish information about the 
ionisation states of the catalytic aspartic acid groups. Such information is difficult to obtain 
in a direct fashion from X-ray data because protons are not observed in protein electron 
density maps. In addition, calculations using molecular dynamics have predicted that these 
ionisation states will vary with the interactions experienced as a result of each individual 
inhibitor bound in the active site.92 For the complex formed between HIV-1 PR and the 
cyclic urea DMP-323 (37, page 42), NMR and X-ray evidence show that both aspartic 
acids are protonated.93 In similar complexes formed with KNI-272 (14, page 27),94 and 
pepstatin A,95 NMR evidence indicates that just one aspartic acid is protonated.
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Most pertinent to catalysis are the chemical properties of the aspartic acid 
residues in the unbound enzyme. The bell-shaped curve discussed above,90 had been 
thought to confirm the presence of one protonated and one unprotonated aspartic acid 
residue in unbound HIV-1 PR at the optimal pH (5.5 - 6 ) of the enzyme. However, a 
recent report has been published with NMR evidence that contradicts this.95 The authors 
prepared a sample of HIV-1 PR in which Asp25 and Asp25' were 96% i^C-enriched at the 
quaternary centre of the side-chain carboxyl group. The chemical shift of this carbon atom 
is sensitive to the ionisation state of the acid and, on the basis of the presence of a single 
resonance in the NMR spectrum at pH 5.93, it was suggested that both aspartic acids 
are ionised at this pH. The authors proposed that a rapid equilibrium exists between all 
three ionised forms of the catalytic diad, in which the diprotonated form is predominant and 
the monoprotonated form is catalytically active.
1 .6  Inhibitors for HIV-1 PR
Since it was proposed that HIV-1 PR was an appropriate target for antiviral 
i n t e r v e n t i o n , 6 7  an enormous amount of work has been devoted to developing inhibitors. 
There are a number of complementary strategies that have been adopted in this search. 
These include random screening, the incorporation of transition state mimetics into suitable 
peptide sequences and the use of computer modelling both to assist in the de novo design 
of inhibitors and to evaluate the inhibitory potential of known compounds. The 
employment of all these strategies to discover HIV-1 PR inhibitors will be described 
below.
1.6 .1  Random Screening
Many groups have set up high throughput screening assays to enable the testing 
of large numbers of compounds which originate from either natural sources or from
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collections of synthetic compounds. As early as 1988, the US National Cancer Institute set 
up a mass screening programme to test 10,000 compounds a year for anti-HIV activity.96 
There are two principal advantages of this process. Natural products are a continuous and 
proven source of new lead compounds in drug discovery programmes. The other is the 
possibility of discovering inhibitors without the pharmacological problems inherent to 
rationally discovered peptide mimetics (see section 1.6.4)
Natural products have proved useful as lead compounds. Whilst such 
compounds have diverse structures and none have become drugs, it is interesting 
nevertheless to consider some of them briefly.
An examination of porphyrins revealed that they are active against HIV-1 PR at 
micromolar concentrations. In particular, the availability of a series of carborane ester 
derivatives of porphyrins synthesised as experimental boron neutron-capture therapeutics 
led to the discovery that compound 5 (the tetrakiscdiVhovoxiQ carboxylate ester of a 
poiphyrin) had an IC50  of 185 nM.^7 The hydrophobic nature of the carborane cages were 
thought to be responsible for most of the binding interaction. However, the antiviral 
activity of this and similar compounds was severely impaired by their binding by the 
albumin present in the blood stream.
OCOB10C2 H11
X ^O C O B ioC2Hii
Another novel PR inhibitor (6 ) was purified from Hypoxylon fragiforme, a 
fungus isolated from the bark of the American beech tree. Unfortunately, 6  (IC50 = 3 |xM)
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also inhibited pepsin.^^ Studies are currently in progress to improve both the potency and 
the selectivity of this c o m p o u n d . ^ ^ d O O
A screening programme of existing compounds identified a crude sample of 
penicillin dimer with enzyme activity. Purification revealed the penicillin dimer to be 
inactive; the inhibition was shown to be caused by 7 (a C2 -symmetrical dimer; I C 5 0  =  
60 nM) which was an artifact of the purification p r o c e s s ,  Development work on 7 gave 
more potent inhibitors 8 - 1 0  (IC5 0  = 0.9 - 4.8 nM).^^i Analogue 9 was selected as a 
candidate for drug development but poor pharmacokinetics ended the interest in this series 
of compounds.!®^
7: R = OMe 
8 : R = NH2 9: R = NHEt 
10: RzzNHCH^PHNH OO HN
A final and extremely successful series of inhibitors found through random 
screening shall be discussed in depth later (see section 1.6.5.1).
1 . 6 . 2  Peptidomimetic Inhibitors: Use of Transition State Surrogates
Armed with the knowledge of both the classification of HIV-1 PR as an aspartic 
acid proteinase and of natural and synthetic substrates, the design of inhibitors was initiated 
by applying transition state mimicry. This concept, originally proposed by Pauling,1^ 3 is 
based on the premise that an enzyme has a higher affinity for the transition state than for 
either product(s) or reactant(s) and proved extremely effective when designing renin 
inhibitors.'^® In this approach, a Pi*Pi- pair are replaced with a proteolytically stable 
dipeptide surrogate. The task of developing the first inhibitors was considerably facilitated 
by the vast body of information accumulated from 2 0  years work into the design of 
inhibitors for renin.'^® Inhibitors of HIV-1 PR were first reported in 1989, designed by
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"tailoring" renin inhibitors "to fit" HIV-1 These inhibitors were very potent with
little residual renin-inhibitory properties.
Some successful examples of dipeptide mimetics (with the actual transition state 
analogue of the scissile bond boxed) are shown below (Fig. 1.8).
Reduced amide
OH
Pi
Hydroxymethylene Hydroxymethylcarbonyl
Pi O
Hydroxyethylene
Pi Pi'
Hydroxyethylamine
O OMe
Pi O
Phosphonamidate 
methyl ester
Figure 1.8: Some dipeptide mimetics incorporated into HIV-1 PR inhibitors
Each mimetic incorporates some but not all of the features of the transition state. 
They all possess tetrahedral geometry at the position designed to mimic the carbonyl group 
of the scissile peptide bond. However, other required characteristics cannot be met on 
chemical grounds. Some mimetics {e.g. hydroxymethylcarbonyl and hydroxyethylamine 
derivatives) contain more backbone atoms and some contain fewer atoms {e.g. 
hydroxymethylene derivatives). Intuitively, these mimetics might be expected to lead to 
poor inhibitors as their peptidic portions should be out of synchronisation with the pockets 
into which they are designed to fit. As will be described, however, some have made very 
good inhibitors.
It is useful to review some of the highlights of the work in this field, 
particularly as all four HIV-1 PR inhibitors currently on the market, resulted directly or 
indirectly from this approach. Furthermore, whilst describing the inhibitors, comments
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will be made about the medicinal chemistry that led to their development. This should give 
some idea as to how much the state of the art has advanced over the last decade.
The earliest reported inhibitors incorporated the reduced amide surrogate. Many 
of the early compounds were of only modest potency (although inhibitors effective at 
subnanomolar concentrations have since been reported). However a co-crystal of an 
inhibitor containing this mimetic (11, MVT-101) and HIV-1 PR provided the first detailed 
three dimensional structure of HIV-1 PR in its inhibited form.^8  The modest inhibition of 
HIV-1 PR by most members of this series has been attributed to its comparative lack of 
functionality; this prevents effective hydrogen bonding to the catalytic aspartic acid 
residues.
HQ,
Ac-Thr-llGs^^ ^  A^^GIn-Arg-NHz
i H n
11, MVT-101 12, SDZ-PRI-053 ^  OCH3
The archetypal aspartic acid PR inhibitor pepstatin A (3), contains the 
hydroxymethylene (statine) surrogate and is a moderate inhibitor of HIV-1 PR 
(IC 5 0  ~ 1 |iM). Originally, however, use of this surrogate did not deliver potent 
inhibitors, probably because it failed to project a residue into Si*. This problem was solved 
through the development of a different synthetic route, which enabled the incorporation of 
substituents at the 2-position. This led to the development of a highly potent series of 
inhibitors culminating in 12 (SDZ-PRI-053; Ki = 9.5 nM).^05
Hydroxymethylcarbonyl (norstatine) derivatives had previously been used as 
renin inhibitors. In contrast to renin inhibitors, potency was only achieved with the amino 
acid proline in the Pi position {e.g. 13, KNI-1 0 2 ; IC5 0  = 89 nM).i®6 An extensive 
structure-activity study was undertaken, in which the pyrrolidine ring of proline was 
exchanged for heterocyclic 5-membered r i n g s . O n e  exceptionally potent analogue
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containing a thiazolidine ring (14, KNI-272; Kj = 5.5 pM) is active against a wide 
spectrum of HIV-1 strains and is currently undergoing phase II clinical trials. ^ (^ 7,108
OH ^SCHa
Cbz-Asn-NF
P h- -  o  |N '  o
13, KNI-102 14, KNI-272
The extremely high potency of 14 is attributed in part to conformational 
preorganisation of this compound caused by the norstatine-thioproline bond being locked in 
the trans configuration. This is supported both by quantum mechanical calculations and by 
the conformations seen in crystal structures: both the free and PR-bound forms of 14 are 
very similar. The binding of 14 in the active site of HIV-1 PR is therefore thought to be 
more favourable entropically than most other linear peptidomimetic inhibitors. 
Conformational preorganisation is an important factor behind the potency of the smaller 
non-peptidic compounds and will be discussed later (see section 1.6.5.2).
A general point worth raising about the KNI series of norstatine inhibitors is 
that they all incorporate an unnatural amino acid, phenylnorstatine [(2R,3S)-3-amino-2~ 
hydroxy-4-phenylbutyric acid]. Unnatural amino acids have been widely employed to 
stabilise peptidomimetic HIV-PR inhibitors towards proteolysis. This is because they are 
not recognised by cellular proteinases. A similar strategy employed to evade metabolic 
degradation has been the use of D-amino acids in place of the natural L-amino acids. 
Compounds that contain such surrogates have been shown to retain inhibitory activity, 
although modifications to side chains need to be engineered on account of the reversal of 
the stereochemistry.
Five different transition state mimetics were directly compared in a study 
conducted by Dreyer et al. in which the surrogates were incorporated into the substrate 
Ser-Ala-Ala-Phe*Pro/Gly-Val-Val-OCH3 .ii^ The reduced amide analogue gave the
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poorest inhibition (Ki = 19 |iM). The hydroxyethylene-containing compound gave the 
greatest inhibition (Ki = 62 nM).m This outcome guaranteed an extensive investigation of 
the hydroxyethylene suiTOgate and has ultimately yielded an inhibitor (15, indinavir; Ki = 
0.34 nM),ii^ which is now in clinical use.^ ®'^
Modifications to the hydroxyethylene surrogate have led to other novel 
inhibitors. Through computer modelling s t u d i e s , i t  was calculated that an analogue of 
15 bound to HIV-1 PR such that the aminoindan NH and the a-CH were nearly coplanar 
(the comparable atoms and bonds are shown in red in 15). Incorporation of these atoms 
into a 5-membered lactam ring (shown in red in 16) combined with additional stmctural 
features has delivered a series of potent inhibitors including 16 (IC5 0  = 5 nM).i^3 These 
y-lactams have shown significant oral bioavailability in dogs,^^^ no doubt as a result of the 
elimination of the indan amide bond.
15, indinavir
PhOH
OH
Pb
16
Compound 16 is another example of the constraining of an inhibitor into its 
bioactive conformation similar to that described previously for 14. Such confonnationally 
constrained peptidomimetic inhibitors have been extensively reported. There are many 
publications which describe the advantages of macrocycles over the acyclic peptidic 
inhibitors from which they are derived. Benefits include the protection of amide bonds 
from proteolysis, increased water solubility (and lipid solubility),!!^ and the entropie 
benefits of conformational preorganisation akeady described.
In a highly novel approach to the construction of rigid molecular stitictures, the 
Amos B. Smith III group have developed |3-strand peptidomimetic inhibitors, analogues of 
which have recently been shown to have good bioavailabilities, These compounds were
28
designed with the knowledge that HIV-1 PR binds its substrates and inhibitors by 
generating p-pleated sheets.!!"^ Flanking the hydroxyethylene surrogate with linked 
pyrrolinones as |3-strand mimetics enabled a reduction in the number of amide bonds. 
Compound 17 (IC5 0  =1.3 nM) was more active in a cc//-based anti-HIV assay than 
corresponding peptidic inhibitor 18 (IC5 0  = 0.4 nM), despite the in vitro IC5 0  values 
indicating the reverse. This suggested that the premise that lowering the number of peptide 
bonds aids the transport of these inhibitors into cells is c o r r e c t . ! ! 4^18
H H 
° P h '
18
A second type of compound, developed by the Gani group at St Andrews, has 
also been shown to aid in cell-uptake properties. By incorporating the phosphonamidate 
methyl ester transition state surrogate in a series of compounds derived from one of the 
HIV-1 cleavage sequences, moderate inhibitors of PR were derived. All the analogues 
prepared had a marked ability to enter cells, as demonstrated by the approximate 
equivalence of IC50 values found for both solution- and cell-based assays.!!^
Finally, the hydroxyethylamine surrogate has arguably proved to be the most 
successful of the transition state mimetics in generating potent HIV-1 PR inhibitors. 
Extensive structure-activity studies of inhibitors containing the hydroxyethylamine 
analogue of the Phe-Pro scissile bond have shown that inhibitors could be truncated to 
occupy only 8 3 -8 2 '.^^°
Further modification of the Py proline to the decahydroisoquinoline group led 
to the discovery of 19 (saquinavir; Ki = 0.1 nM),!20 the first HIV-1 PR inhibitor to be 
approved for clinical use.!®  ^ Further manipulation enabled truncation of the N-terminal
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end to just Pi and ? 2  and led to the identification of 2 0  (nelfinavir; Ki = 2  nM),i^^ which 
has improved bioavailability compared to 19 and is itself now approved for clinical use. 1^ 4
OH OH
NHOJ< ON SPh O
19, saquinavir 2 0 , nelfinavir
1 . 6 .3  Exploitation of the C2 -Symmetry of HIV-1 PR
An elegant approach to the design of HIV-1 PR inhibitors exploits the C2 - 
symmetrical nature of the enzyme. Such a design approach has never been adapted for any 
other enzyme target. As this has been discussed already (see sections 1.5.2 and 1.5.3), it 
is sufficient to summarise that as the symmetry-related pockets Sn and Sn’ should be 
indistinguishable in the native enzyme, duplication of either the N- or C-terminus of a 
substrate or inhibitor by a C2 -operation should produce inhibitors with novel structural 
f e a t u r e s .  2^.2 pour C2-symmetrical inhibitors have already been mentioned (compounds 7 - 
10). Their discovery was serendipitous, in contrast to virtually every other C2 inhibitor. 
The majority of such compounds have been designed by performing C2 operations 
(Fig. 1.9) on the transition state of the Phe*Pro cleavage site and have duplicated the 
N-terminal side.^^^ This is partly because this side, the "P region", had been shown to be 
of greater importance in the binding of renin inhibitors. 123 Also, the Pj residue in Phe*Pro 
is Phe. As may be seen from cleavage sequences. Pi and P% are often aromatic residues.
As with those discussed earlier, the initial symmetrical inhibitors were still 
highly peptidic. An enormous number have been synthesised and r e v i e w e d .  124-126 After 
the modification of an initial symmetrical compound identified by rational design, 2 1  
(ritonavir; Kj = 20 pM), which does not display perfect C2 symmetry was identified, 12? 
and is currently licensed for clinical use.m^
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Figure 1.9: Symmetry operations on PheWro giving C2~symmetrical transition state
mimetics: after defining a hypothetical axis of symmetry based on the C2- 
symmetry o f the enzyme, one half is deleted and a C2 operation on the 
other half provides two distinct chemically stable core unitsd^
N
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1 . 6 .4  Problems with Substrate-Based Peptidomimetic Inhibitors
Desirable properties in drugs are the combination of good bioavailability with 
pharmacological efficacy, long duration of action and minimal toxicity. Such a valuable 
portfolio of properties is not generally bestowed upon the peptide-based or large inhibitors 
described above. Antiviral potencies of these compounds frequently do not parallel their
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ability to inhibit an enzyme in vitro. They suffer from a number of problems outlined
below;ll5»l28
• Their unique structural features mean that the peptides are poorly soluble in the 
water present in most parts of the body and are poorly transported across 
cellular membranes.
• Whilst the gastrointestinal (GI) tract provides amply for the digestion of food, 
notably protein, the onslaught of degradative enzymes (particularly proteinases) 
ensures that relatively few intact peptides enter the portal vein.
• Those drugs that survive the hostile environment of the GI tract quickly 
encounter the liver through which the portal blood supply must pass before 
more widespread distribution. Removal of alien substances here is known as 
the "first pass effect" and can prevent their further distribution. The propensity 
of a compound towards biliary excretion is governed most notably by its 
molecular weight. Excretion is favourable for compounds whose molecular 
weight exceeds 500 although other factors such as lipophilicity, solubility and 
ionic charge also affect this property.
• Once through the liver, drugs are subject to degradation in the kidney, blood 
and in various other tissues. Furthermore, HIV-1 PR inhibitors have been 
shown to tightly bind to plasma proteins (> 98%), reducing still further their
antiviral activity. ^ 28
Although no class of drugs is exempt from the problems of oral bioavailability, 
tissue distribution, metabolism and excretion, and protein binding, these problems have 
been a particular problem with peptide-based drugs. In particular, these and other 
problems specific to the pharmacokinetics associated with HIV-1 PR inhibitors have been 
r e v i e w e d .  128 As a result of the above problems, many groups have departed from the 
traditional peptidomimetic routes described earlier and instead have sought to discover 
small non-peptidic inhibitors (NPIs).
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1 .6 .5  Non-Peptidic Inhibitors (NPIs)
Two complementary strategies have been employed in the search for novel PR 
NPIs. These are the rational design of new compounds and the screening of known 
compounds. Both these approaches have been successful insofar as two series of highly 
potent inhibitors have been discovered, both containing central rigid cyclic structures from 
which groups are projected into the central (S2-S2 O subsites. Rather than diluting the 
following discussion by covering the large numbers and types of NPIs so far identified, 
ranging from metal i o n s , 129-132 jg fullerene d e r i v a t i v e s ,  133-135 focus will be directed 
primarily on these two series.
1 . 6 .5 . 1  NPIs Found by the Screening of Known Compounds
The omission of the adjective "random" from the above title seeks to emphasise 
a sense of direction prevalent in many approaches to the screening of large numbers of 
compounds. This has been achieved by the use of computers to assist in the lead discovery 
process. One of the first examples of this was the use of the computer programme DOCK 
to identify potential inhibitors of HIV-1 PR. DOCK searched 10,000 compounds in the 
Cambridge Crystallographic Database for a shape complementary to the enzyme's active 
site. 136 Using this technique, bromoperidol (22) was identified and a closely related 
analogue, the known antipsychotic drug, haloperidol (23) was found to be a weakly active 
inhibitor, albeit at toxic concentrations (Ki = 1 0 0  mM).i36
22, bromoperidol: X = Br
23, haloperidol: X = Cl
Since the application of X-ray crystallography to HIV-1 PR-inhibitor 
complexes, it has been possible to construct pharmacophores mimicking key features of 
enzyme-inhibitor interactions. These include the binding of the central hydroxy group in
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both hydroxyethylamine and hydroxyethylene inhibitors to the active site aspartic acid 
residues and the interactions with the flap water molecule. Such pharmacophores may then 
be used in a more directed search of databases containing the three-dimensional structures 
of known compounds. This and similar approaches have proved useful in generating lead 
compounds quickly, as all major pharmaceutical companies maintain databases of 
proprietary compounds. In a recent publication, the construction and application of such a 
pharmacophore led to the identification of fifteen previously unknown NPIs. ^ 37 
Furthermore, careful analysis of X-ray data obtained from co-crystals of NPI-PR 
complexes have greatly advanced the rate at which drug discovery programmes have 
progressed. This will become evident later.
In addition to computer-assisted screening of known compounds before their 
biological evaluation, there is of course random screening. Whilst not exactly a testament 
to the intellectual basis driving modern medicinal chemistry, such testing has delivered one 
of the most followed-up NPI lead-compounds to date.
4-Hydroxypyranones and 4-hydroxycoumarins were first observed 
independently by two groups (at Parke-Davis Pharmaceutical Research and at The Upjohn 
Company) to inhibit weakly HIV-1 PR. ^  38,139 The 4-hydroxycoumarin, waifarin (24) 
had been reported to demonstrate anti HIV-1 activity in 1993, but its mechanism of action 
was not known. 140 in 1994, however, the same compound was found to have anti-HIV-1 
PR activity in two separate high throughput screening programmes. 138,139 Further 
screening work identified several related compounds including two 4-hydroxycoumarins 
(25,139 and 26,i4i) and the 4-hydroxypyrone 27.141
Ph Ph
.OPhR
OOH
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Subsequent analysis of the crystal structures of HIV-1 PR complexed with 
compounds 25,139 and 26,i42 showed that both bound in a similar fashion to the active 
site and that the 4-hydroxypyrone ring was functioning as the pharmacophore (Fig. 1.10)
l^leSOHN
/ i
C J
O' /  \  'O
A  /  ' AA sp 2 5 " ^ 0  g '^ A sp 25
Figure 1.10: Hydrogen bonds formed between the 4-hydroxypyrone pharmacophore 
and the Asp25, Asp25\ IleSO and IleSO' residues o f the active site o f PR
The establishment of the mode of binding of the 4-hydroxypyrones served as a 
springboard from which a number of series of potent inhibitors have evolved. One of the 
most important obsei^vations made of the crystal structures was that the flap water molecule 
had been displaced by the lactone oxygen atoms of the pyrone ring. Such a displacement 
has been part of the design strategy for NPIs of a number of groups and is discussed later 
(see section 1.6.5.2). Additionally, the X-ray crystal stiuctures showed the importance of 
the C-3 residue, viz. that it was able to interact with S% and S2 and/or S3 .139,M2
Medicinal chemists chose next to synthesise analogues of compounds 25 and 
26 by varying the nature and length of the C-3 substituent, and by investigating the effect 
of substitution patterns on both aromatic r i n g s .  142,M 3 Most of these derivatives were good 
inhibitors. It was noted, however, that a decrease in activity was observed in both series of 
compounds when there was no branching at the a-position of the C-3 substituent.
Whilst the C-3 substituent was interacting with Si-S3 , the position and rigidity 
of the fused benzene ring posed a serious obstacle to any further development of the
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potential of the 4-hydroxypyrone pharmacophore. Although there was an interaction 
between the benzene ring of the inhibitor and S^, it was limited and so attention at Parke- 
Davis turned to the development of the 4-hydroxypyrone lead 27. Insertion of one 
methylene group between the sulfur atom and phenyl group of the C-3 substituent led to a 
modest improvement in activity (IC5 0  = 1670 nM 3000 nM) .^ 4 4  insertion of two 
carbon atoms in the same position together with the attachment of a carboxylic acid group 
to the para position of the C- 6  phenyl group (thought to interact with an arginine residue in 
S3 O gave compound 28, which had significantly enhanced inhibitory activity (IC50  = 
160 nM).i44
HO
. 0
S
OH
Unfortunately, as a result of the presence of the sulfur atom, this and other 
analogues failed to achieve any interaction with both Si and S2 (the probable cause of the 
benefits arising as a result of branching at the a-position of the C-3 substituent described 
earlier). Incorporating the sulfur atom in the |3-position enabled the introduction of a 
number of substituents at the a-position. 1^ 5 a  variety of analogues were prepared, the 
most potent being compound 29 (Fig. 1.11; IC5 0  of 58 nM). An X-ray crystal structure of 
a 29-HIV-l PR co-complex revealed the same substituent binding pattern (S% - Sr) that 
had been predicted by modelling (Fig. 1.11); differences were seen, however, in the 
hydrogen bonding network from that previously found (Fig. 1.10). Only one flap 
isoleucine amide bond was hydrogen bonded to the oxygen atoms of the lactone and only 
one catalytic aspartic acid formed a direct hydrogen bond to the enol of the inhibitor. The 
second aspartic acid was indirectly bonded through a bridging water molecule. This had 
not been observed previously in any other crystal structure and may provide evidence for 
the existence of separate lytic and flap water molecules (see section 1.5.5, page 21).
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IleSO' NH
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Asp25'
Figure 1.11 : Hydrogen bonds and subsite interactions derived from a crystal structure 
o f a 29-HIV-l PR complex
Elsewhere (at Upjohn), the potential of 4-hydroxypyrone analogues was also 
being explored439 Based around 4-hydroxycoumarin 25, the fused benzene ring was 
replaced with a flexible and substituted C- 6  tether in the pyrone template to yield compound 
30. The substituents pendant from the central pyrone ring interacted with 8 2 -8 2 - and its 
enzyme inhibition (Ki = 38 nM) and antiviral activity against clinical isolates of HIV-1 
enabled it to be the first 4-hydroxypyrone analogue to enter clinical trials. It displayed 
good oral bioavailability in animal models and all four constituent diastereoisomers 
demonstrated good Kj values (14 - 109 nM).i39 Whilst it proved to be well tolerated by 
humans, phase I clinical trials were discontinued because of the identification of more 
potent inhibitors.
OH
An alternative strategy to overcome the limitations imposed by the fused 
benzene ring in compound 25 was also pursued at Upjohn. By replacement with more
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flexible cycloalkyl rings, compounds much more potent than 25 (Ki= 1000 nM) were 
discovered. It transpired than an 8 -membered ring was the optimum size (31; Kj = 
75 nM); through X-ray crystallography this was shown to be because the cyclo-octyl ring 
effectively filled the pocket. 1^ 7 Through iterative substitution of the a-carbon of the 
C-3 substituent of 31, a cyclopropyl ring (32) was found to be the most potent inhibitor 
(Ki = 15 nM) of a series of compounds. 1^ 7
31: R = ethyl 
32: R = cyclopropyl
OH R
Previously substitution of an amide group at the rn^m-position of the free 
phenyl group in analogues of 25 had resulted in a significant increase in activity.^43 
Similarly, amide-containing substituents were attached to the mera-position of the phenyl 
group in compound 32. Although, several of these proved to be potent inhibitors 
(Kj < 1 5  nM), they later proved to have very little antiviral activity. 4^8 Subsequently, 
other analogues of compound 32 were prepared and a series of sulfonamides gave very 
encouraging results.149 Whilst simple alkyl substituted sulfonamides had activity little 
better than the parent compound 32, their phenyl analogues (33; Kj = 3 nM and 34; 
Ki = 0.8 nM) proved much better. A crystal structure of a 33-PR complex showed that 
the sulfonamide functionality was forming hydrogen bonds with the Gly48 and Asp29 
residues and that the phenyl group was filling $3,149 Furthermore, the antiviral activities 
of sulfonamide derivatives have turned out to be the best of the 4-hydroxypyrone series 
discovered so far. Consequently, compound 34 was selected for clinical trials.i^^
R
33: R = H 
34: R = CN
HN
OH
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Modelling studies suggested two further structures upon which to attach 
substituents. Both the tetronic,^^^ acid and dihydropyrone rings,^^^152 contain sp  ^
centres at their C-5 and C- 6  atoms respectively (Fig. 1.12). They provide novel 
opportunities for investigating binding interactions with the little explored 8 2 - and S3 ' in 
addition to Si-, both by enabling the ability to substitute twice at these positions and 
through the difference in bond angles exhibited by sp^ and sp  ^carbon atoms.
Tetronic acid: \__/
HO V
Dihydropyrone:
OH
Figure 1.12: Molecular structures related to 4-hydroxypyrone and 4-hydroxycoumarin
Outside the paper in which it was originally suggested, there appears to have 
been little work reported on inhibitors based on the tetronic acid template. ^ 46 However, the 
dihydropyrone ring has prompted further efforts to invent ever more potent inhibitors.
The saturation of the 5,6-double bond which distinguishes the 4- 
hydroxypyrone and 4-hydroxydihydropyrone templates was shown to alter the optimum 
cycloalkyl ring size from eight to six carbon atoms in compounds analogous to 33 and 
34.153 Structure-activity studies have also proved that 2-pyridyl sulfonamides have better 
antiviral activity than phenyl sulfonamides. 153 Through such studies, cyclohexyl- 
dihydropyrone 35 (K; = 50 p M ) , i 5 3  and more complex chiral C-6 -disubstituted 
dihydropyrone 36 (Ki = 8  p M ) , 154455 proved to be potent NPIs. Currently, compound 
36 is being evaluated prior to its probable entrance into clinical trials. 154
HN'^'O ^
35
OH
S3
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1 .6 .5 . 2  The Rational Design of Non-Peptidic Inhibitors
Whilst structure-based design was used to deliver the clinical candidates 
described above, the initial lead was discovered by random screening. A second highly 
successful series of cyclic compounds have evolved from an initial lead invented by the 
application of an entirely de novo design strategy. 156 These were developed after initial 
consideration of the structural features believed to be essential to the development of any 
NPI. These features (outlined below) were then incorporated into appropriate molecular 
templates (Fig. 1.13).
• An initial pharmacophore was generated which contained a hydroxyl group. It 
was expected that this would bind to the catalytic aspartic acid residues.
• An entirely novel idea was to incorporate an atom or atoms capable of 
displacing the flap water molecule. It was reasoned that such a displacement 
would be favourable on entropie grounds.^57
• Such an entropie benefit was in danger of being offset by the entropy lost upon 
the binding of such inhibitors. To counter this, it was proposed that cyclic 
inhibitors be designed. The entropy "toll" charged by a cyclic inhibitor (as 
opposed to a flexible linear inhibitor) could thus be "prepaid" during synthesis 
and would ensure positive effects from the displacement of the flap water.
• Finally, it was desired to build these structural features within a framework that 
would allow the attachment of C2-symmetrically related Pi and and possibly 
? 2  and ? 2 ' groups. Through incorporation of all these features, it was hoped to 
depart from the multisubsite interactions made by peptidomimetic inhibitors. 
This would enable a reduction in the molecular weight of inhibitors thereby 
increasing their bioavailability.^^ 5
Fig. 1.13 shows how these structures were refined to generate the cyclic urea 
structure. A cyclohexanone ring (A) was chosen as the initial hypothetical cyclic structure
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with the ketone oxygen atom designed to displace the flap water molecule. This was 
expanded to a seven-membered ring to allow the introduction of a diol (B). Diaminodiols 
had proved to be superior inhibitors to diamino alcohols. 124-126 Further elaboration to the 
cyclic urea (C) was based on two considerations. Firstly, there was precedent for cyclic 
ureas as excellent hydrogen bond acceptors. 158-160 Secondly, it was realised that the seven 
membered cyclic urea was synthetically accessible by cyclisation of a phenylalanine derived 
diaminodiol with carbonyl diimidazole (CDI). This places a phenyl group in both S\ and 
Si' and closely mimics the aromatic amino acids phenylalanine and tyrosine commonly 
found in these pockets. Finally conformational analysis predicted the optimal 
stereochemistry to be that shown in D. This skeleton is in fact derived from (D )- 
phenylalanine.
Pi'PV PhPh PhOH HO OH HO OH
\Ph
A B C D
Figure 1.13: Evolution of a template for cyclic non-peptidic HIV-l PR inhibitors
The design process was now complete. Synthetic chemists began to corroborate 
both the hypothesis of cyclic urea inhibitors and the conformational analysis. Simple cyclic 
ureas derived from both enantiomers of phenylalanine were tested against HIV-1 PR. This 
showed that the (D) phenylalanine-derived urea was indeed 1000-fold more potent than the 
(L) phenylalanine-derived analogue. ^  56
By attaching a number of different hydrophobic substituents to the urea nitrogen 
atoms of D, interactions with S2 and S2 ’ were optimised. The optimal substituent was 
found to be a para-hydroxymethylbenzyl group. This gave compound 37 (DM? 323; Ki = 
0.23 nM) which exhibited sufficient bioavailability and selectivity and had antiviral
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properties that permitted it to enter clinical trials. NMR and crystallographic studies 
showed that amongst the interactions it had been designed to make, it had indeed displaced 
the flap water molecule; the urea oxygen atom was shown to be coordinated to the amide 
bonds of Ile50 and 50’ (Fig. 1.14).i6i
AspSO’v.^ Ile50\ Jle50 ^.Asp30
1 Q  H H o  t*^2 ' \  /  ^ 2
HO 'o'' oH
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A  ; /  AAsp25"^C> b '^ A sp 2 5H H
Figure 1.14: Hydrogen bonds and subsite interactions derived from a crystal structure 
o f a 37-HIV-l PR complex^^^
Unfortunately compound 37 was withdrawn from clinical trials as a result of 
variable bioavailability in humans, caused primarily by its poor solubility in both aqueous 
and lipid media. Attempts were made to circumvent this problem by transforming it into 
a water soluble phosphate ester (3 8 ). This prodrug was shown to be hydrolysed to the 
parent drug by phosphatase enzymes in the gastrointestinal tract. However, it transpired 
that the benzyhc hydroxymethyl groups of the parent dmg were metabohcaUy unstable and 
this line of development was discontinued.
A second more soluble analogue (39, DMP 450; Ki = 0.28 nM) was 
developed. Examination of an X-ray crystal structure of a 39-HIV-l PR co-crystal 
confirmed the same general pattern of binding as is shown for compound 37 above. The 
first pKa of the anilino residue (4.6) is high enough for the amine to be protonated in the 
stomach and for formulation as salts of strong acids, but low enough to be neutral in the
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cytosol. As a result, the greatly improved bioavailability of compound 39 permitted its 
entrance into clinical trials.
KO-P-O O-P-OK
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38 39, DMP 450
The development of the cyclic ureas has prompted a great deal of work related 
to these initial compounds. Both analogues of the 7-membered cyclic ureas themselves and 
related cyclic compounds whose design is either based on the cyclic ureas or on the 
principles from which they were designed (see pages 40-41) have been synthesised and 
tested against HIV-1 PR. Some of representative compounds of the many that have been 
found to be potent inhibitors of PR shall be discussed below.
Many alternatives for the surrogate that displaces the flap water have been 
investigated. By the use of an alternative cyclisation reagents to CDI, the thiourea 41 (Kj =
3.1 nM) was synthesised.A lthough the C=S bond is 40% longer than the C=0 bond of 
the parent urea 40 (Ki = 3.6 and thus shortens the length of the hydrogen bonds
to the flap He residues, such hydrogen bonds are weaker and the Ki stays approximately 
the same. Through the use of a guanidinating agent, compound 42 (Ki = 42 nM) was 
s y n t h e s i s e d . B y  a different route, cyclic sulfamide 43 (Ki = 15 nM) has also been 
prepared. The related phosphordiamidate 44 (Ki = 0.6 nM) was found to be a potent 
inhibitor although it was found to be unstable to hydrolysis.
Ph 40: X = 0= 0  41: X = C=S 
42: X = C=NOH 
43: X = SÜ2
44
43
Much work has been reported on modifications to the phenyl rings of Pi and 
Pi in urea 40,1^? through the addition of substituents onto the phenyl ring. Whilst such 
modification has not made drastic differences to the potency of such analogues (no 
inhibitors had a lower Kj than 37), it was seen, as with compounds 38 and 39, that a 
superior cellular antiviral activity profile could be created.
Similarly, work has been done to augment favourable interactions made by P% 
and P2 '. As with the 4-hydroxypyrone series, incorporation of heterocycles in P2/P2 ' has 
been reported. Representative of their class of heterocyclic P2/P2 '-containing cyclic ureas 
are 45 (XU348; Kj = 0.25 nM),i^* and its structurally constrained analogue 46 (Kj = 
18 pM),i^^ which exhibit excellent antiviral activity. Compound 46 was selected for in 
vitro bioavailability studies. Unfortunately, whilst its enzyme inhibitory properties 
translated well to a cell-based assay, poor aqueous solubility has been shown to be 
responsible for disappointing bioavailability. Work is in progress to improve the aqueous 
solubility of compound 46 and similar analogues.
45 46
As has already been mentioned, a number of inhibitors closely related to the 
above series of seven-membered ring cyclic ureas have been reported. Several 
representative examples are discussed below.
Cyclic oxamide 47 (Kj = 40 nM) was synthesised because it possessed a 
structural core complementary to 37 in which the number carbonyl groups and hydroxyl 
groups were reversed.!'^® In a series of azacyclic ureas exemplified by compound 48 
(Kj = 5 pM) deletion of two stereogenic centres and one of the hydroxyl groups possessed 
by the cyclic ureas showed that an element of structural simplification could be achieved
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with retention of excellent activity. Unfortunately, the compounds of this series proved not
to be orally bioavailable.i^hi72
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Two series of compounds have been synthesised through ring contraction 
reactions of 40.^^3,174 These reactions generate inhibitors lacking either one hydroxyl- 
bearing carbon atom such as 49 (Ki = 15 nM) ,^ ^ 3  both hydroxyl-bearing carbon atoms 
such as 50 (Kj = 55 nM) ,^ 7 4  possessed by the parent compound 40. The potency of 
compound 50 is remarkable considering that it contains no hydroxyl group capable of 
hydrogen bonding to Asp25 and Asp25'. It would appear that the phenethyl groups are 
critical for maintaining effective interaction with Pi and Pi- from the condensed five- 
membered ring as the analogue containing benzyl groups at P% and Pi* (51); (K, = 15,500 
nM) is a considerably weaker inhibitor.
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Finally, there are many examples of alternative cyclic structures that attempt to
incorporate the flap water molecule into inhibitor design. Three of these are shown below. 1I
A series of seven-membered cyclic sulfones typified by compound 52 (Kj = 0.6 nM) have jf
45 I
. 1
been shown to be potent N P I s .  1^5 a  combination of database searching and design work 
gave sulfoxide 53 ( K i  = 7000 nM) and similar a n a l o g u e s . ^^6 The naturally occurring 
cyclic urea biotin was substituted to give modest inhibitors such as 54 (K, = 570 nM).^77
PhH2 CO OCHgPh Ph"
OH OH OH
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1 . 6 .6  Other methods of Inhibiting HIV-1 PR
All the inhibitors described so far in section 1.6 are examples of reversible 
competitive inhibitors of HIV-1 PR, i.e. the inhibition may be overcome by the presence of 
excess substrate and the inhibitor competes with substrate for the same target (the active site 
of the enzyme). It is possible to inhibit enzymes in other ways and two such strategies will 
now be briefly discussed.
EPNP (4) is an example of an irreversible inhibitor, that is to say it reacts with 
the catalytic aspartic acid residues to form covalent ester bonds. There have been a number 
of reports of irreversible inhibitors that show greater specificity towards PR than EPNP 
does.i'^8 -1 8 1  Even so, the specificity of these inhibitors for HIV-1 PR is still derived 
principally from their reaction with the catalytic aspartic acid residues. Thus irreversible 
inhibitors can circumvent the problems of resistance associated with the great majority of 
anti-HIV drugs;8.9 i f  the catalytic aspartic acids mutate PR will not f u n c t i o n .^ 9  However 
the reactivity of the epoxides and other electrophilic groups such as a,p-unsaturated 
ketones incorporated into irreversible inhibitors is such that the in vivo efficacy of 
inhibitors containing such reactive chemical groups is greatly diminished. Consequently 
irreversible inhibitors have not received as much attention as the reversible competitive 
inhibitors described eaiiier.
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The target of both reversible and irreversible inhibitors discussed above is the 
active site of HIV-1 PR. However, an alternative approach to the inhibition of multiple 
subunit enzymes is possible. The importance of the dimeric structure of HIV-1 PR to its 
activity has already been stressed. Prevention of the association of the two subunits should 
abolish catalytic activity. As the interfacial |3-sheet portion is highly conserved amongst 
HIV-1 isolates, this approach may have an advantage in delivering inhibitors less 
susceptible to point mutations than many of the inhibitors discussed above. It has been 
noted that 3000 of the combined monomers' surface area is buried upon dimer 
formation and therefore 1500 could be the potential target area to which dimérisation 
inhibitors could bind.79
One of the "inhibitors" chosen to try to complex with this vast target area was 
HIV-2 PR. There have been several reports concerning the study of heterodimers formed 
from one subunit each of HIV-1 PR and HIV-2 PR. In one study, in which these two 
different monomers were mixed, a reduction in the expected activity of the heterodimeric 
enzyme was o b s e r v e d .  1^2 This was thought to be caused by the formation of a disordered 
dimer interface. In a second experiment, one subunit of HIV-1 PR was covalently linked 
to one subunit of HIV-2 PR. The hybrid was fully active suggesting that in contradiction 
to the earlier report, the different subunits folded in a similar fashion, despite the difference 
in sequence homology. This conclusion was supported by a third study which 
investigated the activity of two single chain tethered HIV-1 PR/HIV-2 PR h e t e r o d i m e r s .  
They were found to be just as active towards two distinct substrates as were two other 
tethered HIV-1 PR and HIV-2 PR homodimers.
Despite these ambiguous results, it is clear that disruption of the dimer interface 
is a possible way to inactivate HIV-1 PR. An alternative "protein engineering" strategy has 
been reported. Amino acid substitutions are identified at the dimer interface of HIV-1 PR 
that should prevent self-association of defective monomers and facilitate preferential 
association of heterodimers. 1^ 5 Following the in vitro expression of such HIV-1 PR 
monomers containing such substitutions, the infective capability of HIV-1 was reduced.
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Although the inactivation of HIV-1 PR has been achieved through heterodimer 
formation, this has been reported quite recently (1996). Much earlier, attempts were made 
to inactivate HIV-1 PR through the use of small peptides mimicking the unique sequences 
of its C- and N-termini. This is because it had been calculated that the formation of the 13- 
sheet (see section 1.5.3) is the main driving force behind the association of monomers, 
accounting for around 50% of the interfacial area of the h o m o d i m e r .^ ^  The synthesis and 
testing of peptide fragments corresponding to these terminal sequences have been reported 
by a number of groups and some cause a reduction of HIV-1 PR activity in vitro.
For example, the tetrapeptide Ac-Thr-Leu-Asn-Phe-C0 2 H was found to moderately inhibit 
the dimérisation of HIV-1 PR. The complex formed between it and monomeric HIV-1 PR 
had an monomer-dimer equilibrium constant (K^) of 45 It is difficult to compare
this inhibition favourably with the IQ of dimeric HIV-1 PR (approximately 4 nM).i^^ This 
extremely low value is caused by the two domains of HIV-1 PR forming such a tight 
complex themselves. However, a recent report describes the further improvement in the 
inhibitory power of such peptides such that they are effective inhibitors at sub-micromolar 
concentrations (comparable to the inhibition caused by pepstatin A).^^  ^ The authors also 
found poorer inhibition from peptides derived from N-terminal segments relative to their C- 
terminal counterparts. This was anticipated as such peptides, like the N-terminal segments 
that they mimic, are attached to the outside of the |3-sheet and form only one hydrogen 
bond per peptide linkage. This may be seen by examination of Fig. 1.15. In all cases, 
kinetic studies have identified at least one mode of inhibition, that of the prevention of 
dimérisation. It was therefore possible to show that some of the peptides tested exhibited 
additional competitive (active site) inhibition, sometimes giving rise to the synergistic 
inhibition of HIV-1 PR.188
Whilst the number of reports of research into this aspect of HIV-1 PR inhibition 
is small compared to the number of active site-targeted inhibitors, the strategy holds great 
promise. Work reported within a single paper documented how a series of compounds had 
been improved 1000-fold in potency. 1^8 Encouraging results have recently described the 
use of crosslinked peptides containing the N- and C-terminal regions of HIV-1 PR
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(Fig. 1.16). There has even been a report describing the synergistic effects 
encountered from the tethering of an inhibitor targeted towards the active site to one 
directed towards the interfacial d o m a i n . This is similar to an exceptionally ambitious 
strategy in which peptidonucleosides (a peptidic HIV PR inhibitor tethered to a nucleoside 
HIV RT inhibitor) were found to exhibit weak levels of synergism when evaluated for 
antiviral activity against both PR and RT.^^*
C -term inal sequences
N -term inal sequences
Figure 1.15: Representation o f the use o f cross-linked interfacial peptides in the 
inhibition of dimérisation. The HIV-1 PR homodimer is shown on the 
left. On the right is a complex of monomeric HIV-1 PR complexed with 
an inhibitor comprising C- and N-terminal sequences, linked by a tether of 
varying length.
Finally and most encouragingly, is both the report of an NPI of HIV-1 PR 
dimérisation and the manner in which it was discovered. Consideration of the structures of 
several peptidic inhibitors led to the derivation of a pharmacophore. By searching the 
Cambridge Crystallographic Database, polycyclic triterpenes were identified as potential 
inhibitors. They were subsequently assayed and found to have IC5 0  values of 
approximately 1 |iM.i92 This avenue of investigation must therefore be considered to still 
be in its infancy, with the promise of much more to come.
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1 .7  Conclusion and Prospects for the future
Whilst the discovery of an effective vaccine is still a long way away, research 
has recently demonstrated that attenuated vesicular stomatitus virus, which causes a mouth 
infection in cattle, kills HIV-infected cells in vitro?"  ^ However, a cure is still remote. In the 
meantime, pharmacotherapeutic advances in the treatment of AIDS have delivered an 
armoury of treatments: nucleoside and non-nucleoside reverse transcriptase inhibitors and 
proteinase inhibitors have been approved for use both individually and in combination in 
antiviral chemotherapy. 1^ 4 Combination therapy is currently in use in the clinic, and has a 
number of advantages over monotherapy. Through the use of combinations of drugs 
directed towards a single target, the different spectrum of escape mutations produced may 
prevent cross-resistance. Furthermore, the use of two or more drugs directed towards the 
same or different target enzymes {e.g. PR and RT) in therapeutic regimes normally foster at 
the least additive and sometimes synergistic effects greatly enhancing efficacy over toxicity. 
Unfortunately, such multiple therapy regimes have given rise to increasing concerns about 
their cost to public and private health insurance programmes and thus patients' access to 
pharmaceutical innovation.
The cost of manufacture of the complex HIV-1 PR inhibitors currently approved for clinical 
use is a serious problem. However, the few steps that are required to produce most of the 
NPIs discussed in section 1.6.5 should allow companies to avoid some of the supply 
problems that have plagued earlier peptide-based HIV-1 PR i n h i b i t o r s . These "second 
generation" inhibitors address some of the fundamental problems associated with large 
peptide-like inhibitors (see section 1.6.4). Although some of these were discovered 
through serendipity, others have been discovered by the searching of 3-dimensional 
databases; others have been discovered through rational design. Whatever the origin of the 
lead, subsequent structure-based design has been used to optimise the hydrophobic and 
hydrogen bonding interactions that these inhibitors make with the active site, and is 
continuing to deliver ever more potent inhibitors of HIV-1 proteinase.
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C h a p t e r  t w o  
R e s u l t s  a n d  d is c u s s io n
Results and Discussion
2 .1  Aim of Project and Design of Potential Inhibitors
As a result of the problems encountered in vivo with large and peptidic
HIV-1 PR inhibitors (see section 1.6.4),^^^ and renin i n h i b i t o r s , i t  was decided to
develop small compounds in an attempt to try to overcome these difficulties. Therefore, a 
design similar to that which led to the development of the cyclic urea series of inhibitors 
was undertaken.
When the research described here was started, there were no published reports 
concerning the preparation of small NPIs of HIV-1 PR. The cyclic ureas discussed earlier 
(see section 1 .6 .5.2 ) were only actually published in 1994,1^^ following a poster 
presentation in June of the previous year.l^^
2 . 1 .1  General Considerations in the Design Strategy
The features that were considered when designing our target compounds were 
broadly similar to those that led to the discovery of the cyclic ureas. These are as follows:
• The best inhibitors, including those approved for clinical use (15,19, 20 and 
2 1 ), contain secondary hydroxyl groups which replace the nucleophilic water 
molecule and hydrogen bond to Asp25 and Asp25'. We wished, therefore, to 
incorporate a hydroxyl group into our potential inhibitors.
• We also reasoned that both entropie benefit and specificity towards HIV-1 PR 
over other aspartic proteinases could be derived from the displacement of the 
flap water. It was anticipated that this displacement could be achieved by the 
presence of a heteroatom, which would hydrogen bond to the amide NH group 
of the flap residues Ile50 and Ile50’.
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• We wished to build these structural features within a framework that would 
allow the attachment of Ca-symmetrically related Pi and P% groups. However, 
we wanted to investigate whether effective inhibitors could be developed in the 
absence of other subsite interactions. It was hoped that both the displacement 
of the two water molecules critical to the proteinase enzyme and the presence of 
symmetrically related Pi and Pi- groups would confer sufficient specificity 
towards the PR. By minimising the reliance of inhibition on extensive subsite 
interactions, both the molecular weight and the complexity of synthesising 
potential inhibitors could be reduced.
• Finally, it was hoped that any inhibitors would not be susceptible to resistance 
resulting from point mutations.^»^ However, because the interactions with the 
catalytic apparatus of the enzyme were to be made through hydrogen bonds, 
these inhibitors would avoid the problems associated with irreversible inhibitors 
(see section 1.6.6, page 46).
2 .1 .2  Design of the Basic Template for the Target Compounds
With these structural features in mind, we set out to design appropriate cyclic 
compounds. This process was facilitated through molecular modelling of the interior of the 
enzyme’s active site and was performed with the aid of Dr Wilkie, a computational chemist 
in the Gani group. The enzyme's active site is shown schematically overleaf (Fig. 2.1).
Fig. 2.1 shows the catalytic aspartic acids and flap isoleucine residues, and the 
amino acids that are close to them in the active site. The line drawn between the oxygen 
atoms of the two water molecules forms an axis of Ca-symmetry which almost exactly 
relates each Xaa to its partner Xaa'. Critical to the ability of any cyclic compound to 
displace both water molecules from the active site is the exact position and orientation of its 
water molecule-surrogates. Specifically, these should be located approximately 5.3 -5.6 Â 
from each other to enable effective hydrogen bonding with the catalytic aspartic acids and 
the flap isoleucine residues. There is, perhaps, an element of variability in this distance
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caused by the flexibility of the flaps (see section 1.5.3, page 16). The precise orientation 
of the heteroatom lone pairs is crucial, however, as the isoleucine residues are disposed to 
one another through an axis perpendicular to that which relates Asp25 and Asp25'.
Gly48T
Asp29
X
Gly27
Ile50
I
\ /
H" 'H
Ile50'
I
5.3-5.6 À
P
-  -  -  W -  -
Gly48'T
Asp25 Asp25'
X
Gly27' Asp29'
Figure 2.1: Schematic representation o f the active site o f the enzyme, showing the 
positions of both structural and nucleophilic water molecules
Taking all these factors into consideration, appropriate cyclic structures were 
designed and refined (Fig. 2.2).
Pi T  Pi' OH
Pi T  Pi'OH
B
Y
Pi T  Pi' 
OH
Ph Ph
OH
X = O, S, SO, SO2 , P(0)0H, CH2
D
Figure 2.2: Refinement o f the template for non-peptidic inhibitors
All the structures initially considered were based on a cyclohexane ring 
containing a secondary hydroxyl group designed to interact with the flap isoleucine
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residues. Attention was then given to the heteroatom(s) with which to displace the flap 
water molecule. Both the hydroxyl (A) and carbonyl (B) groups were deemed unsuitable 
because they do not place the lone pairs of the oxygen atoms in the correct orientation for 
hydrogen bonding to the amide bonds of IleSO and IleSO'. Consideration was therefore 
given to the inclusion of a heteroatom within the ring itself (C). Incorporation of an 
oxygen atom was examined first; however, modelling studies suggested that the adjacent 
methylene groups would interact adversely with the residues of the flap. As the C-S bond 
is 0.4 Â longer than the C-O bond (1.8 À va- 1.4 Â), we hoped that the introduction of a 
sulfur atom might alleviate this problem. Additionally, the presence of a sulfur atom would 
enable the displacement potential of the synthetically accessible sulfoxide and sulfone 
analogues to be investigated. The phosphinic acid analogue was not pursued because of 
the focus that subsequently developed on sulfur-containing compounds (see later). The 
manner in which such a phosphinic acid-containing compound might have bound to the 
proteinase enzyme would have proved interesting; peptide-based phosphinic acids are 
potent HIV-1 PR inhibitors, as a result of the strong interaction between the phosphinic 
acid and the aspartic acids. 1^ 9 Finally, we decided to include the methylene-containing 
analogue because it could not hydrogen bond to the amide bonds of Ile50 and IleSO'. This 
would allow the strengths of the interactions which the oxygen- and sulfur-containing 
analogues were making with the flaps to be determined qualitatively.
2,1.3: Borinic and Boronic Acids Inhibit Serine Proteinases
At this stage in the design process, our attention was drawn to the well-known 
inhibition of serine proteinase inhibitors by boronic and borinic acids (Fig. 2 .3 ).200-203
OH OH OHI I I
HO^^'OH R'^'OH
Boric Acid Boronic Acids Borinic Acids
Figure 2.3: The Boron Acids
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Serine proteinases operate by a different mechanism to any of those proposed 
for HIV-1 PR; in the proteolysis that they catalyse, the scissile peptide bond is directly 
attacked by an active site serine residue. A significant feature of the inhibition of serine 
proteinases by boronic and borinic acids is the formation of a tetrahedral boronates and 
borinates ("ate" complexes) between the electrophilic boron atom and nucleophilic serine 
residue (Fig. 2 .4 ) .2 0 2  it is thought that "ate" complexes are good mimics of the transition 
state in amide bond hydrolysis.
HO. OHI.Ser-OH + B-R  ► Ser-O-B-R
X ' X
X = OH: boronic acid X = OH : boronate
X = R' : borinic acid X = R' : borinate
Figure 2.4: Formation o f "ate" complexes between boronic and borinic acids and a 
serine residue
Whilst there aie very few reports of borinic acids acting as inhibitors of serine 
p r o t e i n a s e s ,2 0 0 - 2 0 3  possibly as a result of their susceptibility to atmospheric oxidation,204 
they are generally better than their boronic acid counterparts. For example, compared to 
phenyl boronic acid, diphenyl borinic acid is 30-times more potent an inhibitor of 
a-chymotrypsin and 60-times more potent as an inhibitor of bovine t r y p s i n .2 0 5  This 
difference has been attributed, at least in part, to the higher electrophilicity of the boron 
centre in borinic than in boronic acids. This is reflected in their pKa values (Fig. 2.5).
Ph OH X = Ph, pKg = 6.2
'B-OH + 2 H2 O  ph-B-OH H3 O+ X = OH, p K a = 8 . 8X' X X = Me, pK^  = 8.1
Figure 2.5: Comparison of the acidities of borinic and boronic acids
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As the boron atom in diphenyl borinic acid is more electrophilic, the equilibrium 
of the reaction between it and water lies further to the right and hence the pKa is lower. If 
methyl phenyl borinic acid (X = Me) and phenyl boronic acid (X = OH) are compared, it 
appears that the replacement of a methyl with a hydroxyl group results in greater 
stabilisation of the acid than its conjugate base. It might have been thought that a greater 
stabilisation of the negative charge in the conjugate base by the hydroxyl group wquld 
make phenyl boronic acid the stronger acid.
2 . 1 . 4  Incorporation of the Borinic Acid Functionality into the Template
for the Target Molecules
Although the serine and aspartic proteinases operate by different mechanisms, 
we hoped that the electrophilicity of the boron centre in borinic acids particularly would 
enable such compounds to function as inhibitors by forming "ate" adducts with the catalytic 
aspartic acids of HIV-1 PR and we sought to test this hypothesis. In order to do this we 
wished to synthesise a series of cyclohexanols based on structure D in Fig. 2.2. After 
testing them against the proteinase enzyme in an in vitro assay, it was aimed to establish 
what effect the borinic acid had on inhibition by incorporating it in exchange for the 
hydroxyl group in a directly comparable series of compounds.
2 .2  Synthesis of Cyclic Heteroatom-substituted Cyclohexanols
It was envisaged that the desired alcohols could be prepared by the reduction of 
the C=C bonds present in cyclic alcohols 61-63 (see Scheme 2.1, overleaf). The ketones 
58-60 were all synthesised using the simple base-catalysed aldol reaction (Scheme 2.1) 
developed by C a m p , 2 0 6  a procedure which gave better yields than the acid-catalysed 
syntheses previously r e p o r t e d .202.208 Novel alcohols 62 and 63, which had previously 
been made by C a m p ,2 0 6  through reduction of the carbonyl groups in 59 and 60 with 
sodium borohydride in ethanol, were re-prepared and fully characterised. It was not
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possible, however, to isolate the only known alcohol in this series, 61,209 without it 
decomposing almost immediately. It could be synthesised by reducing ketone 58 [the 
reduction of all three ketones could be monitored by both colour change (bright yellow to 
colourless) and by TLC] with subsequent precipitation from ethanol by the addition of 
water. However, when the white precipitate was left to dry for less than 5 minutes, either 
at the pump or under reduced pressure (the procedure used to produce 62 and 63), it was 
found to decompose consistently. ^H and NMR spectroscopic analysis of the partially 
dry solid revealed that it was the desired product. The spectra contained, amongst other 
resonances, a NMR signal at ô = 81.04 ppm, indicative of the hydroxyl-bearing 
carbon atom, and a ^H NMR signal corresponding to the phenylmethylene protons, upfield 
from its position in the spectrum of its parent ketone 58 [Ôh (CH=C) = 7.84 ppm in 58 
and 6.61 ppm in 61]. The failure to isolate alcohol 61 was a disappointment as it reduced 
our ability to determine how effective the heteroatom present in other analogues was at 
interacting with the flap isoleucine residues.
(i)_
O O OH
X = CHz: 55 58 61X = 0: 56 59 62X = S: 57 60 63
Reagents and Conditions: (i) Benzaldehyde, NaOH, H2 0 -EtOH, 0->25 °C, 1-16 h, 
62-68%; (::) NaBH4 , EtOH, 0->25 °C, then H2O, 92-94%
Scheme 2.1: Preparation o f 4-heterosubstituted cyclohexanols 61-63
Attention was then directed towards the syntheses of the novel alcohols 65, 66 
and 68 (Scheme 2.2). Sulfoxide 64 and sulfone 67 were prepared by modifications to 
published p r o c e d u r e s . 210.211 Compound 64 had previously been made by the oxidation of 
sulfide 60 with sodium metaperiodate,2io but the use of mCPBA was found to result in a
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higher yield. Sulfone 67 could also be synthesised by the oxidation of 60 with mCPBA 
but the reaction gave a higher yield when hydrogen peroxide was used as the oxidant, over 
a period of 3 days.
The novel alcohols 65, 6 6  and 6 8  were prepared in excellent yields by the 
reduction of ketones 64 and 67 with sodium borohydride. Column chromatography using 
2 % ethanol in dichloromethane as the eluant enabled the diastereoisomers 65 (Rp= 0 .1 2 ) 
and 6 6  (Rp= 0.08) to be separated (Scheme 2.2).
Ph
OII
PhPh
64
(i)
O
60
Ph
O
S>t
OH
65
Ph
PhPh.
67
+
Q ■
Sd-
Ph^xgds^^^^x^ ,Ph 
OH 
66
Ph  ^ ,Ph
OH 
68
Reagents and Conditions', (i) mCPBA, CH2 CI2 , 25 °C, 2 h, 77%; (ii) NaBH^, EtOH, 
0->25 °C, 20 min, then H2O, 89-90%; (iii) H2O2 , AcOH, 0->25 °C, 72 h, 59%
Scheme 2.2: Preparation o f 4-heterosubstituted cyclohexanols 65, 66 and 68
Attempts both to crystallise these alcohols and to form potentially more 
crystalline derivatives by reaction with 4-bromobenzoyl chloride were unsuccessful. The 
assignment of stereochemistry was made, therefore, on the basis of their IR spectra. There 
exists a sharp absorption at 3358 cm-  ^ in the spectrum of 65 in contrast to the broader 
absorption at 3367 cm'^ in that of 6 6 . This suggests the presence of an intramolecular 
hydrogen bond in the solid state.^^^ There is also a difference between the two alcohols in
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the stretching frequencies of their C-O bonds. The absorption occurs at 1001 cm-] in 65, 
and at 1035 cm-] in 6 6 . It has been demonstrated,^]^ that the former is characteristic of an 
axial hydroxyl group and the latter of an equatorial. The presence of an axially oriented 
hydroxyl group would permit the formation of an intramolecular hydrogen bond between it 
and the oxygen atom of the sulfoxide if both groups are on the same face of the six 
membered ring. This stereochemical requirement is met in 65.
The five target 4-heterocyclohexanols (62, 63, 65, 6 6  and 6 8 ) were tested 
against the proteinase enzyme using the in vitro assay described in Chapter 3. The testing 
turned out to be near impossible because of the extremely low solubility of most of the 
alcohols in the assay buffer (see also Appendix 2). In particular, 62, 65 and 6 6  proved 
too insoluble to determine an IC50  value. Compounds 63 and 6 8  were found to be 
moderate inhibitors of the enzyme with IC5 0  values of approximately 40 and 80 |aM 
respectively. Whilst these inhibitors were relatively poor compared with those discussed in 
Chapter 1, we were greatly encouraged because of their extremely small size and the 
relatively few interactions that they could be making with the enzyme.
The analogous benzyl analogues (Fig. 2.6) were our original targets as the 
benzyl group most closely mimics the side-chains of the common Pi and Pp residues 
phenylalanine and tyrosine. However Camp had previously failed to synthesise the benzyl
OH OH
Ph
OH OH OH
Ph
62, 63, 65, 6 6  and 6 8 Benzyl Analogues Hydroxybenzyl Analogues
X = O, S, so , SO2
Figure 2.6: Other series o f cyclic alcohols that may inhibit HIV-1 PR
59
analogues of alcohols 62 and 63 by reduction of the C=C bonds using hydrogen gas and 
10% palladium on charcoal. 0^6 Employing this method to try to reduce the C=C bonds in 
olefinic ketones 64 and 67 also proved unsuccessful. Whilst the outcome of these 
experiments was disappointing, modelling studies had suggested that, in alcohols 63 and 
6 8 , sp2 character was forced upon the central six-membered rings by the presence of the 
phenylmethylene substituents. It was thought that the C=C bonds imparted rigidity to the 
central ring and helped align correctly the hydroxyl group and heteroatom(s) of these 
inhibitors with the catalytic aspartic acids and flap isoleucine residues of the enzyme
(Figs. 2.7 and 2.8).
Gly27Asp 25
Asp 29
He 50
L
Gly 48
H
Figure 2.7: Inhibitor 63 docked in the active site of HIV-1 PR, showing the interaction 
with the catalytic aspartic acids and the flap isoleucine residues
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Thus, because it appeared that the presence of the double bonds was beneficial to inhibitor 
potency, it was decided to discontinue attempts to synthesise the a,a'-dibenzyl series of 
alcohols. Modelling studies also helped explain the greater inhibition of the sulfone 6 8  
over sulfide 63. It appears (from a comparison of Figs. 2.7 and 2.8) that the oxygen 
atoms of sulfone 6 8  make for a better interaction with the isoleucine NH groups than does 
the sulfur atom of 63.
Gly 27Asp 25
Asp 29
Gly 48
He 50
o
Figure 2.8: Inhibitor 68 docked in the active site ofHIV-I PR, showing the interaction 
with the catalytic aspartic acids and the flap isoleucine residues
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Whilst these studies were in progress, the first publication concerning the 
identification and synthesis of non-peptidic inhibitors appeared from SmithKline 
Beecham.1'7^ A number of compounds that are extremely closely related in structure to 
ours were disclosed, the most potent being compound 53 (page 46; Kj = 7 pM). Although 
disappointing, it was encouraging that our inhibitors had been discovered entirely through 
rational design, whilst the initial template at SmithKline Beecham had been identified by the 
use of a version of DOCK (page 33). Notably, compound 53 and other related 
compounds all contained hydroxyl groups which aie capable of acting as hydrogen bond 
donors to the amide carbonyl groups of Gly27 and Gly27' (see Fig. 2 .1 ). Also, an 
analogue in which the sulfoxide group was exchanged for a methylene group possessed no 
activity against the proteinase enzyme.
As a result of some of the conclusions drawn from this publication, and from 
modelling studies carried out by Dr Wilkie, we decided to attempt the synthesis of another 
series of cyclohexanols containing hydroxybenzyl side-chains (see Fig. 2.6), before 
embarking on the syntheses of borinic acid-containing compounds. It was predicted that 
the two hydroxyl groups, incorporated into benzyl substituents, would make strong 
interactions with Gly27 and Gly27' (see Fig. 2.1).
2 .3  Attempted Synthesis of Cyclic ftisHydroxybenzylated Heteroatom -
substituted Cyclohexanols
It was thought that the best route to obtaining the desired hydroxybenzyl 
analogues of alcohols 62, 63, 65, 6 6  and 6 8  (Fig. 2.6) would be to follow the sequence 
of reactions outlined in Scheme 2.3. We did not intend to separate the diastereoisomers 
formed in any reaction until the (mixtures of) diastereoisomers of the target ^ijaldols had 
been assayed against HIV-1 PR. In the event of measurable activity, thereby making such 
separations necessary, the use of the TBDMS rather than the TMS group would have been 
employed as it is a less labile group when present during purification by column
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chromatography. However, the TMS group was preferred as it is stable to base (in the 
second aldol reaction), but not to borohydride in the reduction step (Scheme 2.3).
Q O ^  OH O .. OTMS
(i)-(iii)^ f ^ P h  ...... A X :
X" "XT ^X ^
69: X = S
OH O ^  OTMS OH OH  ^ OH
.(j)_,(ii[L i ^ ’ph..... (y).._
70: X = S
Reagents and Conditions: (i) LDA, THF, -70 °C; (ii) benzaldehyde, -70 °C; (iii) 
NH4 Cl(aq.); (iv) U 2S, MeCN, MeaSiCl, 25 °C; (v) NaBH4 , EtOH, then H2 O, 25 °C.
Scheme 2.3: Proposed synthesis o f a,a'-his(hydroxyphenylmethyl)-4-hetero-
cyclohexanols
The synthetic strategy to access the target bis-aldoi compounds requires non- 
aqueous conditions in order for the aldols themselves to be prepared. (Previously, 
benzaldehyde was condensed with cyclohexanone and its 4-thio and 4-oxo derivatives 
using sodium hydroxide as base in aqueous ethanol, giving the dehydrated bis enone 
products). Fortunately, a published procedure existed for the preparation of aldol 6 9 , 
in which it was claimed that it could be formed in 98% by the aldol reaction shown in 
Scheme 2.3. This showed high selectivity towards the anti diastereoisomer (80% d.e,), as 
expected from the Zimmerman-Traxler Model.215 This model predicts that the most 
favourable 6-membered transition state is that in which the maximum number of 
substituents lie in the equatorial conformation (Fig. 2.9, overleaf).
63
Ph
Figure 2.9; Transition state that gives the anti-diastereqisomer 69 in Scheme 2.3
Many careful repetitions of the published procedure for the preparation of 69, 
in which a solution of benzaldehyde in THF is added to the lithium enolate of 
tetrahydrothiopyran-4-one, followed by the rapid (within 30 seconds) addition of saturated 
aqueous ammonium chloride failed to give any of the required products. Only on one 
occasion did a compound, thought to be the bis aldol 70 (Scheme 2.3), precipitate as a 
white solid from an ethereal solution following the reaction workup (in 24% yield). It was 
not, unfortunately, possible to obtain either a mass spectrum to corroborate the crude 
NMR spectrum or to repeat the synthesis.
Some time after the isolation of 70, an air-sensitive product thought to be the 
aldol 69 (crude NMR spectrum) was isolated in 33% yield. However, because a 
considerable amount of time had been unsuccessfully devoted to the same capricious 
reaction, it was decided to start work on the borinic acid-containing target compounds.
2 .4  Syntheses of the Borinic Acid-containing Compounds
The synthesis of a series of borinic acid-containing analogues of inhibitors 63 
and 6 8  required a completely different synthetic strategy to be developed. Initially it was 
hoped that it would be possible to react sulfide 71 with either two equivalents of w-BuLi or 
of magnesium metal to give a ^ wmetallated intermediate which could then be reacted with a 
boron-containing electrophile, such as a boron trihalide or a trialkyl borate. This would 
give, after quenching with ammonium chloride solution, borinic acid 72 (Scheme 2.4).
64 !
(i) èwmetallate
Br Br (lO boron-contammg electrophile B
(iii) aqueous ammonium chloride OH
71 72
Scheme 2.4: Attempted preparation of 72 by a hismetallation strategy
Although a mixture of geometrical isomers of sulfide 71 was prepared in a 
straightforward three-step synthesis from a-bromocinnamaldehyde (Scheme 2.5), it 
proved impossible to purify these isomers by column chromatography. Attempted 
distillation resulted in total decomposition, probably as a result of the elimination of HBr to 
foiTTi the highly conjugated and reactive compound, phenylallenyl sulfide.
O ^ B r
Ph Br Ph Br bI
73 74 71
Reagents and Conditions: (I) NaBH4 , MeOH, 25 °C, 2 h; (ii) PPI13, Brz. CCI4 , 0-^77 °C, 
1 h, 82% (from 73); (iii) Na^S.PHzO, MeOH, 25 °C, Ar, 2 h, 94%
Scheme 2.5: Synthesis o f sulfide 71
The presence of strong base in both of the hismetallation strategies attempted 
almost certainly caused the elimination of HBr from sulfide 71. Both attempts to form a 
dianion of 71 failed. Even when the temperature of the solution of 71 in THF or ether was 
lowered to -100 °C, its colour turned black immediately the M-BuLi was added. After the 
subsequent additions of trimethylborate and then ice-cold saturated aqueous ammonium 
chloride, analysis by TLC indicated the presence of many inseparable products.
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An alternative method of preparing 72 was, therefore, sought and it was 
decided to adopt the dihydroboration protocol developed by Brown et 6 -2 2 0  This 
procedure uses the commercially available reagent monochloroborane, as its dimethyl 
sulfide complex (MCBS), to connect two double (Scheme 2.6a), or two triple 
(Scheme 2.6b) bonds together through a boron atom. It was hoped to extend this 
methodology and cyclise diyne 75, thereby affording the intermediate cyclodialkenyl 
chloroborane (76; Scheme 2.6c), which would give borinic acid 72 on quenching with 
ammonium chloride solution.
JMCBS MCBS
01
MCBSII II
Ph Ph 
75 c
Ph ‘B'ICl
76
Ph
Scheme 2.6: Cyclisation reactions using MCBS
The known sulfide 75,^ 21-223 ^^s prepared as a substrate for such a cyclisation 
reaction (Scheme 2.7).
Ph
.OH
Ph
77
BrH
II (i) . 11 ®  .  11 ®  .  11 1I i ^  1I ^  11 * 11 1
Ph
78
Ph Ph 
75
Reagents and Conditions', (i) n-BuLi, THF, -40—>-10 °C, 1 h, then (CH20)n -10—>25 °C, 
3 h, then H2 O, 90%; (ii) pyridine, PBrs, ether, 0-^50 °C, 2 h, 65%; (iii) Na2 S.9 H2 0 , 
MeOH, 25 °C, Ar, 16 h, 99%
Scheme 2.7: Synthesis o f sulfide 75
66
Unfortunately, several attempted cyclisations of sulfide 75 with MCBS showed 
no evidence for the expected borinic acid 72 but instead a large number of products when 
examined by TLC and NMR spectroscopy. The reaction was attempted using different 
ratios of 72 and MCBS and tried at different temperatures. It had been expected that 
cooling the reaction to -30 °C and below would have been beneficial as this has been shown 
to retard dihydroboration of internal alkynes.^^ Ether was always used as a solvent as it 
had proved to be far superior to THF, because of the strong ability of THF to complex to, 
and deactivate, m o n o c h l o r o b o r a n e .^ ^ ^  This lack of success was disappointing; however, 
although the cyclisation has been reported using diene substrates,2 19 such cyclisations have 
not, to the best of our knowledge, been performed on diynes. The failure of the reaction 
may arise as a result of both a propensity of the diyne to dihydroborate and a failure of it to 
react regioselectively with MCBS. The problem of regioselectivity may be appreciated by 
consideration of the transition state in a hydroboration reaction. In it, the carbon atom not 
being bonded to the boron atom has a slight partial positive charge. In reactions not 
governed solely by steric effects, the regiochemistry is influenced by the stabilisation of 
this charge. In the internal diyne 75, such a partial positive charge may be stabilised by 
either the phenyl group or by the sulfur atom. Hence a number of potential products may 
be envisaged. In an attempt to counter the problem of products resulting from 
dihydroboration of the diyne, the known dienes 79,^25,226 and 80,^27 were reacted with 
MCBS.
P h  P h
79 80
Sulfide 79 (cinnamyl sulfide) was prepared in a similar fashion to sulfides 71 
and 75, by the reaction of cinnamyl chloride with sodium sulfide nonahydrate. Sulfide 80 
was prepared by refluxing indan-2-one in toluene with Lawesson's reagent; the initial
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product of this reaction, indan-2 -thione, then reacts with its tautomeric thioenol resulting in 
the elimination of hydrogen sulfide to give 80. Unfortunately, neither of these products 
gave the desired borinic acids on treatment with MCBS. The failures of all of the 
cyclohydroboration reactions is both difficult to understand and very disappointing. 
Consequently, it was necessary to design alternative borinic acid-containing targets that 
might prove easier to synthesise.
2 .5 Design of Alternative Borinic Acid-Containing Compounds
As the target borinic acids described in section 2.4 may have been too unstable 
to isolate, the logical next step, therefore, was to design of a series of potentially more 
stable target molecules. Diphenyl borinic acid, in addition to its ability to inhibit serine 
proteinases, is also reported to be relatively s t a b l e . ^^ 5 Because of these properties, it was 
decided to modify the first set of target borinic acids (72 being the sulfide-containing 
analogue) to the cyclic diphenyl borinic acids 81-85 shown in Fig. 2.10.
X = CO: 81 
X = SO2 : 82 
X = O: 83
X = S: 84
X = SO: 85
±>
Li Li
I I
or
MgBrMgBr
b2 +
6 h
Trialkyl borate 
or
Trihaloborane
Figure 2.10: Target diphenyl borinic acids, synthons and synthetic equivalents
The synthetic strategy envisaged for these target compounds was more 
straightforward than those attempted in section 2.4. It required the hismetallation of 
compounds containing two phenyl groups joined through an atom or atoms designed to
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mimic the flap water molecule, and reaction of these metallated compounds with one 
equivalent of a boron-containing electrophile, such as a trialkyl borate or a more reactive 
trihaloborane.
The syntheses of these compounds were predicted to be relatively easy. 
However, we were aware that the phenyl groups of these potential inhibitors were 
positioned very close to their centres and, therefore, to the borinic acid and flap water 
surrogates. Such clustering of all the important groups of these compounds threatened to 
endanger their interaction with their respective "partners" within the active site of HIV-1 PR 
{i.e. Si, Si', the catalytic aspartic acids and the amide bonds of the flap isoleucine 
residues). However, the 4-hydroxycoumarin series of inhibitors (page 34) contain a 
benzene ring fused to the central six-membered ring. This reassured us that, whilst our 
template might not deliver potent inhibitors, it would be a valid one with which to test the 
inhibition of HIV-1 PR with borinic acids.
Only four cyclic diphenyl borinic acids have been reported; these were 
described between 1955 and 1961 (compounds 83 and 86-88).^2,8-231 j^st one of these 
(83) was actually characterised as the free borinic acid.^^o the remaining three being 
isolated as their ethanolamine esters. They were all prepared from the reaction of dilithiated 
precursors (because of the tendency of di-Grignard precursors to precipitate from 
s o l u t i o n ) ,^ 3 0  and a variety of boron-containing electrophiles.
86 87
O NHg
83 88
Ethanolamine is very useful for the stabilisation and characterisation of diaryl 
borinic a c id s .204 R reacts readily with them, even in solutions that are not completely 
water-free, to give air-stable and sharp-melting ethanolamine esters. These derivatives are 
known to hydrolyse very rapidly to the parent acids in aqueous s o l u t i o n . 2 0 i . 2 0 4  indeed,
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the actual ethanolamine esters of borinic acids have been assayed directly against serine 
proteinases as the equivalent of borinic a c id s .2 0 1 .2 0 3
2 .6  Syntheses of Cyclic Diphenyl Borinic Acids
The first cyclic diphenyl borinic acid (of the type illustrated in Fig. 2.10) whose 
synthesis was attempted was 81 (X = CO). It was decided to begin with this compound 
for several reasons. Firstly, the inhibition of HIV-1 PR by cyclic ureas had recently been 
disclosed. We had rejected the carbonyl group as a water-surrogate in our original design 
process (Fig. 2.2). It was of great interest, therefore, to synthesise borinic acid 81 and 
compare its potency against the proteinase enzyme with an analogous compound which 
contained a heteroatom or atoms that we thought would better interact with the flap 
isoleucine residues (either compound 82 or 85). Although a diaryl ketone is a poorer 
hydrogen bond acceptor than a urea, it satisfied our principal requirement that it is located 
outwith the central six-membered ring, and should therefore experience fewer adverse 
interactions with flaps than might be predicted to occur with the known diaryl ether- 
containing analogue (83, X = O).
2 .6 .1  Attempted Synthesis of Borinic Acid 81
The retrosynthesis depicted in Fig. 2.10 revealed that a di-anionic synthon was 
required. In order to generate an appropriate synthetic equivalent of this, it was necessary 
to prepare a derivative of 2,2'-dibromobenzophenone (92; Scheme 2.8) in which the ketal 
group had been protected. The dilithiated intermediate could then be generated by lithium- 
halogen exchange.
2,2'-Dibromobenzophenone is a known compound, first synthesised in 
1915.232 The synthesis was extremely lengthy and gave a poor yield. Other syntheses 
have since been published. It seemed that the most expedient of these was that described 
by Lee et al. (Scheme 2.8).233 in this procedure, a benzoin condensation gave 89 which 
was then treated with 0.3 equivalents of potassium bromate in aqueous alkali. Heating of
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this solution under reflux was reported to cause an oxidation-benzilic acid rearrangement to 
give benzilic acid 90, which spontaneously collapses to give benzhydrol 91.
We decided to follow this procedure in order to obtain our desired starting 
material. Benzoin 89 was synthesised through an alternative benzoin reaction that uses a 
thiazolium salt as the catalyst, not the cyanide ion.^ 3 4  y^e use of these conditions to effect 
the benzoin condensation, gave, in addition to the desired product, a small {ca. 5%) but 
consistent amount of an additional product, benzil 94 (see Scheme 2.10, page 73), thought 
to result from oxidation of 89 in situ. All attempts to synthesise benzhydrol 91 from 
benzoin 89 failed. After modifying the reaction conditions, it was found that the use of a 
full equivalent of potassium bromate in this reaction enabled the synthesis of impure 
benzilic acid 90 in approximately quantitative yield. No evidence was ever observed for 
decarboxylation and thus production of benzhydrol 91 This was confirmed by repeating 
these reactions after the independent preparation of 91 (by reduction of 92 with sodium 
borohydride). Comparison of the TLCs of these reaction solutions with that of authentic 
91 showed that it was never formed under the conditions described by Lee et
CHO
Br
( I ) .
Q OH
Br Br Br Br
90
Br Br
92
OH
Br Br
91
Reagents and Conditions'. (:) KCN, DMF, 25 °C, 48 h; (ii) NaOH, KBrO^, H%0, 100 °C, 
20 h; (iii) PCC, Celite, CH2CI2 , 25 °C, 6  h, 40% (over 3 steps).
Scheme 2.8: The preparation of benzophenone 92 reported by Lee et al.^ -?^
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As a result o f the d ifficulty  in obtaining the desired benzophenone 92, an 
alternative Friedel-Crafts approach was tried in which the acylation of bromobenzene with 
2-brom obenzoyl chloride was attem pted (Schem e 2.9); unfortunately, the acylation of 
b ro m o b e n z e n e  on ly  o c c u rre d  at th e  p a ra  p o s itio n  to  g ive  the  know n
2,4'-dibromobenzophenone,235,236 jn 30% yield.
Br'
AICI3
25-» 100 °C, 30 min
Br
93
Scheme 2.9: Friedel-Crafts acylation of bromobenzene
As the Friedel-Crafts approach was being investigated, the other publications 
describing the synthesis of 92 were examined. The report from Bickelhaupt et gave 
more experimental details than that from Lee et al?''^ '^  and also described the isolation and 
characterisation of intermediates. Although the latter did not cite the publication of the 
former, Bickelhaupt et a l reported a very similar preparation of 92 (Scheme 2 .1 0 ),^^? the 
principal difference being the greater reliability of their work. Additionally, it was reported 
that benzilic acid 90 could be synthesised from the benzil 94, which in turn was prepared 
by the oxidation of the benzoin 89 with nitric acid (Scheme 2.10). Furthermore, it was 
also reported that benzilic acid 90 could be made by treating benzoin 89 with potassium 
bromate in aqueous alkali, as we had found, but in low (24%) yield. No mention was 
made of the benzhydrol 91.
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Q OH
Br Br
HO^  ^COgH
^  (iii).
Br Br Br Br
89 94 90 92
Rea-gents and Conditions: (i) HNO3 , 100 °C, 1 h, 60%; (ii) KOH, Et0 H-H2 0 , 78 °C, 
15 min, 72%; (iii) NaBiOg, AcOH, 50-60 °C, 5 h, then H3PO4 -H2 O, 25 °C, 16 h, 84%
Scheme 2.10: The preparation o f benzophenone 92 reported by o f Bickelhaupt et al.^ -?^
Each step described by Bickelhaupt et al. worked well and thus adequate 
quantities of benzophenone 92 were prepared. However, after all the effort had been made 
to produce 92, a considerably more efficient synthesis was discovered. The purification of 
both products from the thiazolium-catalysed benzoin reaction (benzoin 89 and benzil 94) 
was not easy; however, once a mixture of them was separated from the residue of the 
benzoin reaction, it proved possible to perform the oxidation-rearrangement reaction 
described above [Scheme 2.8 (ii) or Scheme 2.10 (ii)] on this mixture. The aqueous 
solution of the reaction had to be acidified in order to extract the benzilic acid from it. 
However, it transpired that if concentrated (rather than dilute) hydrochloric acid was used, 
the solution became (unsurprisingly) extremely hot and (surprisingly) was found to contain 
benzophenone 92. This represented a pleasing 60% yield over the two steps. 
Unfortunately, the resynthesis of 92 that led to this discovery was necessitated by its 
decomposition during repeated attempts to protect its carbonyl group. The carbonyl group 
must be protected before exposure to organolithium agents, because its electrophilicity 
results in it being attacked during such reactions.^^s The attempted protection with 
ethylene glycol catalysed by p-toluene sulfonic acid in refluxing toluene, with azeotropic 
removal of water, was not successful. A second procedure developed specifically for the 
protection of diaryl ketones,239 was attempted. This procedure, in which triflic acid 
(TfOH) is used as the acidic catalyst, had allowed the protection of 
2 ,2 '-dichlorobenzophenone (95) to give ketal 96 (Scheme 2.11).239 However, the use of
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this procedure to protect compound 92, failed to deliver any of the desired product, even 
after heating under reflux for 1 week.
MeO. OMe
Reagents and Conditions: (MeO)3CH, MeOH, MeNOg, then TfOH, 5—» 101 °C, 36 h, 92% 
Scheme 2.11: Protection of the carbonyl group in a hindered diaryl ketone
This was another considerable setback. The original reason for wanting to 
synthesise a compound in which the carbonyl group of 92 had been protected was to 
enable the formation of a dilithiated species by lithium-bromine exchange. This di-anion 
was to be reacted with an appropriate boron-containing electrophile. Thus, the most logical 
next step was to prepare ketal 96 and use it in the attempted synthesis of borinic acid 81. 
As lithium-chlorine exchange is rarely successful, this approach required that 96 be used to 
prepare a di-Grignard reagent, rather than its dilithiated derivative.
Benzophenone 95 is a known compound, prepared in four steps from 
2 - c h l o r o b e n z a l d e h y d e , ^ 4 0  a synthesis similar to that of 92 shown in Scheme 2.10. 
However, it proved possible to synthesise it in two steps (Scheme 2.12) by the shortened 
procedure described earlier for the synthesis of 95.
(!), (ii)
Cl 01
95
Reagents and Conditions: (1) 3-ethyl-5-(2-hydroxyethyl)-4-methylthiazolium bromide, 
EtsN, EtOH, 78 °C, 5 h; (ii) NaOH, KBr0 4 .H 2 0 , 100 °C, 5 h, then conc. HCl, 63% 
(over two steps).
Scheme 2.12: Synthesis o f 2,2'-dichlorobenzophenone 95
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Unfortunately, the ketalisation of benzophenone 95 shown in Scheme 2.11 
could not be repeated, despite several attempts in which the reaction was left to heat under 
reflux for up to a week, and in which differing amounts of triflic acid were used. Because 
of the failures to protect the carbonyl groups in either 92 or 95, there was no alternative 
but to attempt the synthesis of the remaining target borinic acids 82-85.
2 . 6 . 2  Synthesis of Borinic Acid 83
The principal target borinic acids were those which contained heteroatoms 
projected from the ring {i.e. ketone 81, sulfone 82 and sulfoxide 85). However, as no 
borinic acids had been made thus far, it was decided to attempt the synthesis of the known 
oxygen-containing borinic acid 83.^30 it was first synthesised by the reaction of 2 ,2 '- 
dilithiodiphenyl ether with either w-butyl metaborate or boron trifluoride etherate to afford 
crude 83 in yields of 42 and 23% respectively (Scheme 2.13).
(I), (ii) or (iii)
Reagents and Conditions: (i) n-BuLi, ether, 35 °C, 72 h; (ii) «-butyl metaborate, 35 °C, 
2 h, 42% [over (i) and (ii)]; (iii) Bp3 .0 Et2 , 35 °C, 1 h, 23% [over (i) and (iii)].
Scheme 2.13: The preparation o f borinic acid 83 reported by Davidson and French^^^
It is useful at this point to discuss how the intermediate 2,2'-dilithiodipheny 1 
ether in Scheme 2.13 was produced. The lithiation took a considerable time, but occurred 
only at the positions ortho to the oxygen atom. Highly regiospecific lithiations such as 
these are known as directed or "ortho" lithiations. They arise from the ability of the "ortho 
directors" to withdraw electron density away from the point of lithiation, to co-ordinate
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with the lithiating agent or both. Four classes of ortho directors that participate in the 
deprotonation shown in Fig. 2.11 have been d e s c r ib e d .^ ^ 8  These are listed in ascending 
order of effectiveness.
^  "Li'
Figure 2.11: Ortho lithiation; n = 0-2 andX  = a directing group 
Class 1: Co-ordination only
When n > 0, the effect of the saturated carbon atom(s) on the acidity of the ortho proton is 
considered neutral. However, X is capable of co-ordinating to the alkyl lithium species if it 
possesses non-bonding electrons. Most effective in this class are amines; much less 
effective are alkoxides, acetals and ketals.
Class 2: Electron-withdrawing only
When X is a halogen, or a carbonyl or trifluoromethyl group, the acidity of the ortho 
proton is markedly increased. However, these groups have very little ability to co-ordinate 
to the lithiating agent.
Class 3: Electron-withdrawing groups with moderate co-ordination potential
In this class, most of the driving force towards deprotonation is the withdrawal of electron 
density from the acidic centre, an effect enhanced upon co-ordination to the lithiating agent. 
Examples of such ortho directors are -NR^R^, -SR «  -OR «  -S0 2 -aryl.
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Class 4: Electron-withdrawing groups with good co-ordination potential
Groups such as -CONRlR^ and 2-pyridines co-ordinate through the nitrogen lone pair in 
addition to their electron-withdrawing properties and are very effective ortho directors.
Returning to the preparation of borinic acid 83, its known s y n t h e s i s , was 
modified to a procedure using trimethyl borate as the electrophile. This did afford the 
desired product, but in a yield of less than 5%. We thought that there were two reasons for 
this poor yield: (a) the extremely long time taken to effect the dilithiation of diphenyl ether 
and (b) the relative volatility (bp = 6 8  °C) of the borate. Consequently, the stronger base 
5 -BuLi was used to reduce the time taken to dilithiate diphenyl ether, and a less volatile 
borate (tri-«-butyl borate, bp = 230 °C) was used. These efforts were successful and 
resulted in us obtaining the desired compound 83 in 61% yield.
2 . 6 . 3  Synthesis of Borinic Acid 84
The conditions successfully used to synthesise borinic acid 83 were used to try 
to make the sulfur-containing analogue 84. Unfortunately, these proved unsuccessful, 
even when the base r-BuLi was used. Compared to diphenyl ether, the poorer reactivity of 
diphenyl sulfide towards organolithium compounds was not surprising as the sulfur atom 
is not able to co-ordinate to lithium as effectively as the oxygen atom. Additionally, its 
electron-withdrawing capability is poorer. Probably because of these reasons, there are no 
reports that claim that 2 ,2 '-dilithiodiphenyl sulfide can be made by direct lithiation of 
diphenyl sulfide. Instead, it is synthesised by the treatment of 2,2'-dibromodiphenyl 
sulfide (99) with w-BuLi. '^^ -^^^  ^ A thorough search revealed only one published synthesis 
of sulfide 99, shown in Scheme 2.14 overleaf.
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Reagents and Conditions: (i) NaHCOg, DMF, 70 °C, 4 h, 96%; (ii) SnCl2 .2 H 2 0 , 
HCl-EtOH, 70-80 °C, 4 h, 70%; (iii) HOSO2 ONO, 16-20 °C, 0.5 h, then CuBr, 45% HBr 
in AcOH, 80 °C, 1 h, 35%
Scheme 2.14; Synthesis o f sulfide 99^ ^^
As this seemed a rather involved synthesis for the complexity of 99, several 
attempts were made to develop a simpler route. It was anticipated that it would be possible 
to synthesise a di-Grignard reagent from 2,2'-dichlorodiphenyl sulfide (102), which, it 
was hoped, could be synthesised by the reduction of 2 ,2 '-dichlorodiphenyl sulfone (1 0 1 ). 
Sulfone 101 is a known compound which has been prepared by the oxidation of sulfide 
102,245 which itself is made by a synthesis closely resembling that for 99 shown above 
(Scheme 2 . 1 4 ).245 However, we hoped that a one step synthesis of 2-chlorodiphenyl 
sulfone (100; Scheme 2.15),246 could be adapted to afford 101.
Cl 01 01 01
Reagents and Conditions: (i)246 \ eq. «-BuLi, ether, -30-(-40) °C, 1 h, then 1 eq. 
PhS0 2 Cl, 30 min, 90%; (ii) 2.2 eq. «-BuLi, THF, -30-(-40) °C, 0.75 h, then 2.5 eq. 
PhS0 2 Cl, 30 min, 99%.
Scheme 2.15; Attempted synthesis o f sulfide 102
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The synthesis o f 101 from  diphenyl sulfone proceeded in alm ost quantitative 
yield. However, all attempts at the selective reduction of its sulfone group failed. Because 
o f the susceptibility o f aryl chlorides to reduction by the reagents used m ost comm only to 
reduce sulfone groups, fo r exam ple DIBAL,247 it was not possible to use them  in this 
instance. O f the m ethods attem pted, the reflux of sulfone 101 with sam arium  iodide in 
T H F-D M PU  and TH F-H M PA,248 and w ith elem ental sulfur in ethanol,249 left the 
com pound unchanged. The reduction o f the sulfone with DIBAL was attempted; however, 
an inseparable m ixture o f products resulted, probably from  unselective de-oxygenations 
and dechlorinations effected by this reductant.
Following the failure to synthesise sulfide 102, the sulfide 99 was prepared 
using the procedure outlined in Scheme 2.14. This worked well except for the final 
Sandmeyer reaction, the yield of which could not be increased above 35%. Sulfide 99 was 
then converted to the desired borinic acid 84 in a yield of 67%, using a method similar to 
that shown for the preparation of 83 in Scheme 2,13. The lithium-halogen exchange 
reaction proceeded very quickly and, at -70 °C, was found to be complete within 5 minutes.
For reasons discussed later, greater quantities of both borinic acid 84 and 
sulfide 99 were required than could satisfactorily be made using the known low-yielding 
synthesis of 99 (23% over three steps). Because of both this, and the fact that the 
synthesis is probably intolerant of additional substitution on the aromatic ring, four further 
methods of preparing 99 were investigated. These are outlined below:
(1) Arylation ofarene thiolate ions
Aryl iodides are known to react with the thiophenoxide ion in liquid ammonia 
under irradiation to form diaryl sulfides in high yield.250 However, under the reaction 
conditions, several 1 ,2 -dihalobenzenes afforded disubstitution products,25i and hence this 
method was ruled out.
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(2) Reaction o f arenediazonium tetrafluoroborates with excess arenethiolate
This procedure has been used to give high yields of diaryl s u l f i d e s . 2 5 2  
Disappointingly though, the reaction between diazonium salt 103,253 and 
2 -bromothiophenol gave an extremely poor yield (8 %) of 99 and was not pursued further 
(Scheme 2.16).
NH2 N2+BF4"a  ^aBr Br (ii) Br Br
103
Reagents and Conditions: (i) NaN0 2 , HCl(aq.), NaBp4 , 0-5 °C; (ii) 2-bromothiophenol, 
NaHCOg, DMF, 90 °C, 30 min, 8 % (over two steps).
Scheme 2,16: Preparation o f sulfide 99 from diazonium salt 103
(3) Nucleophilic substitution of unactivated haloarenes with thiolate ions
In the nucleophilic aromatic substitution of chloride by thiolate shown in the 
first step of Scheme 2,14, the displacement is activated by the presence of the nitro group 
in the ortho position. It is also known that unactivated aryl halides can be displaced by the 
thiolate ion in polar solvents such as DMF and DMSO at high temperatures.254 As the rate 
determining step in nucleophilic aromatic substitutions is almost always the attack of the 
nucleophile, strongly electron-withdrawing substituents such as fluorine or NO2 are the 
"best" leaving groups. With these considerations in mind, 2-bromothiophenol and 
l-bromo-2 -fluorobenzene were reacted using conditions modified from those used to 
prepare 97 (Scheme 2.17, overleaf).
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Of * X) ^  Of "to * Of'TO "Br Br Br Br Br F
99 104
Reagents and Conditions: NaHCOa, DMF, 153 °C, 10 h.
Scheme 2.17: The reaction of 2-bromothiophenol and l-bromo-2-fluorobenzene
Analysis of the products from this reaction by mass spectrometry showed that 
99 had been formed. Despite this, it proved impossible to separate it from by-products of 
similar polarity such as 2-bromo-2'-fluorodiphenyl sulfide (104) and other material 
thought to be disulfides. Attempting to use this mixture to prepare borinic acid 84 was 
unsuccessful and this method of preparation was not pursued further.
(4) Reaction of 2-bromophenyllithium with sulfur dichloride
A synthesis of 2-bromophenyllithium (105) in > 95% yield by the lithiation of 
1,2-dibromobenzene with n-BuLi has been reported by the group of Tamborski 
(Scheme 2.18).255.256 order to prevent lithium halide elimination and thus formation of 
benzyne, this reaction must be performed in a mixture of THF and ether and cooled to 
below -110 °C. At this temperature, 2-bromophenyllithium is stable for at least 2 h, but it 
is extremely temperature sensitive; if warmed to -90 °C, almost all of it decomposes to give 
at least 17 products.255 However, at -110 °C, it has been reacted with a number of 
electrophiles including several chlorosilanes to give silylated products in good yields. We 
hoped that it would be possible to react 2 equivalents of 105 with sulfur dichloride to 
afford 99 in one step (Scheme 2.18). Although, only one equivalent of 105 had been 
found to react with dichlorodimethylsilane (Me2SiCl2),^^  ^this had been attributed to the 
steric bulk of the methyl groups and it was hoped that the reaction between 105 and sulfur 
dichloride would occur with a stoichiometry of 2 :1 .
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Br BrBr Br
105
Reagents and Conditions: (i) w-BuLi, THF-ether, -110 °C, 1 h; (ii) SCI2 , -110-^25 °C, 
16 h, 37% (of 99) and 15% (of 106).
Scheme 2.18: Expedient synthesis o f sulfide 99
This experiment proved very successful. Whilst the optimised yield of sulfide 
99 using these conditions was a modest 37%, this was found to be the best procedure and 
was used repeatedly to synthesise 99. Although the temperature of the reaction was 
maintained between -120 °C and -110 °C (with the use of a slurry of liquid nitrogen and 
pentane), there are two possible reasons for the relatively poor yield. Firstly, even with the 
slow addition of sulfur dichloride, it was difficult to prevent the temperature from rising 
several degrees (although it was possible to prevent it from rising above -110 °C). 
Secondly, the electrophile is known to disproportionate to sulfur monochloride and 
chlorine.
2SCI2 ------------ S2CI2 + CI2
Even although the sulfur dichloride was distilled immediately before its use 
(after the «-BuLi had been added to the solution of dibromobenzene), its disproportionation 
caused partly by the need to add it very slowly to 105 led to the isolation of the disulfide 
106 in around 15% yield. It proved impossible to obtain a pure sample of this disulfide; 
its identification was confirmed by the use of mass spectrometry. Considering the rather 
unusual reaction conditions, the incorporation of around 70% of the sulfur dichloride into 
99 and 106 was pleasing. Despite its unintended synthesis, two attempts were made to 
convert 106 to borinic acid 107 using the same conditions that had been used to prepare 
borinic acid 84 from sulfide 99. These did not work because of the formation of many 
products during the attempted dilithiation. The failure of the lithiation step was almost
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certainly caused by the electrophilicity of the disulfide bond; it was probably attacked by 
either the «-BuLi itself or by monolithiated 106.
s - s
107
2 . 6 . 4  Attempted Synthesis of Borinic Acid 82
As borinic acid 83 was being prepared, attempts were being made to synthesise 
the cyclic borinic acid that contained a sulfone group (82). We envisaged that this would 
be a relatively straightforward process because, as the phenylsulfonyl group is an 
extremely good ortho director, the intermediate 2 ,2 '-dilithiodiphenyl sulfone can be easily 
prepared. Curiously, this dilithiated species is reported to be made by the treatment of 
diphenyl sulfone with three or four equivalents of w-BuLi.257 The necessity for one or two 
extra equivalents of w-BuLi was attributed to the formation of a stable complex between the 
sulfone group and the butyl lithium molecule.^^^
The lithiation of diphenyl sulfone was achieved by treating a solution of it, 
cooled to “30 °C in ether, with n-BuLi, to give a characteristically bright red solution,^^^ 
which decolourised upon quenching with D2O. The use of a moderately low temperature is 
essential as the dilithiated species was found to decompose at temperatures above -20 °C. 
The effect of different numbers of equivalents of n-BuLi on the degree of lithiation was 
investigated by comparing of the NMR spectra of the D2 0 -quenched material: the ortho 
protons of diphenyl sulfone stand distinct {ca. 0 . 2  ppm downfield) from the meta and para 
protons. This ratio (which is 4:6 in diphenyl sulfone) is lower in deuterated material. 
Treatment with one equivalent of n-BuLi led to the incorporation of one deuterium atom. 
However, in contrast to the reported procedure, we found that four equivalents of n-BuLi 
were not required to lithiate diphenyl sulfone twice; only two equivalents were needed.
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Indeed, the use of three and four equivalents led to the incorporation of three deuterium 
atoms into diphenyl sulfone.
After establishing exactly how to synthesise 2,2'-dilithiodiphenyl sulfone, 
attention was turned to reacting it with boron-containing electrophiles. Because of 
problems experienced with an impure batch of starting material, it was decided to 
synthesise the diphenyl sulfone-derived boronic acid (108) by reaction of monolithiated 
diphenyl sulfone with a trialkyl borate before attempting the synthesis of the more 
challenging borinic acid (82). After a number of experiments, in which the temperature of 
the reaction was varied, and two electrophiles (triwopropyl borate and trimethyl borate) 
were used, the highest yield obtained was 32% of 108 (Scheme 2.19). If the reaction was 
allowed to warm above -30 °C before quenching, no products were isolated. Changing the 
solvent to THF was not considered as 2,2'-dilithiodiphenyl sulfone, in which the main 
interest lay, had been found to be insoluble in it. Despite its insolubility, however, it was 
discovered much later that reactions involving dilithiated diphenyl sulfone worked better in 
THF. Through the use of this solvent and by quenching with saturated aqueous 
ammonium chloride, the yield of 108 was increased, to a still moderate (58%).
(i) and (ii)
or (iii) and (iv) B-OH
Reagents and Conditions: (i) «-BuLi, ether, -30 °C, 10 min, then ->-70 °C; (ii) B(0 PF)3 , 
-70->-30 °C, 40 min, then H2 O and HCl(aq.), 32%; (iii) w-BuLi (1 eq.), THF, -30 °C, 
30 min, then ->-70 °C; (ii) B(0 Pd)3 , -70->-30 °C, 30 min, then NH4 Cl(aq.), 58%
Scheme 2.19: Preparations of boronic acid 108
Despite the unsatisfactory preparation of 108, we decided to attempt the 
synthesis of the desired borinic acid 82. This proved to be another unsuccessful
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endeavour. The only product initially isolated was the boronic acid 108. We thought that 
the use of a more powerful electrophile might enable the attack of the second lithiated 
carbon atom on the boron atom (Fig. 2.12). Unfortunately, when a solution of boron 
trichloride in heptane was added to a solution of 2 ,2 -dilithiodiphenyl sulfone, cooled to 
-70 °C, total decomposition resulted. The inability to form the second carbon-boron bond 
was thought perhaps to result from the formation of a chelate ring from the interaction 
between the lithium and sulfonyl oxygen atoms (Fig. 2.12). In an attempt to enhance the
B '  .
Figure 2.12: Prevention of synthesis o f 82 by the formation of a stable chelate ring
reactivity of this lithiated intermediate, the reaction was performed in the presence of 
TMEDA. This experiment was analysed by TLC by extracting small aliquots from the 
reaction vessel and quenching them with dilute hydrochloric acid. TLC indicated the 
presence of a previously undetected compound. However, TLC examination of the organic 
solution resulting from the treatment of the reaction with dilute hydrochloric acid showed 
no sign of this product. Only when the reaction solution was added to ice-cold dilute 
hydrochloric acid was the isolation of a small quantity of it made possible. Subsequent 
analysis showed it not to be the desired borinic acid (82). Instead, it was thought to be a 
small quantity (7%) of the diboronated product 109. The assignment of this structure was 
made on the basis of its ^H, and NMR spectra, and by the presence of an m!z ratio 
of 289 Da in its mass spectrum that corresponds to [M + H]+.
109
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The isolation of this product was perplexing. In addition to 109, the boronic 
acid 108 was also formed in 40% yield. Furthermore, greater than 50% of the diphenyl 
sulfone used in the reaction was recovered intact. This led to the hypothesis that 
intermolecular proton transfers between intermediates might be operating (Scheme 2.20).
A ddition  o f 
2 equivalents 
o f  n-B uL i
U nchanged
d ianion
Dropwise
addition
ofB(OPd)3
C harge equilibration  
ach ieved  through in ter­
m olecu lar proton transfers
Li
Li B 110
R ing  closure: 
rap id  step
111
A ddition  o f  rem aining 
B (0 P r‘)3,then w orkup 
o f reaction
HOsg.OH
B-OH
HO
108
+ R eturneddiphenyl
sulfone
Scheme 2.20: Possible mechanism for the formation of diboronated product 109
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We thought that, as the borate is added dropwise, it reacts with the 2,2'-dilithiodiphenyl 
sulfone species to afford the boronate 110. The rapid ring closure of this intermediate, 
caused by the intramolecular attack of the remaining carbanion on the boron atom, could 
generate a charge imbalance between borinate 1 1 1  and the remaining 2,2'-dilithiodiphenyl 
sulfone. Equilibration of charge could be achieved by an intermolecular proton transfer. 
This would explain the isolation of 108 and 109, as well as unchanged starting material. 
The reason for the formation of different quantities of 108 and 109 probably arises 
because of the lower stability of 109, indicated by the difficulty in its isolation.
Experiments were undertaken to circumvent this problem, if it was indeed 
occurring, in two different ways. In one, the dilithiated diphenyl sulfone was added to a 
chilled solution of triwopropyl borate; in a second, n-BuLi was added to a chilled solution 
of both the borate solution and diphenyl. Nevertheless, in neither case was the desired 
borinic acid isolated.
Because trialkyl borates appeared to be too unreactive to allow the formation of 
the desired cyclic structure, and boron trichloride appeared to be too reactive, the use of 
boron-containing reagents of intermediate electrophilicity was considered (Fig. 2.13).
ORI Cl1 011 011
RO'^'OR RO"^"OR RO^^'GI o r ^ 'o i
Trialkyl Chlorodialkoxy Dichloroalkoxy Boron
borates borane borane trichloride
ILo'B-CI
112, B-Chloro- 
catechol borane
Figure 2,13: Different boron-containing electrophiles
The only commercially available dichloroalkoxyborane or chlorodialkoxyborane 
is B-2-chlorocatecholborane (112). Addition of this to a solution of 2,2'-dilithiodiphenyl 
sulfone, cooled to -70 °C, again resulted in total decomposition. Rather than undertake a
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study of the syntheses and reactivities of different chlorodialkoxy boranes and 
dialkoxychloro boranes, we decided to investigate alternative ways of making the target 
borinic acid.
Diphenylborinic acid has been prepared in 42% yield from tetraphenyl tin by its 
treatment with diborane and hydrolysis of the resultant borane (Scheme 2 .2 1 ).^^9 We 
envisaged, therefore, that the target borinic acid 84 could be prepared by similar treatment 
of the known organotin compound (113).260 However, this was not pursued for two 
reasons. Firstly, the yield of 113 (from 2,2'-dilithiodiphenyl sulfone and stannic chloride) 
was only 15%.260 Secondly, it had not been possible to prepare borinic acid 115 from the 
related tetraaryl tin compound (114), implying that the ortho substituent had prevented the 
transmetallation reaction from occurring.
9OH
113
OH
84
CHg
Sn114 X 115
Reagents and Conditions: B2H6 , THF, 65 °C, then water. 
Scheme 2.21: Preparation of borinic acids from tetraaryl tin compounds
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The next approach that we pursued was the attempted oxidation of the sulfur 
atom in the borinic acid synthesised previously (84). An advantage of this approach was 
that it might have enabled the sulfoxide-containing borinic acid 85 to be prepared. It had 
proved impossible to lithiate diphenyl sulfoxide in the manner attempted with diphenyl 
sulfone. This is known to result from the attack of the sulfoxide group by the
organolithium.261
W hilst aware o f the susceptibility o f boron-containing com pounds towards 
oxidation, the use of sodium  periodate in an oxidative cleavage reaction in the presence of a 
b o ro n a te ,262 prom pted us to use this w ell-know n sulfide oxidant,263 in the attem pted 
oxidation o f the sulfide functionality in borinic acid 84. No oxidation was observed in 
either aqueous m ethanol or aqueous acetone. This may have resulted from  the very poor 
insolubility o f 84 in these solutions. To try to overcom e this insolubility problem , the 
reaction was perform ed in the presence of Aliquot 336 under phase-transfer conditions,264 
using dichlorom ethane and w ater as solvents. These conditions resulted  in the slight 
decom position of 84, but otherwise failed to alter the starting m aterial; consequently other 
oxidants were tried. The use o f sodium  hypochlorite, using phase-transfer catalysis also 
failed  to affect 84 in any w ay.264 Furtherm ore, the use o f Oxone®,265 and sulfuryl 
chloride,266 did not affect the starting material. Attempted oxidation with mCPBA gave an 
inseparable m ixture containing m any products, probably as a result, at least in part, of the 
oxidation o f the boron atom. Finally, the oxidant dim ethyldioxirane was prepared (116, 
Schem e 2 .2 2 ),267,268 and its ability to oxidise the sulfide functionality o f borinic acid 84 
was investigated.
CH3COCH3 + KHSO3 --------------------------- T C  1160-0
Reagents and conditions: H 2O, NaHCOg, pH ~ 7.4, 5—>25 °C, ca, 5%
Scheme 2.22: Preparation of dimethyldioxirane, 116
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However, although the dimethyldioxirane was shown to be capable of oxidising 
diphenyl sulfide, no oxidation of compound 84 was observed when treated with it. In an 
attempt to understand the inability to oxidise the sulfur atom in borinic acid 84, it was 
crystallised and X-ray diffraction data obtained (see Fig. 2.14).
IT T l
01 117
Figure 2.14: Two representations of 117 generated from crystallographic data
Two aspects of its structure were immediately clear from the data obtained:
• Firstly, the compound thought to have been borinic acid 84 had in fact been 
isolated as the borinic anhydride (117). This was in agreement with both the 
micro-analytical data and the IR spectrum which did not contain an absorption 
corresponding to BO-H. The NMR spectrum of 117, however, does 
contain a singlet (Ô = 9.33 ppm) that corresponds to the acidic proton of the
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borinic acid. Presumably borinic acid 84 is formed through the hydrolysis of 
borinic anhydride 117 by the traces of water present in deuterated DMSO. It 
proved to be impossible to obtain a NMR spectrum of the anhydride itself.
• Secondly, it had been thought that the failure to oxidise the sulfur atom might 
have been caused by its forming an intramolecular Lewis acid-Lewis base 
complex with the boron atom. This, however, would have resulted in the 
puckering of the central ring; examination of the structure reveals it to be almost 
totally flat (see Fig. 2.14). It may well be that this ring is aromatic as has been 
proposed for the central ring of the analogous oxygen-containing borinic acid 
83,230 The involvement of lone pairs of the sulfur atom in aromatic bonding 
may explain, in part, the resistance of the sulfur atom to oxidation.
Such was the interest in the synthesis of borinic acid 82, we decided to 
investigate other methods of preparation. As one of the problems in the initial approach 
had been effecting ring closure through the use of boron-containing electrophiles, an 
alternative cyclisation strategy was envisaged. We thought that it might be possible to 2,2'- 
dilithiate the A,iV-dimethylethanolamine ester of diphenyl borinic acid (118),269 before 
treatment with either thionyl chloride or sulfuryl chloride. This would achieve ring closure 
with the use of sulfur-containing electrophiles (Scheme 2.23). It was thought that the 
pendant N, A-dimethyl(ethyl) group might act as an ortho director. Unfortunately, this 
seemed not to be the case as quenching, with D2 O, a solution of 118 in THF that had been 
treated with two equivalents of n-BuLi did not show any sign of deuterium incorporation.
(i) rt-BuLi
I____I
118
Scheme 2.23: Alternative strategy to synthesise borinic acids 82 and 85 using 
protected diphenyl borinic acid
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One of the causes of the failure to prepare borinic acid 82 by oxidising the 
sulfide in 84/117 is thought to have been the susceptibility of the boron atom to oxidation. 
This had precluded the successful use of oxidants such as mCPBA and alkaline hydrogen 
peroxide. It was thought that if this ability of boron to be oxidised could be exploited, it 
might be possible to prepare 82. By the formation of a cyclic borane derived from 
diphenyl sulfone, followed by the selective oxidative cleavage of the alkyl or aryl group not 
derived from diphenyl sulfone, we hoped to realise this goal (Scheme 2.24).
" ^  Form ation  o f  O xidativeI J  — - - - - -   I I^  borane cleavage
R
R = Me:119 82
R = Ph: 120
Scheme 2.24: Potential synthesis of target 82 by an oxidative cleavage reaction on a
diphenyl sulfone-derived borane
In principle, "R" in Scheme 2.24 could be any group. However, it was decided 
to try to make borane 119, in which R = Me, first. The use of a methyl-containing 
electrophile was expected to minimise any steric hindrance during the cyclisation reaction. 
To try to prepare 119, 2,2'-dilithiodiphenyl sulfone was treated with the commercially 
available reagent diwopropoxymethylborane, followed by the addition of saturated aqueous 
ammonium chloride (Scheme 2.25). This reaction was performed in THF, from which the 
dianion precipitated. Rather than being disadvantageous, the poor solubility of the dianion 
is thought to have been to the benefit of its reaction with the diwopropoxymethylborane. 
Because the majority of the dianion is not in solution, it is not free to react with itself (the 
reason thought to lie behind its reported instability at temperatures greater than -30 °C).^58 
As the temperature of the solution in THF was increased, however, more of the dianion 
gradually dissolved. Thus, because the dissolution of the dianion is a slow process, it is 
always more probable that it will react with the diwopropoxymethylborane than with itself.
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Following the workup of the reaction described above, two products were 
isolated. However, neither of these was the expected compound (119).
............
I I  I I  : i  I :  II_ _ _ II
■p:
121 122
Reagents and Conditions: (i) n-BuLi, THF, -30 °C, 30 min; (ii) (PdO)2BMe, -30 °C, 1 h, 
then -425 °C, 16 h; (iii) NH4 Cl(aq.), 7% (of 121) and 52% (of 122).
Scheme 2.25: The isolation of 122y the complex of borane 119 and ammonia
The isolation of a small quantity (7%) of dibenzothiophene (121) is not 
understood at all, in contrast to that of the ammonia adduct of the desired borane (122). It 
is thought to result from the interaction between 119 and ammonia generated in solution 
during the quenching of lithium wopropoxide and n-BuLi. The highly novel structure 
proposed for 122 was confirmed by X-ray crystallography. From the structure elucidated, 
it was determined that one of the hydrogen atoms of the ammonia molecule is hydrogen 
bonded to an oxygen atom of the sulfone group (Fig. 2.15).
Figure 2.15: Representation of 122 generated from crystallographic data
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Following the synthesis of 122, attempts were made to cleave oxidatively its 
B-Me bond. In the oxidative workup procedure that commonly follows the hydroboration 
of unsaturated carbon-carbon bonds, alkaline hydrogen peroxide is normally used. 
However, because the exact concentration of aqueous hydrogen peroxide is not normally 
known, it was decided to investigate the use of an alternative oxidant, sodium perborate 
(123).270 The mechanisms for both sodium perborate and peroxide oxidations are thought 
to be the same (Scheme 2.26). At this point, it was not at all clear how the presence of the 
ammonia ligand would affect the oxidation of 1 2 2 .
Na+
Hq o - q  pH-X A"HO 0 - 0  OH
123
Na+ R -B —0 - 0 —X ■>3 aR":
R-B-Ok
X  “  B (0H )2 : sodium  perborate  oxidation
X  = H: hydrogen perox ide oxidation
HOX
Scheme 2.26: The mechanism of the oxidative cleavage of boranes by sodium perborate 
(123) and hydrogen peroxide
Treatment of a solution of 122 in THF with an aqueous solution containing one 
equivalent of sodium perborate gave none of the desired product (82) when stirred at room 
temperature overnight. It had been intended not to use more than one equivalent of oxidant 
to prevent over-oxidation of the boron atom. The use of alkaline hydrogen peroxide was 
attempted but this too had no effect. When the solution was heated to 50 °C for 30 min, an 
inseparable mixture of products was obtained. We decided, therefore, to investigate the 
effect of excess alkaline hydrogen peroxide. After heating at 50 °C for 2 h, phenol 124 
(13% yield) and diphenol 125 (31% yield) were isolated. Diphenol 125 must have
124 125
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resulted from the migration of the phenyl groups in preference to the methyl group. It is 
known that the ability of a group to migrate to an electron-deficient oxygen atom is 
determined by its ability to stabilise the partial positive charge developed in the transition 
state during such a migration.27i Although, the methyl group is known to have poor 
migratory aptitude, it had been thought that it would migrate in preference to the electron- 
deficient phenyl sulfonyl groups. This, however, appears not to be the case. The 
generation of 124 and 125 is thought to result from the series of reactions shown in 
Scheme 2.27. Migration of one phenyl group would give the cyclic borinate 126 which 
probably hydrolyses to give the intermediate borinic acid 127. The major product 125 is 
formed from another cycle of oxidation-rearrangement and hydrolysis. The minor product 
124 is probably formed by the side-reaction of non-oxidative hydrolytic cleavage of the 
bond connecting the remaining phenyl group to the boron atom. As only a small quantity 
(20 mg) of 124 was produced from 122, its identity was confirmed by comparison with 
an "authentic" sample that was synthesised independently (from the oxidation of boronic 
acid 108 with sodium perborate).
HO" 1P-Me NH3
122 126 127
124 or 125
Scheme 2.27: Probable intermediates in the syntheses o f 124 and 125
The failure of yet another attempted synthesis of borinic acid 82 was 
disappointing; nevertheless it was thought that the parent borane (119) might behave 
differently from the ammonia adduct 1 2 2  under the oxidising conditions that had generated 
124 and 125. The synthesis of 119 was therefore attempted. When the reaction in which 
it was synthesised was quenched with aqueous citric acid, rather than ammonium chloride
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solution, the desired product was thought to have been isolated on the basis of its NMR 
spectrum. However the resultant oil, in contrast to crystalline white solid 122, 
decomposed shortly after its synthesis.
The surprising isolation of 122 prompted two attempts to make similar 
complexes for two reasons: both to try to develop novel HIV-1 PR inhibitors and out of 
curiosity. We envisaged that, if instead of quenching the reaction with aqueous ammonium 
chloride (see Scheme 2.25), the reaction was treated with hydroxyammonium chloride 
solution or hydrazine hydrochloride solution, it would be possible to synthesise the 
compounds 128 and 129 respectively.
I I
Me NH2X
X = OH: 128 
X = NH2 : 129
Although it proved impossible to synthesise the hydrazine derivative (129), the 
hydroxylamine adduct 128 was prepared in 38% yield, and X-ray diffraction data obtained 
in order to corroborate its structure (Fig. 2.16).
Figure 2.16: Two representations of 128 generated from crystallographic data
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It was expected that the hydroxyl group might hydrogen bond to the sulfonyl 
oxygen atoms in 128. However, it was determined that such a non-bonding interaction is 
only made to one of the these oxygen atoms (Fig. 2.17). As can be seen from the 
representation below, it was again found that the amine itself interacts with both the oxygen 
atoms of the sulfone.
Figure 2.17: A further representations o f 128 generated from crystallographic data
While it had proved possible to synthesise 128, it was decided not to submit the 
small quantities obtained to an attempted oxidative cleavage reaction. Instead we thought 
that the phenyl borane (1 2 0 ), on account of the superior migratory aptitude of the phenyl 
group over the methyl group, would allow the generation of the desired borinic acid 82 by 
applying the oxidative cleavage protocol. Additionally, it was of great interest to discover 
whether phenyl borane 120 would form similar Lewis acid-Lewis base complexes with 
amines to those formed by methyl borane 119. The same conditions used to prepare 122 
were employed to try to synthesise 1 2 0 , except for the use of diwopropoxyphenylborane in 
place of diwopropoxymethylborane. In addition to the synthesis of a small quantity of 
dibenzothiophene (121), a white crystalline solid was obtained. The mass spectrum of this 
product contained an m!z ratio of 322 Da thought to correspond to the [M + H]+ ion. 
Additionally, the mass spectrum indicated the presence of boron. [Mass spectrometry 
indicates the presence of a boron atom if two adjacent peaks are found in the ratio 4:1. 
These arise from the presence of both isotopes of boron: (80% abundant) and
(20% abundant)]. The IR spectrum did not contain a great deal of information other
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information other than an absorption at 3479 cm k These data correspond to the ammonia 
adduct of 120 having been formed (130). However, the and NMR spectral data 
did not corroborate this structure nor did they assist in the elucidation of the correct one; 
they only contained chemical shifts that corresponded to aromatic proton and carbon atoms, 
plus an additional broad singlet in the spectrum. In order to establish the correct 
structure. X-ray diffraction data were obtained for these crystals. The structure deduced 
was not 130 but the borinic acid 131 (Fig. 2.18), formed from the incomplete reaction 
between diwopropoxy-methylborane and 2 ,2 '-dilithiodiphenyl sulfone.
Ph NHg
130
HO
131
Figure 2.18: A representation o f 131 generated from crystallographic data
This was disappointing as the phenyl borane 120 had been considered to be an 
excellent candidate for conversion to borinic acid 82. The reason thought to be behind the 
failure to synthesise 120 was a steric one. An attempt was made, therefore, to prepare an
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analogue of 119 in which the methyl group was replaced by an allyl group. The reagent 
diwcipropoxyallylborane is not commercially available but the preparation of analogous 
dimethoxyallylborane from allylmagnesium bromide and trimethyl borate has been 
d e s c r i b e d . 2 7 2 ,2 7 3  However, the attempted preparation and reaction of this reagent with 
2 ,2 '-dilithiodiphenyl sulfone did not yield any products that contained the allyl group (as 
determined by NMR spectroscopy) and so the investigation into the oxidation of 
diphenyl sulfone-derived boranes was not pursued further.
One final attempt to synthesise borinic acid 82 was then undertaken. Of the 
problems encountered with the lithiation strategy initially attempted, one was thought to be 
that of intermolecular proton transfer reactions (see Scheme 2.20). It was thought that if 
such reactions could be prevented, it might prove possible to make 82. In an attempt to 
achieve this, we decided to mask two of the four acidic hydrogen atoms ortho to the 
sulfone group in diphenyl sulfone. This was achieved by the reaction of 
2,2'-dilithiodiphenyl sulfone with two equivalents of TMS chloride to form sulfone 132 
(Scheme 2.28). It was envisaged that by treatment of this compound with another two 
equivalents of n-BuLi, followed by one equivalent of a trialkyl borate, borinic acid 133 
could be synthesised. Simple TBAF-deprotection would then afford 82.
TMSo nTMS TMS^ ^TMS
Reagents and Conditions: (i) n-BuLi, THF, -30 °C, 1 h, then ->-50 °C then TMS-Cl, 
-50->25 °C, 16 h, 81%; (ii) n-BuLi, THF, -30 °C, 30 min, then ->-70 °C then B(OR)3 , 
-70->-30 °C, 30 min; (iii) TBAF, THF, 25 °C.
Scheme 2.28: Alternative proposed synthesis o f borinic acid 82
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Although, the required Z?w(trimethylsilyl)diphenyl sulfone 132 was readily 
obtained, when it was treated with either tri-n-butyl borate or boron trifluoride etherate, the 
predicted product (133) was not isolated. In both cases, the same product, whose identity 
could not be elucidated, was obtained. Both the and NMR spectra provided 
evidence for a symmetrical product in which C- 6  and C-6 ' no longer bore hydrogen atoms. 
In the spectrum, there are three multiplets which correspond to six aromatic hydrogen 
atoms when compared to the singlet that represents two equivalent TMS groups. The 
spectrum contains, in addition to the TMS singlet, six resonances, three of which appeared 
to correspond to quaternary aromatic carbon atoms. On the basis of this information we 
postulated that this product might be the borinic anhydride 134. However, as the same
TMS •IMS
B-O-B
TMS TMS
134
product was isolated from the reaction of 2 ,2 '-^w(trimethylsilyl)-6 ,6 '-dilithiodiphenyl 
sulfone with diwopropoxyphenylborane, and the product did not contain boron (according 
to NMR spectroscopy), this structure had to be dismissed. Despite its structure not 
being known, the product was treated with TBAF, and was found to afford exclusively 
dibenzothiophene-5,5-dioxide 136. We concluded, therefore, that the unknown product 
thought at first to be 134 was in fact 4,6 -è/5 (trimethylsilyl)-dibenzothiophene-5 ,5-dioxide 
(135).
135, R = TMS 1
136, R = H I
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The mechanism by which 135 is formed from 132 when treated with n-BuLi is 
not known. The failure of this approach led us to abandon the attempted synthesis of 
borinic acid 82.
As has already been described, compound 82 could not be synthesised directly 
from diphenyl sulfone by the initial lithiation strategy (see Schemes 2.19 and 2.20). This 
may be because either the intermediate borinate formed during this reaction, or the borinic 
acid 82 that results from its hydrolysis, is so electrophilic that it is attacked by water, when 
the reaction is quenched, thereby causing the formation of boronic acid 108. Similar 
electronic effects may have prevented the synthesis of the diphenyl sulfone-derived phenyl 
borane (1 2 0 ); as already discussed, however, this may arise more as a result of the steric 
bulk of the phenyl group than because of the stability of the product, or the intermediate 
borinate.
The most unusual compounds to have been synthesised from all the above 
reactions are the ammonia (122) and hydroxylamine (128) adducts of the target diphenyl 
sulfone-derived methylborane (120). Why exactly ammonia complexes only to borane 
120 is not understood as it is undoubtedly present during the quenching of many of the 
reactions discussed above.
2 .7  Design of Acyclic Borinic and Boronic Acids
A final set of target molecules, whose syntheses again we hoped would be 
easier than all of those previously described, were designed. The rationale for this came 
initially from an idea to synthesise a single compound that would resemble, as closely as 
possible, borinic acid 82. As has been demonstrated (by the syntheses of compounds 122 
and 128), the co-ordinative bond formed between nitrogen- and boron-containing 
compounds can be very strong. On the basis of these considerations, compound 137 was 
designed.
HO OH
X = SOg: 137 
X = S: 138
X = O: 139
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Although we hoped that the sulfone present in boronic acid 137 could be 
generated from the oxidation of the sulfur atom in the analogous sulfide-containing boronic 
acid 138, were this not to prove possible 138 itself would still be a valid target compound. 
The oxygen-containing analogue (139) was also thought to be worthy of examination.
In addition to these pyridine-containing boronic acids, it was decided to try to 
synthesise the following two final sets of compounds:
• the sulfur- and oxygen-containing analogues (140 and 141) of the previously 
synthesised sulfone-containing boronic acid (108).
• three closely related borinic acids (142 - 144), differing only from the boronic 
acids 108,140 and 141 in the replacement of one of their hydroxyl groups 
with a methyl group.
1  V  u ' T "
X = SO2 : 108 X = SO2 : 142
X = S: 140 X = S: 143
X = O: 141 X = O: 144
It was intended that any inhibition of HIV-1 PR exhibited by boronic acids 140 
and 141 could be compared directly with the cyclic borinic acids 83 and 84 (the 
compound obtained when borinic anhydride 117 is dissolved in aqueous solution) 
synthesised earlier. The purpose in making borinic acids 142-144 was to assess whether 
the borinic acid functionality might be better than the boronic acid group at binding to the 
catalytic aspartic acids even if the cyclic borinic acids 83 and 84 proved to be inactive. It 
was hoped that these more flexible acyclic analogues might be active on account of being 
able to adapt their conformations to complement the active site. The small methyl group 
was not expected to sabotage the interaction of the borinic acid group contained within 
these molecules with the active site. This premise was based on the earlier successful
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development of inhibitors of the phosphonamidate methyl ester class by Camp and others 
within the Gani group at St Andrews (see page 2 9 ).^ 19,206
2 .8  Syntheses of Acyclic Borinic and Boronic Acids
2 .8 .1  Attempted Syntheses of Pyridyl-containing Boronic Acids
We intended to synthesise sulfide 137, the precursor to borinic acid 138, by 
treating sulfide 145 with n-BuLi, followed by reaction with a trialkyl borate [Scheme 
2.29 (ii)].
a r  * ^  Gc'DBr
145 138
Reagents and Conditions', (i) NaHCOg, DMF, 130 °C, 2 h, 54%; (ii) n-BuLi, THF, 
-70 °C, then B(OR)3 , -70->25 °C.
Scheme 2.29: Attempted synthesis o f sulfide 138 by a lithiation strategy
The reaction between 2-bromothiophenol and 2-bromopyridine under the same 
conditions used to generate sulfide 97 gave the desired sulfide 145 in 54% yield. 
However, its attempted lithiation and subsequent reaction with tri-n-butyl borate resulted in 
the total decomposition of the starting material, as determined by TLC. The failure of the 
lithiation may have resulted partially from a Ziegler-type alkylation of the pyridine ring 
(Fig. 2.19). '^74 Consequently, an alternative method of synthesising 138 was sought.
HO OH
103
Bu-Li
145
Bu
a ~  * ' “X )Br
Figure 2.19: Possible Ziegler-type reaction between n-BuLi and sulfide 145
The ipso borodesilylation strategy developed independently by K a u fm a n n ,2 7 5  
and Snieckus et a l . , ^76 seemed an appropriate strategy to adopt. This procedure exploits 
the well-known electronic effect of the TMS group on electrophilic aromatic substitution 
reactions.
Aryl silicon bonds are thought to be cleaved by electrophilic reagents in a 
mechanism similar to that which operates in normal electrophilic aromatic substitutions. 
However, for most electrophiles, substitution of the silyl group is faster than for the 
replacement of a hydrogen atom (the so-called "ipso effect"). This is thought to result from 
preferential stabilisation by the silicon atom of the P-cation contained within one of the 
resonance forms of the intermediate addition complex (Fig.
TMS TMS. E
+r Otherresonance
forms
Figure 2.20: ipso Substitution of trimethylsilylbenzene
We hoped that ipso borodesilylation of the sulfide 147 would afford the desired 
boronic acid 138. However, an acceptable synthesis of 147 was uncovered only after a 
number of attempts. At first, it was thought that it could be prepared from the reaction 
between 2-bromopyridine and 2-(trimethylsilyl)thiophenol (146), using the same
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conditions previously employed to make sulfides 97 and 145. However, the main product 
isolated under these conditions was the sulfide 148 (62%), which did not contain the TMS 
group. The desired sulfide 147 was formed in a yield of 12% (Scheme 2.30).
a '
146
NaHCOa
DMF, 100 “C N.^  ^ T M S
147 (12%) 148 (62%)
Scheme 2.30: Initial synthesis o f sulfide 147
It was thought that the cause of the cleavage of the carbon-silicon bond was the 
presence of aqueous base during the reaction. The reaction conditions were, therefore, 
changed. The sodium salt of thiol 146 was pre-formed by treating 146 with sodium 
hydride, before the addition of 2-bromopyridine. By heating this mixture under reflux in 
THF (65 °C), small quantities of the desired sulfide 147 were formed. However, the 
reaction proceeded extremely slowly in this solvent. When exchanged for the higher- 
boiling solvent, 1,4-dioxane (bp 99 °C), although the yield was modest even after heating 
under reflux for 48 h, a sufficient quantity was obtained to permit the borodesilylation 
reaction to be studied.
One of the reasons for attempting to optimise the yield of 147 was to minimise 
the number of times that the high-yielding but odorous synthesis of thiol 146 had to be 
prepared. The procedure,^^^ involved the dilithiation of thiophenol, followed by treatment 
with two equivalents of TMS chloride. The intermediate silylsulfide (149) was then heated 
under reflux in methanol to afford the desired thiol in 94% overall yield (Scheme 2.31).
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SH ^  ,STMS ^ S H
TMS TMS
149 146
Reagents and Conditions', (i) w-BuLi, TMEDA, cyclohexane, 25 °C, 24 h, then TMS-Cl, 
25 °C, 16 h; (ii) MeOH, 65 °C, 9.5 h, 94% (over 2 steps).
Scheme 2.31: Synthesis o f 2-(trimethylsilyl)thiophenol 146
With an adequate quantity of 147 secured, it was discovered that the desired 
borodesilylation reaction could not be performed. The reaction in which a solution of 147 
in dichloromethane was treated with a solution of boron tribromide, also in 
dichloromethane, was repeated a number of times. Although the starting material was 
consumed, none of the resultant mixture of products could be identified and the 
borodesilylation route to boronic acid 138 was not pursued further.
Considering that the reason for the failure of the borodesilylation route to 
deliver 138 was not understood, it was perhaps rather ambitious to apply the same reaction 
to another attempted synthesis of borinic acid 82 from sulfide 132 (Fig. 2.21).
TMSn oTMS
B orodesilyation  ? ^
OH
132 82
Figure 2.21: A borodesilylation strategy to borinic acid 82
Additionally, as the ipso borodesilylation reaction is simply a directed electrophilic aromatic 
substitution, it might be expected to be retarded by the presence of the adjacent electron- 
withdrawing sulfone group. However, as other ipso desilylation reactions have proceeded 
in the presence of electron-withdrawing groups (e.g. C02H),279 the attempted 
diborodesilylation of 132 appeared to be worthwhile. However, the two main products
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isolated following the reaction between 132 and boron tribromide did not contain boron (as 
determined by mass spectrometry) and were discarded.
Before completing the study of the borodesilylation reaction, curiosity prompted 
two final attempts at successfully applying it in two other syntheses. We reasoned that it 
should be possible to synthesise borinic anhydride 117 and borinic acid 107 (perhaps 
isolable also as its anhydride) through diborodesilylation reactions performed on sulfide 
150 and disulfide 151 respectively (Scheme 2.32). The electron-donating properties of 
the sulfide or disulfide groups were expected to provide an additional driving force for 
substitution at the positions occupied by the TMS groups.
Sulfide 150 was synthesised from sulfide 99 by sequential treatment with two 
equivalents each of w-BuLi and TMS chloride. Disulfide 151 was synthesised by sodium 
perborate oxidation,280 of the previously prepared thiol 146. However, whilst the 
addition of aluminium chloride enabled the synthesis of 117 in 48% yield, application of 
this and other methods only caused the decomposition of the second starting material, 151
Br Br
99
(i)
TMS TMS
150
(ii)
SH
TMS
146
(iii) S-S
TMS TMS 
151
(ii)
S-S
107
Reagents and Conditions: (i) w-BuLi, THF, -70 °C, 30 min, then TMS-Cl, -70^25 °C, 
1 h, 61%; (ii) AICI3 , CH2 CI2 , -70 °C, then BBrg, -70^25  °C, 16 h, 47% (of 117); 
(iii) NaB0 3 .4 H2 0 , Aliquot 336, MeOH, 25 X , 1 h, 73%
Scheme 2.32: Application o f ipso diborodesilylation to the synthesis o f borinic 
anhydride 117, and to the attempted synthesis o f borinic acid 107
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2 .8 .2  Syntheses of Borinic and Borinic acids Derived from  Diphenyl
Sulfone, Diphenyl Sulfide and Diphenyl E ther
Finally, attention was turned to the syntheses of the two additional sets of 
compounds described on page 102. Of these, boronic acid 108 had already been 
synthesised. The related borinic acid (142) was prepared from 2-lithiodiphenyl sulfone 
and diwopropoxymethylborane, but was found to be unstable (Scheme 2.33). It was 
therefore stabilised by the formation of its ethanolamine ester (1 5 2 ).204 Rather 
frustratingly, this protection could not performed on the crude product, as an intractable 
viscous yellow oil was formed. Instead the derivatisation was carried out on 142 
(following its purification by column chromatography). Although the ethanolamine ester 
152 was obtained this way, the yield was disappointingly low (36%).
(i)
0 s_.0
^  (ii)
Me^^'OH
142
Reagents and Conditions’, (i) n-BuLi, THF, -30 °C, 30 min, then B(OPri)2Me, -30 °C, Ih, 
->25 °C, 1 h; (ii) ethanolamine, ether, 0 °C, 36% (over two steps).
Scheme 2.33: Preparation of borinic acid 142 and its ethanolamine ester 152
Of the remaining four compounds, it was expected that the two based on the 
diphenyl ether skeleton (141 and 144) could be synthesised directly from diphenyl ether 
like the cyclic borinic acid 84. At the time, unfortunately, it proved impossible to obtain a 
quality solution of j^-BuLi. Therefore, the lithiation of diphenyl ether was attempted using 
f-BuLi. However, addition of difjopropoxymethylborane to the resulting solution,
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afforded, after quenching the reaction, a mixture of the products 147, 153 and 83 
(Scheme 2.34).
+
B.Me' OH
144 (7%)
+
153(16%) 83 (33%)
Reagents and Conditions'. f-BuLi, THF, -70—>25 °C, 30 min, then, B(OPr^)2Me, -50 °C, 
2 h, then ->25 °C, Ih.
Scheme 2.34: Products obtained from the first attempted preparation o f borinic acid 144
In addition to these products, 40% of starting material was recovered intact. 
Although it is not known how the 2-phenoxyphenol (153) was produced, it would seem 
that the only way in which the borinic acid 83 could have been generated is by the 
dilithiation of diphenyl ether and the reaction of the 2 ,2 '~dilithiodiphenyl ether with 
triwopropyl borate. This could be a contaminant in the diwopropoxymethylborane.
Because of this failure, it was decided to synthesise the 2-lithiodiphenyl sulfide 
and 2-lithiodiphenyl ether required to make 140 & 143 and 141 & 144, respectively, by 
lithiation of the appropriate bromo-compounds 154 and 155. The syntheses of these are 
shown in Scheme 2.35 overleaf. The preparation of the known sulfide 154,^81 was 
achieved using the method of Hilbert and J o h n s o n . Out of curiosity, another 
preparation of 99 was attempted by a modification of this procedure. Although this was 
successful, only a low yield of 32% was achieved. The 2-bromodiphenyl ether 155 was 
prepared from 2-aminodiphenyl ether according to a known p r o c e d u r e . 2 8 3
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NH2 hs 
+
Br
(i). (ii).
154 (48%)
(iii)
NH2
155 (73%)
a NH2 HS5 , " :o (iv), (ii) Br Br
99 (32%)
Reagents and Conditions', (i) H2 S0 4 (aq.), NaNÛ2 , 0-3 °C, then NaOAc; (ii) NaOH, Cu, 
H2 O, 0-5 °C, then ->90 °C, Ih.; (iii) 48% HBr, NaN0 2 , 0-5 °C, then CuBr, 48% HBr, 
100 °C, 30 min; (iv) HCl(aq.), NaN0 2 , 0-2 °C, then NaOAc.
Scheme 2.35: Preparation o f154, 155 and 99 from aromatic amines
Aryl bromides 154 and 155 were then used to synthesise both the boronic 
acids 140 and 141 and the borinic acids 143 and 144. Although like 142, these borinic 
acids were found to be unstable, it proved possible to prepare their corresponding 
ethanolamine esters (156 and 157) directly from the crude mixtures containing 143 and 
144. The preparation of 140,141,156 and 157 are shown in Scheme 2.36.
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Br
X = S :154 
X = 0:155
HO' OH
X = S: 140 
X = 0 : 141
X = S: 156 
X = 0 : 157
Reagents and Conditions: (i) w-BuLi, THF, -70 °C, 30 min, then B(OPF)3 , -70 °C, 
30 min, -70-^25 °C, 1 h, 80% (of 140), 84% (of 141); (ii) n-BuLi, THF, -70 °C, 
30 min, then B(OPF)2Me, -70 °C, 30 min, -70-^25 °C, 1 h; (iii) ethanolamine, 2 d, 59% 
(of 156 from 154), 82% (of 157 from 155).
Scheme 2.36: Preparation of boronic acids 140,141 and protected borinic acids 156 
and 157
Although all three ethanolamine esters (152,156 and 157) are highly stable 
crystalline solids, and proved relatively straightforward to characterise, the same cannot be 
said about the analogous series of boronic acids (108,140 and 141). Boronic acids are 
recognised as being notoriously difficult to characterise because of the ease with which they 
fully or partially dehydrate to oligomeric anhydrides (Fig. 2.22).^^^
?
HO'®'OH
(a) (b)
9
0 ' ® " 0
R^B'o ^B'r
(c)
Figure 2.22: A boronic acid in the form of the free acid {a) and as a dehydrated dimeric 
(b) or a dehydrated trimeric (c) anhydride
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Although the boronic acids 140 and 141 both gave, in addition to *H, and 
1 NMR spectral data consistent with the structures of the free acids, miz ratios 
corresponding to [M + H]+ ions, great difficulty was found in obtaining the elemental 
analyses for carbon and hydrogen that would corroborate these structures. As 140 and 
141 were highly crystalline, X-ray diffraction data were obtained for both to determine if 
they had been isolated as dehydrated oligomers. However, both were found to be present, 
at least in the crystals studied, as the free acids (Fig. 2.23).
Figure 2.23: Representations o f 140 (left) and 141 (right) generated from X-ray 
crystallographic data
Paradoxically, although boronic acid 108 exhibited NMR spectra consistent with and gave 
the C and H analyses appropriate for the structure of the free acid, it proved impossible to 
observe an mJz ratio that corresponded to the M+ or [M + H]+ for the free acid.
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2 .9  Testing of Boron-Containing Compounds and Conclusion
All of the boron-containing compounds described above (83,108,109,117, 
118, 122, 128, 131, 140, 141, 152, 156 and 157) with the exception of 118 (the 
A^,A-dimethylethanolamine ester of diphenylborinic acid), were tested against HIV-1 PR in 
the in vitro assay described in Chapter 3. In addition the commercially available 
compounds phenylboronic acid and diphenylborinic acid (as its ethanolamine ester) were 
tested. [Ethanolamine was not found to inhibit the enzyme and the ethanolamine ester of 
diphenyl borinic acid was found to hydrolyse within five minutes of its addition to the 
assay buffer. Thus this and the other ethanolamine esters (152,156 and 157) were all 
tested without deprotection].
Unexpectedly, none of the above compounds were found to be inhibitors of the 
enzyme (when tested at concentrations of up to 200 |xM; see also Appendix 2). This was 
obviously a great disappointment. Although it had been feared that the groups designed to 
interact with the enzyme might be too close to one another, it could not have been 
anticipated that no activity would be detected, especially as, by the time the synthetic work 
was complete, a variety of boron-containing compounds had been prepared. Indeed, the 
boron atoms in compounds 122 and 128 were not expected to play any role in binding.
It may be, therefore, that the failure of all these compounds to inhibit HIV-1 PR 
is a consequence of the closeness of the phenyl group(s) to the boron atom. However, as it 
had not been possible to synthesise the more desirable targets (see pages 64 - 6 8 ), it had 
proved necessary to design different targets in order to prepare any borinic acids at all. 
Other potential targets, such as 158, in which the inclusion of a group designed to interact 
with the flap isoleucine residues has been sacrificed for synthetic reasons, have since been 
considered, but lack of time did not permit their study.
P h . ,nÇ } n . P h
OH 
158
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C h a p t e r  t h r e e  
E x p e r im e n t a l
Experimental
General procedures
and NMR spectra were recorded on Bruker AM 300 (^H, 300 MHz), 
Varian Gemini 500 (^H, 500.3 MHz), Varian Gemini 300 (^H, 300 MHz; 75.4 MHz) 
or Varian Gemini 200 (^H, 200 MHz; 50.3 MHz) spectrometers. Chemical shifts are 
described in ppm downfield from tetramethylsilane and are reported as follows: position, 
(Ôh or Ôc) [relative integral, multiplicity (s = singlet, d = doublet, t = triplet, dd = doublet 
of doublets, m = multiplet and br = broad), coupling constant (J /Hz, if of practical 
importance) and assignment (numbered according to the lUPAC nomenclature for the 
compound)]. ^H spectra were referenced internally on CHCI3 (ô 7.27 ppm) or (CH3)2SO 
(Ô 2.47 ppm), NMR spectra were referenced internally to the central resonances of 
either C^HCls (Ô 77.0 ppm) or (CH3)2SO (Ô 39.7 ppm). ^^ B NMR spectra were recorded 
on a Bruker AM 300 spectrometer at 96.3 MHz and are described in ppm downfield from 
boron trifluoride etherate, which was referenced as an external standard in a co-axial cell. 
Infra-red spectra were recorded on a Perkin-Elmer 1710 FT-IR spectrometer. The samples 
were prepared as Nujol mulls or as thin films between sodium chloride discs. The 
frequencies (v) as absorption maxima are given in wavenumbers (cm-^) relative to a 
polystyrene standard. Microanalyses were determined in the microanalytical laboratory at 
the University of St Andrews. Mass spectra and accurate mass (HRMS) measurements 
were recorded in St Andrews on a VG 70-250 SE or a Kratos MS-50, by the E.P.S.R.C. 
service at Swansea on a VG AZB-E, or at GlaxoWellcome Medicines Research Centre, 
Stevenage, on a Hewlett-Packard Engine (Thermospray), a VG MicroMass Platform (ES), 
or a Finnigan 4600 (Cl). Major fragments are given as percentages of the base peak 
intensity (100%). Multiple signals arising through the presence of isotopes of chlorine or 
bromine are all given; however, the base peak intensity given refers to the major peak. 
Melting points were determined on either a Reichert hot stage (< 230 °C) or an 
Electrothermal (>230 °C) apparatus and are uncorrected.
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Reagents were used without purification unless otherwise stated. Quantities of 
reagents were calculated from the manufacturers' stated purities. Experiments were 
conducted at room temperature (20-25 °C) unless otherwise stated. All reactions that 
employed organometallic regents or other moisture sensitive reagents were performed in 
dry solvent under an atmosphere of dry nitrogen or argon in oven-dried and/or flame-dried 
glassware. Solutions in organic solvents were dried over anhydrous magnesium sulfate 
and concentrated or evaporated under reduced pressure on a Büchi rotary evaporator unless 
otherwise stated. Flash column chromatography was performed according to the method 
of Still et with Fluka Kieselgel (220-400 mesh). Analytical TLC was carried out on 
0.25 mm precoated silica gel plates (Whatman PE SIL G/UV) and compounds were 
visualised by UV fluorescence, ethanolic phosphomolybdic acid, iodine vapour or aqueous 
potassium permanganate.
The solvents used were either distilled or of analar quality and petrol refers to the 
portion of petroleum ether that boils between 40 and 60 "^ C. Solvents were dried according 
to literature procedures: ethanol and methanol were dried over magnesium turnings; 
cyclohexane, dichloromethane, DMF, pyridine and triethyl amine were distilled over 
calcium hydride; THF and diethylether (referred to as ether) and 1,4-dioxane were dried 
over sodium and benzophenone. Organolithium solutions were titrated according to the 
method of Kofron and B a c l a w s k i . 2 8 6  All other chemicals were of analytical grade or were 
recrystallised or distilled before use.
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2,6-bis(Phenylmethylene)-cyclohexanone, 58
To a stirred solution of NaOH (15 g, 375 mmol) in aqueous ethanol (50% v/v; 120 cm^), 
cooled to 0 °C, was added dropwise over 30 min a solution of cyclohexanone (9.81 g, 
100 mmol) and benzaldehyde (21.22 g, 200 mmol) in ethanol (50 cm^). The solution was 
stirred for a further 16 h and the resultant yellow solid filtered and washed with water 
(10 X 100 cm3). Recrystallisation from acetone gave yellow crystals (18.65 g, 68% ) ,  
mp 116-118 °C (lit.,208 118-119 °C) (Found: C, 87.4; H, 6.7. Calc, for CzoHigO: C, 87.55; 
H, 6 .6 %) (HRMS: found [M + H]+, 275.1436. Calc, for C2 0 H 1 9 O: 275.1436); 
'Omax(Nujol)/crn-i 1662 (CO) and 1606, 1576 and 1569 (C=C); 6h(200 MHz; C^HClg) 1.80 
(2 H, m, 2 X 4-H), 2.95 (4 H, m, 2 x 3-H and 2 x 5-H), 7.30-7.60 (10 H, m, Ar-H) and 
7.84 (2 H, s, 2 X C=CH); 0c(50.3 MHz; C^HClg) 22.97 (C-4), 28.42 (C-3 and C-5), 
128.33, 128.55 and 130.33 (Ar-CH), 135.91 and 136.13 (Ar-C quaternary, C-2 and C-6 ), 
136.88 (C=CH) and 190.33 (CO); m/z (Cl) 275 (100%, [M + H]+).
Tetrahydro-3,5-ôi;s(phenylmethylene)-4Ær-pyran-4-one, 59
O
A solution of sodium hydroxide (1 g, 25 mmol) in aqueous ethanol (50% v/v; 20 cm^) was 
prepared and cooled to 0 °C. Benzaldehyde (1.06 g, 10 mmol) was dissolved in the minimum 
volume of ethanol (5 cm^) and added to a solution of tetrahydro-4//-pyran-4-one (500 mg, 
5 mmol) in ethanol (5 cm^). Half of this mixture was added dropwise to the alkaline solution 
with vigorous stirring and the reaction mixture was left for a further 15 min at 25 °C. The 
remainder was then added and the resultant mixture was left to stir for a further 1 h. The 
yellow precipitate was filtered then washed with water ( 1 0 0  cm^) to remove excess alkali.
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Recrystallisation from ethanol-acetone gave yellow plates (897 mg, 65%), mp 181.5-182.5 °C 
(lit.,207 185 °C) (Found; C, 82.35; H, 5.95. Calc, for CigHisOz: C, 82.6; H, 5.85%) 
(HRMS: found [M + H]+, 277.1229. Calc, for C19H 17O2 : 277.1228); t)„ax(Nujol)/cm-' 
1668 (CO) and 1612 and 1582 (C=C); 8h(200 MHz; C^HCls) 4.95 (4 H, s, 2 x 2-H and 
2 X 6 -H), 7.30-7.60 (10 H, m, Ar-H) and 7.85 (2 H, s, 2 x C=CH); 8c(50.3 MHz; 
C^HCla) 68.58 (C-2 and C-6 ), 128.65, 129.36 and 130.43 (Ar-CH) 133.02 and 134.67 
(Ar-C quaternary, C-3 and C-5), 136.44 (C=CH) and 185.50 (CO); m/z (Cl) 277 (100%, 
[M + H]+).
Tetrahydro-3,5-éfs(phenylmethylene)-4;H-thiopyran-4-one, 60
O
This was prepared in an manner identical to pyranone 59 by using sodium hydroxide (1 g,
25 mmol), benzaldehyde (1.06 g, 10 mmol) and tetrahydrothio-4H-pyran-4-one (580 mg,
5 mmol). This afforded a yellow solid which was recrystallised from acetone to give 
yellow crystals (900 mg, 62%), mp 150-151 °C (lit.,207 1 4 9 - 1 5 1  °C) (HRMS: found 
M+, 292.0922. Calc, for C^H ^SO : 292.0922); t)max(Nujol)/cm ' 1660 (CO) and 1600, 
1577 and 1569 (C=C); 8h(200 MHz; C^HCls) 3.95 (4 H, s, 2 x 2-H and 2 x 6 -H), 
7.20-7.55 (10 H, m, Ar-H) and 7.80 (2 H, s, 2 x C=CH); 8c(50.3 MHz; C^HCls) 30.13 
(C-2 and C-6 ), 128.63, 129.00 and 130.08 (Ar-CH), 133.90 (C-3 and C-5), 135.14 
(Ar-C quaternary), 136.92 (C=CH) and 189.00 (CO); m/z (Cl) 293 (100%, [M + H]+).
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Tetrahydro-3,5-ôisf(phenylmethylene)-4Jï-pyran-4-ol, 62
OH
To a suspension of pyranone 59 (168 mg, 610 |Limol) in ethanol (3 cm^) was added sodium 
borohydride (25 mg, 660  |Limol) in three portions over 15 min. The reaction was followed to 
completion {ca. 1 h) both by colour change (yellow to colourless solution) and by TLC. Water 
(5 cm3) was added to the solution and the resultant white precipitate filtered off and washed 
with more water (10 cm^). Recrystallisation from acetone-water afforded colourless needles 
(156 mg, 92%) which were prone to decolourisation at room temperature and were stored at 
0 °C in the dark. Mp 115 °C (decomp.) (Found: C, 82.1; H, 6 .8 ; M+, 278.1307. C19H 18O2 
requires C, 82.0; H, 6.5% ; M+, 278 .1307); Dmax(Nujol)/cm-^ 3300  (OH), 1599 and 1575 
(C=C) and 1166 (ether); 0h(200 MHz; C^HCla) 2 .48 (1 H, d, 7 6.2 , OH), 4 .55  (2 H, d, 
J  13.6, 1 X 2-H and 1 x 6 -H), 4 .93  (1 H, d, J  6.2 , 4-H), 6 . 6 8  (2 H, s, 2 x C=CH) and 
7 .1 5 -7 .4 0  (10  H, m, Ar-H); 6 c (5 0 .3  MHz; C^HClg) 6 6 .70  (C -2 and C-6 ), 75 .72  (C-4), 
1 2 5 .5 0  (C=CH), 1 2 7 .1 9 , 1 2 8 .3 5  and 1 2 8 .8 0  (Ar-CH) and 1 3 6 .0 8  and 1 3 8 .6 6  
(Ar-C quaternary, C-3 and C-5); m/z (El) 278 (3%, M+), 262  (2, [M + H - 0H]+), 248  
(4, [M - C H 20]+ ) and 91 (100).
Tetrahydro-3,5-ôw(phenyImethylene)-47r-thiopyraii-4-ol, 63
PhvjîX^Xs^ Ph
OH
This was prepared in an manner identical to pyranol 62 by using thiopyranone 60 
(140 mg, 480 pmol) and sodium borohydride (20 mg, 480 jamol). This afforded a white 
solid which was recrystallised from acetone-water to give colourless needles (136 mg, 
94%) which were prone to decolourisation at room temperature and were stored at 0 °C in 
the dark, mp 117-119 °C (Found: C, 77.55; H, 6.3; M+, 308.0875. C19H 16O2S requires
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c , 77.5; H, 6.15% ; M+, 3 0 8 .0 8 7 9 ); t>m ax(Nujol)/cm -^ 3367  (OH) and 1598 and 
1576 (C=C); 0h(200 MHz; C^HClg) 2 .0  (1 H, br s, OH), 3.54  (2 H, d, J  13.6, 1 x 2-H 
and 1 X 6 -H), 3.86  (2 H, d, J  13.6, 1 x 2-H and 1 x 6 -H), 4 .79  (1 H, s, 4-H), 6.63 (2 H, 
s, C=CH) and 7 .2 5 -7 .4 0  (10 H, m, Ar-H); 0c(50 .3  MHz; C^HClg) 26.23  (C-2 and C-6 ), 
80 .58  (C -4), 124 .87  (C=CH), 127.11 , 128.36 and 128.94 (Ar-CH) and 136.23 and 
1 40 .23  (Ar-C quaternary, C -3 and C -5); m /z (E l) 2 9 4  (8% , M+), 278 (15 , 
[M + H - OH]+), 187 (85) and 91 (100).
Tetrahydro-3,5-ôis(phenylm ethylene)-4iï-thiopyran-4-one-l-oxide, 64
O
To a stirred solution of thiopyranone 60 (309 mg, 1 mmol) in dichloromethane (20 cm^) was 
added dropwise mCPBA (225  mg, 1 mmol) in dichloromethane (8 cm^). The resultant 
solution was stirred for 2 h, diluted with dichloromethane (50 cm^) and extracted with aqueous 
sodium hydrogen-carbonate (5% w/v; 3 x 25 cm^). The organic phase was dried and 
evaporated to leave a solid which was recrystallised from methanol to give bright yellow 
crystals (240  mg, 77% ), mp 155-159  °C (lit.,2io 155-160  °C) (Found: C, 74.1; H, 5.4; 
M+, 308.0875. Calc, for C19H 16O2 S: C, 74.0; H, 5.25%; M+, 308.0879); Vmax(Nujol)/cm-] 
1662 (CO), 1597 and 1570 (C=C) and 1049 (SO); 0h(200 MHz; C^HCls) 4.22 (4  H, s, 
2 X 2-H  and 2 x 6 -H), 7 .4 0  (10  H, s, Ar-H) and 8.05 (2 H, 2  x C=CH); 0 c (5 0 .3  MHz; 
C^HClg) 50 .30  (C-2 and C-6 ), 126.27 (C-3 and C-5), 127.86, 129.67 and 129.75 (Ar-CH), 
134.11 (Ar-C quaternary), 144.40  (C=CH) and 187.61 (CO); m/z (E l) 308 (18% , M+), 
292 (33, [M - 0 ]+ ), 260  (42, [M - SO]+) and 115 (100).
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cis- and ^ran 5’-T e tra h y d ro - 3 ,5 -ftjs(p h en y lm eth y len e)-4 jff - th io p y ran - 4 -o I-l-  
oxides, 65 and 6 6
s i  s iPhs„sXP^ Ph
OH OH
65 6 6
To a rapidly stirred solution of thiopyran-4-one-l-oxide 64 (280 mg, 900 pmol) in ethanol 
(5 cm^) was added in four portions over 10 min sodium borohydride (37 mg, 1 mmol). The 
suspension was stirred for a further 20 min. Water (20 cm^) was added and the white 
precipitate was filtered then washed with more water (100 cm^). Purification of the crude 
diastereomeric mixture by flash column chromatography (eluant dichloromethane-ethanol 50:1) 
afforded alcohols 65 (92 mg, 32.9%) and 6 6  (161 mg, 57.6%), both as white solids.
Less polar 65, mp 173-175 °C (Found; C, 73.35; H, 5.8; M+, 310.1024. C19H 18O2 S 
requires C, 73.5; H, 5.85%; M+, 310.1028); t)max(Nujol)/cm ' 3358 (OH), 1074 (SO) and 
1001 (CO); 5h(300 MHz; C^HCls) 2.02 (1 H, d, J 2.0, OH), 3.72 (2 H, d, J  13.5, 1 x 2-H 
and 1 X 6 -H), 4.11 (2 H, d, J  13.5, 1 x 2-H and 1 x 6 -H), 4.95 (1 H, br s, 4-H), 7.12 (2 H, 
s, 2 X C=CH), 7.26-7.39 (10 H, m, Ar-H); 8c[50.3 MHz; (C% 3 )2 SO] 46.04 (C-2 and C-6 ), 
78.77 (C-4), 127.72, 128.61, 128.82 and 130.80 (Ar-CH and C=CH) and 133.88 and 135.77 
(Ar-C quaternary, C-3 and C-5); m/z (Cl) 311 (48%, [M + H]+), 293 (100, [M + H - H2 0 ]+) 
and 243 (83).
More polar 6 6 , mp 168-169 °C (Found; C, 73.2; H, 5.7; M+, 310.1026. CigHigOzS 
requires C, 73.5; H, 5.85%; M+, 310.1028); t)max(Nujol)/crn-> 3367 (OH), 1076 (SO) and 
1035 (CO); 8h(300 MHz; C^HCls) 2.19 (1 H, d, J  2.2, OH), 4.01 ( 2  H, dd, J  11.6 and 1.2, 
1 X 2-H and 1 x 6 -H), 4.30 (2 H, dd, J  11.6 and 1.3, 1 x 2-H and 1 x 6 -H), 4.82 ( 1  H, m, 
4-H), 6.92 (2 H, s, 2 X C=CH) and 7.30-7.43 (10 H, m, Ar-H); 8c[50.3 MHz; (C % 3 )2 SO] 
49.52 (C-2 and C-6 ), 74.70 (C-4), 127.48, 127.90, 128.66, 128.81 (Ar-CH and C=CH) and
120
134.34 and 136.11 (Ar-C quaternary, C-3 and C-5); m/z (El) 310 (6 8 %, M+) and 293 
(100, [M - OH]+).
Tetrahydro-3,5-^ïS'(phenylmethylene)-4/y-thiopyran-4-one-l,1-dioxide, 67
° Î S i °
To a stirred solution of thiopyranone 60  (900  mg, 3 mmol) in glacial acetic acid (9 cm^), 
cooled to 0  °C, was added dropwise aqueous hydrogen peroxide (30%  v/v; 8 cm^). The 
solution became turbid and was stirred at room temperature for a further 72 h. Water (20 cm^) 
was added and the mixture was extracted with dichloromethane (3 x 50 cm^). The combined 
organic extracts were then dried and evaporated to leave a crude solid. Purification by column 
chromatography (eluant petrol-ethyl acetate 1 :1 ) followed by recrystallisation from glacial acetic 
acid gave bright yellow needles (590  mg, 59% ), mp 199-200 °C (lit.,^^0 198-200 °C) (Found: 
C, 7 0 .5 5 ; H, 4 .95 ; M+, 3 2 4 .0 8 1 8 . Calc, for C 1 9H 1 6 O 3 S: C, 70 .35 ; H, 4.95% ; M+, 
324 .0820); Dm ax(Nujol)/cm 'i 1664 (CO), 1598 and 1566 (C=C) and 1333, 1316 and 1129 
(SO2 ); Ôh(200 MHz; C^HCls) 4 .47  (4 H, s, 2 x 2-H and 2 x 6 -H), 7 .3 5 -7 .5 2  (10 H, m, 
Ar-CH) and 8.02 (2 H, s, 2 x C=CH); 0 c(5 0 .3  MHz; C^HClg) 53.11 (C -2 and C-6 ), 126.59  
(C-3 and C-5), 129.02, 129.61 and 130.10 (Ar-CH), 133.47 (Ar-C quaternary), 144.31  
(C=CH) and 186.27 (CO); m/z (El) 324 (16% , M+), 259 (6 8 , [M - SO2  - H]+) and 115 (100).
Tetrahydro-3,5-ibw(phenylmethylene)-4H-thiopyran-4-ol-l,1-dioxide, 68
OH
This was prepared in an manner identical to 65 and 6 6  above by using thiopyran-4-one- 
1,1-dioxide 67  (300 mg, 930 jxmol) and sodium borohydride (32 mg, 1 mmol) to afford a 
pure white solid (270 mg, 89%), mp 160-162 °C (Found: C, 70.5; H, 5.7; M+, 326.0970.
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C igH igO gS requires C, 69.9; H, 5.55% ; M+, 326.0977); 'Omax(Nujol)/cm-i 3492, 3457 and 
3369 (OH) and 1320 and 1 145 (SO2 ); 6h (300  MHz; C^HClg) 2.15 (1 H, d, J  2.0, OH), 4.22  
(4  H, m, 2 X 2-H and 2 x 6 -H), 5 .00  (1 H, d, J  2.0, 4-H), 7 .0 2  (2 H, s, 2 x C=CH) and 
7 .3 1 -7 .4 0  (10  H, m, Ar-H); 0 c (5 0 .3  MHz; C^HCla) 50 .87  (C-2 and C-6 ), 79 .04  (C -4), 
1 2 8 .2 1 , 1 2 8 .6 8 , 1 2 8 .86  and 1 2 9 .7 2  (Ar-CH and C=CH) and 13 3 .24  and 134.43  
(Ar-C quaternary, C-3 and C-5); m/z (El) 326 (15%, M+), 262  (59 , [M - S0 2 ]+) and 
116 (1 0 0 ).
l , l ’-(T hiodi-l-propyne-3,l-diyl)^ isbenzene, 75
P h - = - ^
S
Ph—= — ^
To a stirred solution of bromide 78 (1 .95  g, 10 mmol) in methanol (3 cm^), under an 
atmosphere of argon, was added sodium sulfide nonahydrate (1 .44 g, 6 mmol) in methanol 
(10 cm^). The solution was then stirred for 16 h under argon, diluted with water (50 cm^) 
and extracted with ether (3 x 50 cm^). The combined organic extracts were dried and 
concentrated to afford an oil that was purified by flash column chromatography (eluant 
petrol) to give a pale yellow oil (1 .3 0  g, 99% ); Dmax(thin film)/cm“i 2189  (C=C); 
§h(200 MHz; C%Clg) 3 .74  (4 H, s, 2 x CH2 ), 7.30-7 .33  (6 H, m, meta Ar-H and para 
Ar-H) and 7 .4 4 -7 .4 9  (4 H, m, ortho Ar-H); 0 c[5 0 .3  MHz; (C % 3 )2 SO] 19.90 (CH2 ), 
83 .07  and 86.13 (CsC), 122.61 (Ar-C quaternary) and 128.84 , 128 .94  and 131.78  
(Ar-CH); m/z (Cl) 263 (100% , [M + H]+), 229 (13, [M + H - SH2]+) and 115 (100).
3-Phenyl-2-propyn-l-ol, 77
Ph—= — \
OH
To a stirred solution of phenyl acetylene (5 cm^; 5.38 g, 52.2 mmol) in THF (150 cm^), 
cooled to -40 °C, was added dropwise n-BuLi (2.5 mol dm“3 in hexanes; 2 2  cm^;
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55 mmol). The solution was allowed to warm to -10 °C over 1 h before paraformaldehyde 
(1.8 g, 60 mmol) was added in one portion and the solution allowed to warm further to 
room temperature over 3 h. Water (50 cm^) was added, the layers separated and the 
aqueous layer extracted further with ether (3 x 60 cm^). The combined organic extracts 
were dried and evaporated and the resultant yellow oil purified by flash column 
chromatography (eluant petrol-ethyl acetate 5:1) to afford alcohol 77 as a clear pale yellow 
oil (6.2 g, 90%); Dmax(thin film)/cm-i 3338 (OH) and 2237 (C=C); 0h(200 MHz; C^HClg)
2.10 (1 H, br s, OH), 4.51 (2 H, br s, 1-H), 7.30-7.34 (3 H, m, meta Ar-H and para 
Ar-H) and 7.43-7.48 (2 H, m, ortho Ar-H); 0c(50.3 MHz; C^HClg) 51.54 (C-1), 85.63 
and 87.17 (C-2 and C-3), 122.48 (Ar-C quaternary) and 128.26, 128.44 and 131.63 
(Ar-CH); m/z (El) 132 (74%, M+), 131 (100, [M - H]+), 115 (32, [M - OH]+) and 102 
(42, [M -CH20]+).
(3-Bromo-l-propynyl)benzene, 78
P h - = — \
Br
To a stirred solution of alcohol 77 (4.0 g, 30.3 mmol) and pyridine (450 mm^) in ether 
(5 cm^), cooled to 0 °C, was added dropwise phosphorus tribromide (4 g, 38.4 mmol). 
The mixture was then heated to 50 °C for 2 h, cooled to room temperature and poured onto 
aqueous sodium hydrogen-carbonate (10% w/v; 200 cm^). After extraction with ether 
(5 X 50 cm^), the combined organic extracts were washed with saturated brine 
(2 X 50 cm^), dried and evaporated to leave an oil which was purified by Kügelrohr 
distillation (oven temperature 90 °C; 0.2 mm Hg) (lit. , 222 9 2  °C; 2 mm Hg) to give a clear 
oil (3.83 g, 65%); 'i)max(thin film)/cm-i 2220 (C=C); 6h(200 MHz; C2HCI3) 4.17 (2 H, s, 
3-H), 7.30-7.34 (3 H, m, meta Ar-H and para Ar-H) and 7.43-7.47 (2 H, m, ortho Ar-H); 
0c(50.3 MHz; C2 H CI3 ) 15.28 (C-3), 84.19 and 86.70 (C-1 and C-2), 122.10 
(Ar-C quaternary) and 128.30, 128.83 and 131.84 (Ar-CH); m/z (El) 194 and 196 
(8%, M+), 115 (90, [M - Br]+) and 105 (100).
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l,l'-(T h iod i-l-propene-3 ,l-d iy l)ô isb en zen e, 79
Ph Ph
To a stirred solution of cinnamyl chloride (10 cm^; 10.74 g, 70.4 mmol) in methanol 
(50 cm^), maintained under an atmosphere of argon was added a solution of sodium 
sulfide nonahydrate (9.4 g, 39 mmol) in methanol (150 cm^). The solution was then 
stirred for 1 h under argon, diluted with water (150 cm^) and extracted with ether 
(4 X 50 cm3). The combined organic extracts were combined, washed with brine and 
dried to afford an oil. Purification by flash column chromatography (eluant petrol) gave a 
cloudy oil which solidified on standing (7.63 g, 77%), mp 29-35 °C (from heptane) 
(lit.,225 33-34 °C); Dmax(Nujol)/cm-i 1596 and 1576 (C=C); 0h(200 MHz; C2HCI3) 3.36 
(4 H, d, J  7.2, 2 X CH2 ), 6.24 (2 H, dt, J  15.8 and 7.2, CH2 -C7 7 =CH), 6.50 (2 H, d, 
J  15.8, CH2 -CH=CH) and 7.28-7.46 (10 H, m, Ar-H); 0c(50.3 MHz; C2 HCI3) 33.08 
(CH2), 125.86, 126.22, 127.50 and 128.53 and 132.39 (Ar-CH and C=CH) and 136.66 
(Ar-C quaternary); m/z (Cl) 383 (100%), 267 (22, [M + H]+), 233 (8 , [M + H - SH2 ]+) 
and 117 {44, [C6H5 -CH=CH(CH2)]+).
2 ,2’-Thio6is-lH -indene, 80
A solution of 2-indanone (1.5 g, 11.35 mmol) and Lawesson's reagent (2.25 g, 6.7 mmol) 
in toluene (20 cm^) was heated under reflux for 2.5 h. The solution was then stirred at 
room temperature for a further 1 2  h, before the solvent was removed under reduced 
pressure. The resultant brown residue was purified by flash column chromatography 
(eluant petrol-ethyl acetate 20:1) to afford sulfide 80 as a white odorous solid (739 mg, 
67%), mp 95-97 °C (lit.,227 9 6  °C); i)max(Nujol)/cm-i 1605 (C=C); 0h(200 MHz;
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C^HCls) 3.61 (4  H s, CH2 ), 6 .9 2  (2 H, s, C=CH) and 7 .1 5 -7 .4 2  (8 H, m, Ar-H); 
ô c (5 0 .3  MHz; C^HClg) 42 .51  (CH2 ), 120.31, 123.40, 124.68 and 126.64  (Ar-CH),
133.08 (C=CH) and 139.82, 143.37 and 144.30 (Ar-C quaternary and C=CH); m/z (CI) 
263 (100% , [M + H]+) and 229 (8, [M + H - SH2]+).
lO-Hydroxy-lOiï-phenoxaborin, 83
3  —  "“-o
2 
l^ O a B
OH
To a stirred solution of diphenyl ether (710  mg, 4.19 mmol) in THF (30  cm^) was added 
dropwise j-BuLi (0 .44  mol dm-  ^in hexanes; 20 cm^; 8.8 mmol). The solution was then 
heated under reflux for 1 h. To this boiling solution was added dropwise tri-w-butyl borate 
(1.13 cm3; 964  mg, 4.19  mmol) and the solution heated under reflux for a further 2 h. The 
solution was cooled to room temperature, cautiously treated with hydrochloric acid 
(2  mol dm'3; 20  cm^) then extracted with ether (3 x 50 cm^). The combined organic 
extracts were dried and evaporated to leave a white solid which was purified by flash 
column chromatography (eluant petrol-ethyl acetate 10:1) to give borinic acid 83 as a white 
solid (500  mg, 61%), mp 274 .5 -275 .5  °C (lit.,230 2 85 °C) (Found: C, 73.75; H, 4.8; M+, 
196.0705. Calc, for C12H9 BO2 : C, 73.55; H, 4.65%; M+, 196.0696); Dmax(Nujol)/cm-i 
3295 (O H ), 1346 (BO) and 1144 (ether); 0h[200 MHz; (C2H3)2S0 ] 7 .26-7 .33  (2 H, m, 
2 X 2-H ), 7 .4 4  (2 H , d, J 8 .3 , 2 x 4-H ), 7 .6 5 -7 .7 2  (2 H, m, 2 x 3-H), 8.18 (2 H, d, 
7 7 .3 , 2 X 1-H) and 9 .92  (1 H, s, OH); 0 c [5 0 .3  M Hz; (C2H3)2SO] 117.22 , 122.30,
132.03 and 133.36 (Ar-CH), 120.38 (br, Ar-CB) and 160.82 (Ar-CO); 0b[96.3 M Hz; 
(CH 3 ) 2 C O -(C % 3 ) 2 CO, 3:1] 37.46; m/z (C l) 196 (100% , M+).
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6 i5 (2 -Brom ophenyl)-ethanedione, 94 and l,2 -^ is(2 -b ro m o p h en y l)-2 -  
hydroxyethanone, 89
Br O O Br Br O OH Br
6 ^  6 %
94 89
A solution of 2-bromobenzaldehyde (5.55 g, 30 mmol), 3-ethyl-5-(2-hydroxyethyl)-4- 
methylthiazolium bromide (400 mg, 1. 6  mmol) and triethylamine (900 mg, 9 mmol) in 
ethanol (12 cm^) was heated under reflux for 12 h and then allowed to cool. The mixture 
was poured onto ice, acidified to pH 1 with hydrochloric acid (2 mol dm-3), then extracted 
with dichloromethane (100 cm^). The organic phase was washed with water 
(2 X 30 cm^), dried and then evaporated to leave a crude solid. Purification by flash 
column chromatography (eluant petrol-ethyl acetate 5:1) gave benzil 94 as a bright yellow 
solid (200 mg, 3.5%) and benzoin 89 as a white solid (3.35 g, 60%).
Less polar 94, mp 127-128 °C (from ethanol) (lit.,237 127-128 °C); 
^rnax(Nujol)/cm-i 1678 (CO); 0h(200 MHz; C ^C lg) 7.47-7.55 (4 H, m, 2 x 4-H and 
2 X 5-H), 7.69-7.74 (2 H, m, 2 x  3-H) and 7.99-8.04 (2 H, m, 2 x  6 -H); 0c(50.3 MHz; 
C^HCls) 123.20 (Ar-CBr)), 127.62, 133.33, 134.41 and 134.58 (Ar-CH), 134.10 
(Ar-C quaternary) and 191.13 (CO); m/z (Cl) 367, 369 and 371 (100%, [M + H]+), 339, 
341 and 343 (63, [M + H - CO]+), 323, 325 and 327 (10, [M + H - C0 2 ]+), 261 and 263 
(21, [M + H - Br - CO]+), 209 (5, [M + H -2  Br]+) and 181 (17, [M + H - CO - 2 Br]+).
More polar 89, mp 77-78 °C (from ethanol) (Found: C, 45.7; H, 2.6. 
C i4 HioBr2 0 2  requires C, 45.45; H, 2.7%) (HRMS: found [M + H]+, 368.9138. 
C 1 4H 1 0B 1 * 2 0 2  requires 368.9126); 'Omax(Nujol)/cm-^ 3484 (OH) and 1699 (CO); 
5h(200M H z; C^HClg) 4.46 (1 H, d, J  5.2, OH), 6.35 (1 H, d, J  5.2, 2-H) and 
7.08-7.57 ( 8  H, m, Ar-H); 0c(50.3 MHz; C^HClg) 77.20 (C-2), 119.67 and 124.16
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(Ar-CBr), 126.94, 127.92, 128.85, 129.23, 130.20, 132.21, 133.11 and 133.57 
(Ar-CH), 136.12 and 137.30 (Ar-C quaternary) and 201.45 (CO); m/z (Cl) 368, 370 and 
372 (3%, M+), 351, 353 and 355 (100, [M - 0H]+), 323, 325 and 327 (85, [M - COzHj^), 
273 and 275 (14, [M - Br - OH]+), 211 (32, [M + H -2  Br]+) and 195 (22, [M + H - OH - 
2 Br]+).
2-Brom o-a-(2-brom ophenyl)-a-benzene methanol, 91
Br OH Br
To a solution of benzophenone 92 (340 mg, 1 mmol) in ethanol (30 cm^), cooled to 0 °C, 
was added sodium borohydride (38 mg, 1 mmol). The solution was stirred for 1 h at 0 °C. 
Water (30 cm^) was added and the solution was concentrated under reduced pressure to 
ca. 30 cm^. More water (30 cm^) was added and the solution was extracted with 
dichloromethane (3 x 30 cm^). The combined organic extracts were dried, evaporated and 
purified, firstly by flash column chromatography (eluant petrol-ethyl acetate 1 0 :1 ) and then 
by Kügelrohr distillation (oven temp. 160 °C; 0.7 mm Hg). This gave the desired 
benzhydrol 91 as a clear oil that solidified on standing (314 mg, 92%), mp 69-71.5 °C 
(HRMS: found M+, 339.9095. CnHioBrgO requires 339.9098); Dmax(Nujol)/cm-^ 
3270 (OH); 5h(200 MHz; C^HCls) 2.64 (1 H, d, 7 4.1, OH), 6.42 [1 H, d, J 4.1, 
C/7(OH)], 7.15-7.34 ( 6  H, m, 2 x 4-H, 2 x 5-H and 2 x 6 -H) and 7.59 (2 H, d, J  7.4, 2 
X  3-H); 0c(50.3 MHz; C^HCls) 74.16 [CH(OH)], 123.82 (Ar-CBr), 127.57, 128.62, 
129.37 and 132.91 (Ar-CH) and 140.83 (Ar-C quaternary); m/z (Cl) 340, 342 and 344 
(13%, M+) and 323, 325 and 327 (100, [M - 0H]+).
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^ï5?(2-Bromophenyl)methanone, 92
Method 1; via 2-B rom o-a-(2-brom ophenyI)-a-hydroxy benzene acetic 
acid, 90
H 0^ C 02H
X fBrBr
Method 1.1: Preparation of 90 by the method of Lee et
To a solution of NaOH (770 mg, 19.2 mmol) and potassium bromate (700 mg, 4 mmol) in 
water (3 cm^) was added benzoin 89 (1.5 g, 4 mmol). The mixture was then heated under 
reflux for 20 h. The resultant oil was treated with excess sulfuric acid (4 mol dm-3; 
30 cm3) which caused the precipitation of a sticky yellow solid. Dichloromethane 
(50 cm3) was added, the layers were separated and the aqueous layer was extracted further 
with dichloromethane (2 x 20 cm^). The combined organic extracts were washed with 
brine (2 x 40 cm^), dried and evaporated to leave a pale yellow solid (1.54 g, quant, 
recovery) which was used in method 1.3 below without any further purification; 
'Omax(Nujol)/cm-i 3432 (OH), 2900 (acid OH) and 1706 (CO); 0h(200 MHz; C^HClg)
7.18-7.38 ( 6  H, m, Ar-H) and 7.60-7.70 (2 H, m, Ar-3-H and Ar-3'-H); 0c(50.3 MHz; 
CmCls) 83.73 [C(0 H)(C0 2 H)1 , 122.69 (Ar-CBr), 127.30, 130.10, 130.43 and 135.37 
(Ar-CH), 137.70 (Ar-C quaternary) and 175.12 (CO2H).
Method 1.2: Preparation of 90 by the method of Bickelhaupt et
A mixture of benzil 94 (1.00 g, 2.72 mmol) and KOH (560 mg, 9.8 mmol) in aqueous 
ethanol (55 v/v; 2.55 cm^) was heated under reflux for 15 min. After the mixture had
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cooled to room temperature it was diluted with water (50 cm^), acidified with hydrochloric 
acid (2 mol dm-^; 20 cm^) and then extracted with dichloromethane (3 x 40 cm^). The 
combined organic extracts were washed with brine (2 x 30 cm^), dried and evaporated to 
leave a cream solid (1.07 g, quant, recovery) which was used in method 1.3 below without 
any further purification. All physical properties were identical to those described in method 
1 .1  above.
Method 1.3: Preparation of 92 by the method of Bickelhaupt et #723?
To a vigorously stirred solution of benzilic acid 90 (500 mg, 1.3 mmol) in glacial acetic 
acid (2 cm3), heated to 50-60 °C, was added sodium bismuthate (450 mg, 1.64 mmol). 
The resultant suspension was heated at 50-60 °C for a further 5 h. Addition of phosphoric 
acid (85%, 15 mol dm~3; 270 mm^) and water (400 mm^) caused the precipitation of a 
white solid which was left to stand for 16 h. Ether (50 cm^) was added and the organic 
solution washed with water (2 x 20 cm^). The aqueous extracts were repeatedly extracted 
with ether ( 8  x 20 cm^) and all the combined organic extracts washed with NaOH 
(1 mol dm-3; 30 cm^) and water (30 cm^). The organic solution was dried and evaporated 
to leave benzophenone 92 as white crystals (360 mg, 82%), mp 84-85 °C (from ethanol) 
(lit.,237 84.5-85.5 °C); i)max(Nujol)/cm-i 1678 (CO); 0h(200 MHz; C^HClg) 7.35-7.50 
( 6  H, m, 2 X 3-H, 2 x 4-H and 2 x 5-H) and 7.63-7.68 (2 H, m, 2 x 6 -H); 5c(50.3 MHz; 
C2 HC 1 3) 121.15 (Ar-CBr), 127.29, 131.29, 132.52 and 134.06 (Ar-CH), 139.25 
(Ar-C quaternary) and 195.39 (CO); m/z (Cl) 339, 341 and 343 (100%, [M + H]+), 259 
and 261 (35, [M + H - HBr]+) and 181 (76, [M + H -2  Br]+).
Method 2
A solution of 2-bromobenzaldehyde (1.33 g, 60 mmol), 3-ethyl-5-(2-hydroxyethyl)-4- 
methylthiazolium bromide (1.10 g, 4.0 mmol) and triethylamine (1.8 g, 18 mmol) in 
ethanol (12 cm^) was heated under reflux for 12 h. The solution was cooled to room
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temperature, poured onto ice, acidified to pH 1 with hydrochloric acid (2 mol dm“3), 
extracted with dichloromethane (4 x 50 cm^) and the combined organic extracts dried and 
evaporated. Purification of the resultant oil by flash column chromatography (eluant petrol- 
ethyl acetate 5:1) gave a mixture of benzil 94 and benzoin 89 (6.7 g). To this mixture was 
added a solution of potassium bromate (3.2 g, 18 mmol) and NaOH (3.5 g, 87.2 mmol) in 
water (13 cm^) and the resultant suspension heated under reflux for 18 h. After 
acidification with hydrochloric acid (12 mol dm-3; 30 cm^), the resultant slurry was 
extracted with dichloromethane (4 x 50 cm^) and the combined organic extracts washed 
with saturated brine (2 x 50 cm^), dried and evaporated to afford an oil. Purification by 
flash column chromatography (eluant petrol-ethyl acetate 30:1) gave the desired 
benzophenone 92 as a white solid (3.51 g, 60%). All physical properties were identical to 
those described in method 1.3 above.
(2-BromophenyI)(4’-bromophenyl)methanone, 93
Br O
To a stirred mixture of bromobenzene (20 cm^; 29.82 g, 190 mmol) and 2-bromobenzoyl 
chloride (2.23 cm^; 3.73 g, 17.0 mmol) was added anhydrous aluminium chloride (2.54 g, 
18.7 mmol) in four portions over 10 min. The mixture was then heated to 100 °C for 
30 min. Excess bromobenzene was distilled off to leave a brown residue which was 
purified by flash column chromatography (eluant petrol-ethyl acetate 2 0 :1 ) to afford a pale 
yellow oil. Further purification by Kügelrohr distillation (oven temperature 160 °C; 
0.5 mm Hg) gave a clear oil which solidified on standing (1.74 g, 30%), mp 48-50 °C 
(lit.,235 62 °C and lit.,236 51-52 °C) (Found: C, 46.25; H, 2.2. CnHgBrzO requires C, 
45.90; H, 2.35%) (HRMS: found [M + H]+, 338.9029. CwHioBriOz requires 
338.9020); i)max(Nujol)/cm-i 1674 (CO); 0h(200 MHz; C^HClg) 7.32-7.50 (3 H, m, 
Ar-H) and 7.58-7.12 (5 H, m, Ar-H); 0c(50.3 MHz; C^HClg) 119.42 and 129.136
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(Ar-CBr), 127.33, 128.93, 131.40, 131.57, 131.99, 133.24 (Ar-CH), 134.85 and 140.07 
(Ar-C quaternary) and 194.88 (CO); m/z (Cl) 339, 341 and 343 (100%, [M + H]+), 258 
and 260 (15, [M - HBr]+), 180 (11, [M - 2 Br]+) and 152 (9, [M - 2 Br - CO]+).
^ïs(2-ChIorophenyI)methanone, 95
Cl O Cl
A solution of 2-chlorobenzaldehyde (13.34 g, 95 mmol), 3-ethyl-5-(2-hydroxyethyl)-4- 
methylthiazolium bromide (1.5 g, 5.95 mmol) and triethylamine (3 g, 30 mmol) in ethanol 
(40 cm3) was heated under reflux for 5 h. The solution was allowed to cool to room 
temperature, poured onto ice and acidified to pH 1 with hydrochloric acid (2 mol dm-3). 
The solution was then extracted with dichloromethane (4 x 50 cm^) and the combined 
organic extracts were combined, dried and evaporated to leave impure \,2-bis{2- 
chlorophenyl)-2-hydroxyethanone as a soft yellow solid (14.64 g), which was used in the 
next step with no purification; t>max(Nujol)/cm-  ^3480 (OH) and 1698 (CO); 5h(200 MHz; 
C 2 HC 1 3) 4.43 (1 H, br s, OH), 6.35 (1 H, s, 2-H) and 7.15-7.59 ( 8  H, m, Ar-H); 
m/z (Cl) 281, 283 and 285 (17%, [M + H]+), 265 (95) and 237 (100).
A mixture of the crude l,2 -Z7w(2 -chlorophenyl)-2 -hydroxyethanone (13.64 g), water 
(38 cm2), NaOH (9.61 g, 240 mmol) and potassium bromate (8 . 8  g, 49.45 mmol) was 
heated under reflux for 5 h. The heat source was removed and hydrochloric acid 
(12 mol dm-2; 25 cm^) was added which caused the mixture to boil again. Once cool, the 
mixture was diluted with water (50 cm^) and the solution was extracted with 
dichloromethane ( 6  x 50 cm^). The combined organic extracts were dried and evaporated 
to leave a pale yellow oil which was purified by flash column chromatography (eluant 
petrol-ethyl acetate 10:1) to afford benzophenone 95 (7.46 g, 62.6%) as white solid, 
mp 43-46 °C (from ethanol) (lit.,240 45-46 °C); t )m a x (N u jo l) /cm -i  1668 (CO);
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Ôh(200MHz; C2 HC1 3) 7.30-7.55 (8 H, m, Ar-H); ôc(50.3 MHz; C2 HCI3 ) 126.80, 
130.61, 130.878 and 132.45 (Ar-CH), 132.59 (Ar-CCl), 137.90 [Ar-C(CO)] and 194.26 
(CO); m/z (CI) 251, 253 and 255 (100%, [M + H]+), 215 and 217 (10, [M + H - HC1]+) 
and 139 and 141 (10, [M + H - C6H5C1]+).
2-[(2’-Nitrophenyl)thio]bromobenzene, 97
To a solution of 2-bromothiophenol (12.4 cm^; 19.5 g, 100 mmol) and 
2-chloronitrobenzene (12.0 cm^; 16.1 g, 100 mmol) in DMF (125 cm^) was added sodium 
hydrogen-carbonate (10.1 g, 120 mmol). The suspension was heated at 70 °C for 4 h. 
The sodium chloride that precipitated was filtered off and washed with chloroform 
(2 X 50 cm2). The combined organic extracts were concentrated and the resultant yellow 
oil dissolved in ethyl acetate (600 cm2) and washed with water (2 x 200 cm2). The organic 
solution was then dried and evaporated to leave a bright yellow solid (29.80 g, 96%) which 
was used without further purification, mp 114-115 °C (from ethanol) (lit.,287 116-117 °C) 
^max(Nujol)/cm-i 1515 and 1338 (NO^); Ôh(200 MHz; C2HCI3) 6.77 (1 H dd, J  6.6 and 
1.4, Ar-H), 7.23-7.49 (4 H, m, Ar-H), 7.70-7.81 (2 H, m, Ar-H) and 8.28 (1 H, dd J 8.2 
and 1.6, 3’-H); 0c(50.3 MHz; C2 HCI3 ) 125.30, 125.87, 127.85, 128.83, 131.69, 
133.63, 134.24 and 137.98 (Ar-CH), 130.99, 132.18 and 137.24 (Ar-C-1, Ar-C-2 and 
Ar-C-F) and 144.98 (Ar-CNO^); m/z (Cl) 310 and 312 (100%, [M + H]+), 230 (18, 
[M + H - HBr]+), 214 (20, [M + H - HBr - 0]+) and 184 (6 , [M + H - HBr - N0 2 ]+).
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2-[(2'-Bromophenyl)thio]benzeneamine, 98
Br NHg
To a solution of SnCl2.2H20 (100 g, 452 mmol) in hydrochloric acid (12 mol dm-2; 
150 cm2) was added sulfide 97 (14 g, 45.2 mmol) followed by ethanol (150 cm2). The 
suspension was heated at 70-80 °C for 4 h and then cooled to room temperature. The 
resultant solution was extracted with toluene (5 x 300 cm2) and the combined organic 
extracts dried and evaporated to leave a red solid (12.80 g). The acidic aqueous layer was 
neutralised with aqueous sodium hydroxide (10 mol dm-2) and the precipitated tin salts 
filtered off over celite. The salts were washed with chloroform (4 x 500 cm2) and the 
combined organic extracts dried and evaporated to leave a white solid (5.17 g). 
Purification of both organic solids by flash column chromatography (eluant petrol-ethyl 
acetate 7:1 - 2:1) gave the desired product as a white solid (8.77 g, 70%), mp 67-68 °C 
(from ethanol) (lit.,28? 62-63 °C); Dmax(Nujol)/cm-^ 3463 and 3365 (NH2); §h(200 MHz; 
C2HCI3) 4.32 (2 H, br s, NH2), 6.62 (1 H, dd, J 7.8 and 1.7, Ar-H), 6.77-6.85 (2 H, m, 
Ar-H), 6.94-7.02 (1 H, m, Ar-H), 7.07-7.15 (1 H, m, Ar-H), 7.27-7.35 (1 H, m Ar-H) 
and 7.46-7.56 (2 H, m, Ar-H); 8c[50.3 MHz; (C2H3)2 S0 ] 110.50, 120.16 and 138.09 
(Ar-C-2, Ar-C-1' and Ar-C-2'), 115.44, 117.30, 126.16, 126.78, 128.39, 132.07,
133.00 and 137.63 (Ar-CH) and 151.07 (Ar-CNHz); m/z (Cl) 280 and 282 (90%, 
[M + H]+), 279 and 281 (100, M+) and 199 (45, [M - HBr]+).
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l,l'-Thio6ïs(2-brom obenzene), 99 and ^»(2-bromophenyl)disulfide, 106
Br Br Br Br
,S-S.
10699
Method 1: Method of Wiley et
To stirred sulfuric acid (18 mol dm-3; 8.5 cm^) was added in 5 portions sodium nitrite 
(1.23 g, 17.5 mmol) and the mixture stirred for 30 min. A solution of amine 98 (4.5 g, 
16 mmol) in glacial acetic acid (29 cm^) was added dropwise to the diazotization solution 
at such a rate that the temperature was maintained at 16-20 °C. The resultant brown 
suspension was stirred for an additional 30 min at 16-20 °C then poured slowly onto a 
suspension of cuprous bromide (2.92 g, 20 mmol) in 45% HBr in glacial acetic acid 
(12 cm3) and rinsed with additional 45% HBr in glacial acetic acid (2 x 8  cm^). The 
mixture was partially neutralised by the extremely cautious addition of aqueous ammonia 
(35%, 18 mol dm-3; 29 cm^), then diluted with water (50 cm^) and the resultant solution 
extracted with chloroform (5 x 50 cm^). The combined organic extracts were washed with 
aqueous ammonia (3.2%, 1.8 mol dm-^; 3 x 30 cm^) and water (30 cm^) then dried and 
evaporated to leave a crude red oil. Purification by flash column chromatography (eluant 
petrol-ethyl acetate 100:0.5) afforded sulfide 99 as a white solid (1.95 g, 35%), 
mp 71.5-72.5 °C (from pentane) (lit.,241 67.5-68 °C); 0 h ( 2 0 0  MHz; C^HClg) 7.11-7.29 
( 6  H, m, 2 X 4-H, 2 x 5-H and 2 x 6 -H) and 7.64 (2 H, d, J  7.7, 2 x 3-H); 0c(50.3 MHz; 
C^HCls) 125.77 (Ar-CBr), 128.14, 128.76, 132.38 and 133.47 (Ar-CH) and 135.60 
(Ar-CS); m/z (Cl) 360, 362 and 364 (15%, [M + NH4 ]+), 342, 344 and 346 (20, M+) and 
184 (100, [M - 2Br]+).
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Method 2
To a vigorously stirred suspension of 2-bromoaniline (14.14 g, 82.07 mmol) in 
hydrochloric acid (9 mol dm-^; 40 cm^), cooled to 0 °C, was added dropwise over 30 min a 
solution of sodium nitrite (6 g, 85 mmol) in water (7.5 cm^). The resultant cloudy solution 
was treated with ice-cold water (5 cm^) and the solution decanted from the sediment into 
another ice-cold beaker. A solution of sodium fluoroborate (11 g, 100 mmol) in ice-cold 
water (25 cm^) was added and the cream-coloured precipitate left to stand for 20 min at 
0 °C before it was filtered through a chilled (5 °C) filtration apparatus and washed with 
ice-cold water (2x5  cm^). Drying under reduced pressure in a desiccator over phosphoms 
pentoxide for 3 days afforded crude 2-bromobenzene diazonium fluoroborate 103 as a 
white solid (16 g, 72%) which was used in the next step with no further purification, 
mp 132 °C (decomp.) [lit.,253 1 5 6  °C (decomp.)]; i)max(Nujol)/cm-i 2291 (N=N); 
0h(200MHz; C2HCI3) 7.96-8.04 and 8.13-8.23 (2 H, 2 x m, 4-Hand 5-H), 8.33 (1 H, 
d, J 8.3, 3-H) and 8.87 (1 H, d, J  8.2, 6 -H); §c(50.3 MHz; C^HCh) 118.75 (Ar-CN=N),
124.63 (Ar-CBr) and 130.49, 135.15, 135.35 and 141.95 (Ar-CH); m/z (Cl) 175 and 177 
(10%, [M + H]+), 174 and 176 (100, M+) and 73 (40).
To a stirred solution of 2-bromothiophenol (1 cm^; 1.573 g, 8.32 mmol) and sodium 
hydrogen-carbonate (2 g, 16 mmol) in DMF (20 cm^) was added a solution of diazonium 
salt 103 (4.32 g, 16 mmol) in DMF (20 cm^). The mixture was then heated at 90 °C for 
30 min, cooled to room temperature and poured onto saturated aqueous brine (50 cm^). 
After extraction of the solution with ethyl acetate (4 x 50 cm^), the combined organic 
extracts were washed with water (3 x 80 cm^), dried and evaporated to leave an oil. 
Purification by flash column chromatography (eluant petrol-ethyl acetate 200:1) gave 
sulfide 99 as a white solid (250 mg, 8.7%). Physical properties were identical to those 
described in method 1 above.
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Method 3
A solution of 1,2-dibromobenzene (14.15 g, 60 mmol) in a mixture of ether (45 cm^) and 
THF (270 cm^) was cooled with a liquid nitrogen-pentane slurry such that the temperature 
could be maintained between -110 and -120 °C. «-BuLi (1.6 mol dm-^ in hexanes; 
37.5 cm3; 60 mmol) was added dropwise at a rate that at which the temperature could be 
maintained below -110 °C (45 nun). Freshly distilled sulfur dichloride (2 cm^; 30 mmol) 
was then added dropwise over 30 min. The mixture was stirred at -110 °C for a further 
60 min then allowed to warm to room temperature over 16 h. Saturated aqueous 
ammonium chloride ( 1 0 0  cm^) was added, the layers were separated and the aqueous layer 
extracted further with ether (4 x 100 cm^). The combined organic extracts were dried and 
concentrated to give a yellow oil which. Purification by flash column chromatography 
(eluant petrol-ethyl acetate 100:0.5) afforded less polar impure disulfide 106 as a white 
solid (1.7 g, 15%) and more polar sulfide 99 as a clear oil which crystallised on standing 
( 3 . 8  g ,  3 7 % ) .
Less polar 106 was found to be contaminated with 99, even after several attempts at 
purification: Ô h ( 2 0 0  MHz; C^HClg) 7.24-7.44 ( 6  H, m, 2 x 4-H, 2 x 5-H and 2 x 6 -H) 
and 7.69 (2 H, d, J  7.0, 2 x 3-H); 0c(50.3 MHz; C^HCIg) 123.47 (Ar-CBr), 127.08, 
129.35 and 130.94 (Ar-CH) and 132.54 (Ar-CS); m/z (Cl) 431, 433 and 435 ( 1 7 % ,  
[M + H + C4Hg]+), 375, 377 and 379 (77, [M + H]+) and 59 (100).
More polar 99 had physical properties identical to those described in method 1 above.
Method 4
To stirred molten 2-bromoaniline (4.76 g, 87.65 mmol) was added hydrochloric acid 
(12 mol dm'3; 7.5 cm^; 90 mmol) in water (50 cm^). The mixture was heated to 60 °C to 
effect complete dissolution of the amine. The solution was then cooled to and maintained at
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0-2 °C and vigorously stirred whilst a solution of sodium nitrite (2.36 g, 33.2 mmol) in 
water (6 cm^) was added dropwise. After confirmation of the presence of excess nitrous 
acid (starch-iodide paper), the solution was neutralised to pH 4 with sodium acetate 
(3.31 g, 40 mmol). The resultant clear yellow solution was transferred to a dropping 
funnel and added dropwise to a stirred mixture of 2-bromothiophenol (5.39 g, 
27.65 mmol), NaOH (3.4 g, 85 mmol) and copper powder (2.1 g, 33 mmol) in water 
(20 cm^), cooled to 0-5 °C. After the addition of the diazonium chloride was complete, the 
solution was heated to 90 °C for 1 h. The solution was then cooled to room temperature, 
extracted with ether (3 x 50 cm^) and the combined organic extracts washed with brine 
(2 X 50 cm^), dried and evaporated to leave a jet black oil. Purification by flash colurmi 
chromatography (eluant petrol-ethyl acetate 200:1) afforded a mixture of less polar impure 
disulfide 106 as a white solid (1.8 g) and more polar sulfide 99 as a white solid (3.08 g, 
32.4%). These solids had physical properties identical to those described in methods 1 and 
2 above.
l,I'-Sulfonyl ftis(2-chlorobenzene), 101
To a stirred solution of diphenyl sulfone (2.25 g, 10 mmol) in THF (100 cm^), cooled to 
-30 °C, was added dropwise n-BuLi (1.6 mol dm-3 in hexanes; 13.70 cm^; 22 mmol). The 
red solution was stirred for 45 min at -30 °C and then benzene sulfonyl chloride (4.41 g, 
25 mmol) in THF (50 cm^) was added dropwise. After a further 30 min, aqueous NaOH 
(2 mol dm'3; 20 cm^) and then water (30 cm^) were added. The layers were separated and 
the aqueous layer was extracted further with chloroform (3 x 70 cm^). The combined 
organic extracts were dried and evaporated to leave the product as a white solid (2.86 g, 
99%), mp 185-185.5 °C (from ethanol) (lit.,245 183 °C) (Found: C, 50.05; H, 2.7. Calc, 
for C12H 8CI2 O2 S requires C, 50.2; H, 2.8%); Dmax(Nujol)/cm-^ 1327 and 1158 (SO2);
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Ôh(200 M H z; C^HClg) 7.38-7.61 ( 6  H, m, 2 x 3-H, 2 x 4-H and 2 x 5-H) and 8.42-8.48 
(2 H, m, 2 X  6 -H); ôc(50.3 MHz; C^HCla) 126.89, 131.61, 132.76 and 134.85 (Ar-CH), 
132.41 (Ar-CBr) and 137.34 (Ar-CS0%); m/z (thermospray) 304, 306 and 308 (1 0 0 %, 
[M+ NH4 ]+).
2-(Benzenesulfonyl)-phenyl-boronic acid, 108 and (lO-Hydroxy-lOiH- 
phenothiaborin-4-yl)-boronic acid 5,5-dioxide, 109
HO. .OH 
I Oc^c.0
Il l!
B-OH
HO
108 109
Method 1
To a stirred solution of diphenyl sulfone (450 mg, 2 mmol) and TMEDA (660 mm^;
4.4 mmol) in ether (20 cm^), cooled to -30 °C, was added dropwise «-BuLi (1.6 mol dm*3 
in hexanes; 2.8 cm^; 4.4 mmol). The resultant yellow solution was stirred for 10 min and 
then cooled to -70 °C. Triwopropyl borate (425 mm^; 2.2 mmol) was added dropwise and 
the solution stirred for a further 30 min then poured onto hydrochloric acid (2 mol dm* ;^ 
20 cm^). The layers were separated and the aqueous phase was extracted further with 
ether (3 x 30 cm^). The combined organic extracts were dried and evaporated to leave a 
crude solid which was purified by flash column chromatography (eluant chloroform- 
methanol; 20:1 - 12:1) to afford 108 (210 mg, 40%) and 109 (40 mg, 7%), both as white 
solids.
Less polar 108, mp ca. 110-160 °C (Found: C, 55.3; H, 4.0. C12H 11BO4 S requires C, 
55.2; H, 3.85%); Dmax(Nujol)/cm-l 3456 and 3337 (OH), 1340 (br, BO and SO2 ) and 
1157 (S O 2 ); Ôh[300 M Hz; (C % 3 )2 SO] 7.46-7.67 ( 6  H, m, Ar-H), 7.83 (1 H, d, J  7.5, 
Ar-H), 8.05 (2 H, dd, J  7.5 and 1.2, Ar-H) and 8 . 8 8  [2 H, br s, B(OH)2 ]; ôc[75.4 MHz;
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(C % 3 )2 SO] 128.24, 128.39, 129.31, 129.83, 132.63, 132.91 and 133.87 (Ar-CH),
140.33 (br, Ar-CB) and 142.19 and 142.98 (Ar-CS0 2 ); Ô b [ 9 6 . 3  MHz; 
(CH3)2CO-(C%3)2CO, 3:1] 30.54; m/z (ES+) 733 (13%, [3M - 3 H2 O + H]+), 489 (100, 
[2M - 2 H2O + H]+) and 245 (28, [M - H2O + H]+).
More polar 109, mp 192-194 °C; \)max(Nujol)/cm-i 3223 (OH), 1309 (br, BO and SO2), 
1163 (SO2); Ô h [ 2 0 0  M H z; (C % 3)2 SO] 7.42-8.09 (7 H, m, Ar-H), 8 .2 1  [2 H, s, B(OH)2 l 
and 9.34 [1 H, s, B(OH)]; 5c[75.4 MHz; (C%3)2S0 ] 127.11, 128.93, 131.25, 132.17, 
1 3 2 . 5 7 ,  133.43 and 136.33 (Ar-CH), 135.30 and 140.10 (br, Ar-CB) and 143.46 and
145.14 (Ar-CS0 2 ); 0 b [ 9 6 . 3  M H z ; (CH3 )2 C0 -(C % 3 )2 C0 , 3:1] 21.04 and 28.52; m/z 
(ES+) 289 (100%, [M + H]+) and 271 (28, [M + H - H2 0 ]+).
Method 2
This preparation was similar in manner to method 1 above, but only 1 equivalent of 
n-BuLi was used: the reaction employed diphenyl sulfone (2.26 g, 10 mmol) in THE 
(100 cm3), ff-BuLi (2.4 mol dm-3 in hexanes; 4.6 cm^; 11 mmol), triwopropyl borate 
(2.6 cm3; 1 1  mmol) and saturated aqueous ammonium chloride (30 cm^). Additionally, 
after the addition of the trizjopropyl borate, the solution was warmed to 30 °C and 
maintained at this temperature for 30 min before it was quenched by addition of the 
saturated aqueous ammonium chloride. Purification by flash column chromatography 
(eluant petrol-ethyl acetate 1:1) gave boronic acid 108 (1.53 g, 58%) as a white solid 
which had physical properties identical to those described in method 1 above.
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Dimethyldioxirane 116
H aC -^C H s
0—0
A 2000 cm^ round-bottomed flask equipped with a stillhead, solids addition funnel and 
thermometer was connected to a two-necked receiving flask, which was cooled to -70 °C. 
The reaction flask was charged with a mixture of water (127 cm^), acetone (96 cm^), and 
sodium hydrogen-carbonate (29 g, 35 mmol) and cooled to 0-5 °C. With vigorous stirring, 
Oxone® (2 KHS0 5 «KHS0 4 «K2HS0 4 ) (60 g, 98 mmol) was added in five portions over 
15 min. 3 min after the final addition, a moderate vacuum (80-100 mm Hg) was applied, 
and the cooling flask removed from the reaction flask. The dimethyldioxirane/acetone 
solution distilled {ca, 50 cm^) and collected in the cooled receiving flask. An approximate 
measure of the concentration {ca. 0 . 1  mol dm“3) was obtained by oxidising diphenyl sulfide 
to its sulfoxide with an aliquot of the dimethyldioxirane solution, monitoring the reaction 
by TLC.
10,10'-0xy&w(10jfir-phenothiaborin), 117
Method 1
To a stirred solution of sulfide 99 (1.03 mg, 3 mmol) in THF (50 cm^), cooled to -70 °C, 
was added dropwise «-BuLi (1.6 mol dm'^ in hexanes; 3.75 cm^, 6  mmol). The yellow 
solution was then stirred at -70 °C for a further 5 min. Tri-n-butyl borate (825 mm^; 
690 mg, 3 mmol) added dropwise and the solution was stirred for a further 30 min at 
-70 °C before it was allowed to warm to room temperature over 30 min. Saturated
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aqueous ammonium chloride ( 2 0  cm^) was added, the layers were separated and the 
aqueous layer was extracted further with ether (3 x 30 cm^). The combined organic 
extracts were dried and evaporated to leave a pale yellow solid. Purification of the crude 
solid by flash column chromatography (eluant petrol-ethyl acetate 7:1) gave pure borinic 
anhydride 117 as a white solid (425 mg, 67%), mp 301-303 °C (from ethyl acetate- 
cyclohexane) (Found: C, 71.25; H, 4.0; M+, 406.0822. C2 4H 16B2OS2  requires C, 71.0; 
H, 3.95%; M+, 406.0829); i)max(Nujol)/cm-i 1378 (BO); Ô h [ 2 0 0  M H z ; (C2H 3)2S0] 
7.38-7.44 (2 H, m, 2 x 2-H), 7.60-7.62 (4 H, m, 2 x 3-H and 2 x 4-H), 7.36 (2 H, d, 
7 7.4, 2 X 1-H) and 9.93 (1 H, s, OH, caused by in situ hydrolysis of the borinic 
anhydride); 0c[50.3 MHz; (C % 3 )2SO] 124.08, 125.20, 131.43 and 134.00 (Ar-CH), 
128.57 (br, Ar-CB) and 143.20 (Ar-CS); 0 b [ 9 6 . 3  M H z ; (CH3 )2 CO -(C% 3 )2CO, 3:1] 
30.39; m/z (Cl) 424 (10%, [M + NH4 ]+), 406 (5, M+) and 212 {100, ([M + H2 0 ]/2 )+}.
Method 2
To sulfide 150 (330 mg, 1 mmol) was added anhydrous aluminium chloride ( 6 6  mg, 
500 p,mol). Dichloromethane (20 cm^) was added and the solution cooled to -70 °C. 
Boron tribromide (1 mol dm'3 in dichloromethane; 1 cm^; 1 mmol) was added dropwise 
and the solution was allowed to warm to room temperature over 16 h. Saturated aqueous 
ammonium chloride ( 2 0  cm^) was then added, the layers were separated and the aqueous 
phase was extracted further with ether (3 x 30 cm^). The combined organic extracts were 
dried and evaporated to afford a crude solid. Purification by flash column chromatography 
(eluant petrol-ethyl acetate 7:1) gave pure borinic anhydride 117 (95 mg, 47%) which had 
physical properties identical to those described in method 1 above.
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2-(Dimethylamino)ethyl diphenyl horinate, 118
2 -aminoethyl diphenyl borinate ( 5 0 0  mg, 2 . 2  mmol) was suspended in a mixture of ether 
( 3 0  cm^) and hydrochloric acid (1  mol dm'^; 3 0  cm^). The suspension was vigorously 
stirred for 3 0  min. The layers were separated and the aqueous layer was extracted further 
with ether (3  x 3 0  cm^). The combined organic fractions were then dried and concentrated 
to ca. 1 0  cm3. A mixture of A,A^-dimethylethanolamine (3  cm^) and methanol (3  cm^) was 
then added. The resultant suspension was left to stir for 1 h, during which time a white 
solid precipitated. The solid was filtered and washed with water (3  x 1 0  cm^) to afford 
dimethylethanolamine ester 118 ( 3 7 0  mg, 6 6 % ) ,  mp 1 6 1 - 1 6 4  °C (from ethyl acetate- 
cyclohexane) (lit.,269 1 6 5 - 1 6 6  °C); Dmax(Nujol)/cm-l 1 0 7 2  (C-O); 0 h [ 3 0 0  MHz; 
( C % 3 ) 2 S O ]  2 . 5 2  ( 6  H, s, 2  X CH3 ), 2 . 9 3  [ 2  H, br s, CH2 N(CH 3 )2 ], 4 . 1 1  (2 H, br s, 
CH2OB), 7 . 0 8 - 7 . 2 4  ( 6  H, m, meta and para Ar-H) and 7 . 6 6 - 7 . 7 0  ( 4  H, m, ortho Ar-H); 
0 c [ 7 5 . 4  MHz; ( C % ) 2 SO] 4 6 . 8 0  [N(CH3)2], 6 0 . 1 9  and 60.34 (CH2 CH2 ), 1 2 5 . 8 2  and 
1 2 7 . 1 0  {meta Ar-CH and para Ar-CH), 1 3 2 . 6 3  {ortho Ar-CH) and Ar-CB (not detected); 
6 b [ 9 6 . 3  MHz; {CH^)2 CO -{C m ^)2 CO, 3 : 1 ]  9 . 0 9 ;  m/z (Cl) 2 5 4  ( 1 0 0 % ,  [M + H]+), 
1 7 6  ( 2 8 ,  [M + H - C6Hô]+) and 9 0  ( 1 9 ) .
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Dibenzothiophene, 121 and (10-Methyl-10fir-phenothiaborin-5,5-dioxide)-
ammonia (1:1), 122
^HaC' NHa 
121 122
To a stirred solution of diphenyl sulfone (1.09 g, 5 mmol) in THF (50 cm^), cooled to 
-30 °C, was added dropwise «-BuLi (2.5 mol dm-3 in hexanes; 4 cm^; 10 mmol). The 
resultant yellow suspension was then stirred for 30 min. Diwopropoxymethylborane 
(950 mm^; 720 mg, 5 mmol) was added dropwise and the suspension stirred for a further 
1 h at -30 °C before it was allowed to warm to room temperature over 16 h. Saturated 
aqueous ammonium chloride (30 cm^) was added, the layers were separated and the 
aqueous phase was extracted further with ether (3 x 50 cm^). The combined organic 
extracts were dried and evaporated to leave a pale yellow solid. Purification by flash 
column chromatography (eluant petrol-ethyl acetate 3:1) gave less polar dibenzothiophene 
121 (70 mg, 7%) and more polar ammonia adduct 122 (670 mg, 52%) both as a white 
solids.
Less polar dibenzothiophene 121, mp 97-99 °C (lit. ,^ 8 8  9 7 -IOO °C); bn[200 MHz; 
(C % 3 )2 SO] 7.52-7.56 (4 H, m, Ar-H), 8.03-8.08 (2 H, m, Ar-H) and 8.37-8.42 (2 H, 
m, Ar-H); ôc[75.4 MHz; (C2 H3 )2 S0 ] 122.30, 123.30, 125.00 and 127.35 (Ar-CH) and
135.28 and 138.79 (Ar-C quaternary); m/z (Cl) 185 (100%, [M + H]+).
More polar ammonia adduct 122, mp 2 5 5  °C (decomp.) (from ethyl acetate-cyclohexane) 
(Found: C, 6 0 . 1 5 ;  H, 5 . 5 5 ;  N, 5 . 3 5 .  C 1 3H 1 4BNO 2 S requires C, 6 0 . 2 5 ;  H, 5 . 4 5  
N, 5 . 4 % )  (HRMS: found [M + H]+, 2 6 0 . 0 9 1 3 .  C1 3H 1 5BNO2 S requires 2 6 0 . 0 9 1 7 )  
a)max(Nujol)/cm'i 3 2 8 3 ,  3 2 1 4  and 3 1 6 0  (NH3 ) and 1 3 0 2  and 1 1 5 9  (SO2 ); Ô h [ 5 0 0 .3  MHz
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(C 2 H 3 )2 S0 ] 0.26 (3 H, s, CH3 ), 5.53 (3 H, NH3 ), 7.47-7.50 (2 H, m, 2 x 3-H), 
7.58-7.62 (2 H, m, 2 x 2-H), 7.88 (2 H, d, J 7.0, 2 x 1-H) and 7.86 (2 H, d, J 8.0, 
2 X  4-H); ôc[75.4 MHz; (C2 H3 )2 S0 ] 10.51 (br, CH3 ), 122.46 (C-4), 126.08 (C-3),
131.34 (C-2), 132.03 (C-1), 142.62 (Ar-CS0 2 ) and 155.47 (br, Ar-CB); 8b[96.3 MHz; 
(CH 3 )2 C 0 -(C 2 H 3 )2 C0 , 3:1] -12.29; m/z (CI) 260 (55%, [M + H]+), 243 (100, 
[M + H - NH3 ]+) and 227 (5).
2-(PhenylsulfonyI)phenol, 124 and 2,2’-Sulfonyl^>ïsrphenol, 125
124 125
Method 1
To a stirred solution of ammonia adduct 122 (168 rag, 646 (imol) in THF (5 cm^) was 
added dropwise aqueous sodium hydroxide (3 mol dm- ;^ 750 mm^; 2.25 mmol). Aqueous 
H2O2 (30% v/v; 750 mm^) was added dropwise and the mixture was heated to 50 °C for 
2 h. The solution was then cooled to room temperature and neutralised to pH 7 with 
aqueous citric acid (7.5% w/v). The layers were separated and the aqueous phase was 
extracted further with ethyl acetate (3 x 20 cm^). The combined organic extracts were dried 
and evaporated to leave a white solid which was purified by flash column chromatography 
(eluant petrol-ethyl acetate 2:1) to give less polar phenol 124 (20 mg, 13%) and more polar 
bisphenol 125 (50 mg, 31%), both as white solids.
Less polar 124, mp 98.5-99 °C (lit.,289 98-99 °C); Dmax(Nujol)/crn-i 3360 (OH), 1305 
and 1146 (SO2 ) and 1090 (CO); 0h[200 MHz; (C % 3 )2SO] 6.92 (1 H, d, 7 8.1, Ar-H), 
7.00-7.07 (1 H, m, Ar-H), 7.47-7.69 (5 H, m, Ar-H), 7.89-7.96 (2 H, m, Ar-H) and
10.80 (1 H, br s, OH); 8c(50.3 MHz; C^HClg) 119.14, 120.78, 126.79, 129.18, 129.44,
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133.70 and 136.14 (Ar-CH), 123.46 and 141.60 (Ar-CS0 2 ) and 155.88 [Ar-C(OH)]; 
m/z (Cl) 235 (100%, [M + H]+) and 219 (50, [Ph2S0 2 ]+).
More polar 125, mp 189.5-191 °C (lit.,290 1 89.5-191 °C) (HRMS: found M+, 250.0305. 
Calc, for C12H 10BOS: 250.0300); Dmax(Nujol)/cm -i 3356 (OH), 1310 and 1144 (SO2) 
and 1209 (CO); 0h[200 MHz; (C2 H 3 )2 S0 ] 6.85 (2 H, dd, J  8.2 and 1.0, 2 x 6 -H), 
6.96-7.04 and 7.42-7.51 (2 x 2 H, 2 x m, 2 x 4-H and 2 x 5-H), 7.91 (2 H, dd, /  8.0 and 
1.7, 2 X 6 -H); 5c[50.3 MHz; (C2 H 3 )2 S0 ] 117.35, 119.13, 130 and 135.64 (Ar-CH), 
126.76 (Ar-C-2) and 155.87 (Ar-C-1); m/z (El) 250 (52%, M+), 157 (45, [M - CgHsOl+l 
and 94 (100, [CeHsOH]-»-).
Method 2
To a stirred solution of boronic acid 108 (375 mg, 1.44 mmol) in THF (10 cm^) was 
added in one portion sodium perborate tetrahydrate (220 mg, 1.44 mmol). The suspension 
was stirred for 2  h at room temperature then diluted with hydrochloric acid ( 1  mol dm-3; 
20 cm3) and ether (20 cm^). The layers were separated and the aqueous phase was 
extracted further with ether (3 x 20 cm^). The combined organic extracts were dried and 
evaporated to leave a white solid which was purified by flash column chromatography 
(eluant petrol-ethyl acetate 3:1) to give phenol 124 (310 mg, 92%) which had physical 
properties identical to those described in method 1 above.
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(10-M ethyl-10fir-phenothiaborin-5,5-dioxide)-hydroxyam m onia-N  (1:1),
128
LlOa II
1 -  ^HaC NH2OH
This was prepared in a manner identical to the ammonia adduct 122 and employed 
diphenyl sulfone (1.69 g, 7.5 mmol) in THF (70 cm^), «-BuLi (2.5 mol dm“3 in hexanes;
6.5 cm^; 16.25 mmol), diwopropoxymethylborane (1.5 cm^; 8  mmol) and saturated 
aqueous hydroxy ammonium chloride (30 cm^). Purification of the crude product by flash 
column chromatography (eluant petrol-ethyl acetate 5:1 - 3:1) gave hydroxylamine adduct 
128 as a white solid (791 mg, 38%), mp 190-192 °C (from ethyl acetate-cyclohexane) 
(Found: C, 56.85; H, 5.0; N, 5.0. C13H 14BNO3S requires C, 56.75; H, 5.15; N, 5.1%) 
(HRMS: found [M + H]+, 276.0855. C1 3 H 1 5 B N O 3 S requires 276.0866); 
^max(Nujol)/crn-i 3424 (OH), 3243, 3213 and 3138 (NH3) and 1305 and 1111 (SO2); 
8 h [ 5 0 0 . 3  MHz; (C % ) 2 SO] 0.17 (3 H, s, CH3), 7.35-7.38 (2 H, m, 2 x 3-H), 7.45-7.48 
(2 H, m, 2 X 2-H), 7.79 (2 H, d, 7 7.1, 2 x 1-H), 7.86 (2 H, d, 7 7.1, 2 x 4-H),
8.34 (1 H, t, 7  2.7, OH) and 8.60 (2 H, d, 7  2.7, NH2); 8c[75.4 MHz; (C % 3)2SO] 5.62 
(br, CH3), 122.18 (C-4), 126.28 (C-3), 131.09 (C-2), 133.18 (C-1), 143.02 (Ar-CS0 2 ) 
and 151.33 (br, Ar-CB); 6 3 [96.3 MHz; (CH3 )2 CO -(C% 3)2 CO, 3:1] -8.21; m/z (Cl) 
276 (10%, [M + H]+), 243 (100, [M + H - NHiOHj+l and 219 (23, [PhSOiPh + H]+).
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[2-(Phenylsulfonyl)phenyl](phenyl) borinic acid, 131
B-OH
Method 1
To a stirred solution of diphenyl sulfone (960 mg, 4.25 mmol) in THF (50 cm^), cooled to 
-30 °C, was added dropwise «-BuLi (2.5 mol dm-  ^ in hexanes; 3.6 cm^; 9 mmol). The 
resultant suspension was stirred for a further 15 min. Diwopropoxyphenylborane (1 cm^; 
877 mg, 4.25 mmol) was added dropwise and the suspension was allowed to warm to 
room temperature over 3 h. Saturated aqueous ammonium chloride (30 cm^) was added, 
the layers were separated and the aqueous phase was extracted further with ether 
(3 X 30 cm3). The combined organic extracts were dried and evaporated to leave a pale 
yellow solid which was purified by flash column chromatography (eluant petrol-ethyl 
acetate 3:1) to give borinic acid 131 as a white solid (510 mg, 37%), mp 142.5-145.5 °C 
(from ethyl acetate-cyclohexane) (Found: C, 67.4; H, 4.85; M+, 322.0831. CigH^gBOgS 
requires C, 67.1; H, 4.7%; M+, 322.0835); Dmax(Nujol)/cm-i 3479 (OH) and 1345 and 
1153 (SO2 ); 0 h [ 3 0 0  MHz; (C % 3 )2 SO] 7.26-7.31 (2 H, m, Ar-H), 7.37-7.67 (9 H, m, 
Ar-H), 7.73-7.77 (2 H, m, Ar-H), 7.90 (1 H, dd, J 7.1 and 0.7, Ar-H) and 10.07 (1 H, s, 
OH); 5c[75.4 MHz; (C % 3 )2 SO] 127.67, 127.88, 128.23, 129.28, 129.62, 130.70, 
131.24, 132.76, 133.85 and 134.77 (Ar-CH), 138.61 and 142.79 (br, Ar-CB) and 141.21 
and 143.26 (Ar-CS0 2 ); 8 3 [96.3 MHz; (CH3)2 CO-(C2 H3 )2 CO, 3:1] 44.78; m/z (Cl) 
322 (10%, M+) and 305 (100, [M - OH]+).
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Method 2
This was prepared in a manner identical to method 1 above, but only 1 equivalent of 
rt-BuLi solution was used; the reaction employed diphenyl sulfone (1.69 g, 7.5 mmol) in 
THF (60 cm^), w-BuLi (2.5 mol dm-^ in hexanes; 6.5 cm^; 16.25 mmol), 
dif.yopropoxyphenylborane (1.8 cm^; 1.58 g, 7.65 mmol) and saturated aqueous 
ammonium chloride (30 cm^). Purification by flash column chromatography (eluant petrol- 
ethyl acetate 3:1) gave borinic acid 131 (1.45 g, 60%) as a white solid which had physical 
properties identical to those described in method 1 above.
6is[2-(Trimethylsilyl)phenyl]sulfone, 132
IMS O O TMS
To a stirred solution of diphenyl sulfone (11.25 g, 50 mmol) in THF (600 cm^), cooled to 
-40 °C, was added dropwise «-BuLi (2.1 mol dm‘3 in hexanes; 50 cm^; 105 mmol). The 
resultant suspension was then stirred at a temperature between -30 and -50 °C for 1 h. 
Chlorotrimethylsilane (14.5 cm^; 110 mmol) was added dropwise and the solution was 
allowed to warm to room temperature over 16 h. Saturated aqueous ammonium chloride 
( 1 0 0  cm^) was added, the layers were separated and the aqueous phase was extracted 
further with ether (3 x 100 cm^). The combined organic extracts were dried and 
evaporated to leave a pale yellow solid which was purified by flash column 
chromatography (eluant petrol-ethyl acetate 30:1 - 20:1) to give sulfone 132 as a white 
solid (14.62 g, 81%), mp 138.5-139.5 °C (from ethyl acetate-cyclohexane) (Found: 
C, 59.9; H, 7.1. CigHzaOiSSiz requires C, 59.6; H, 7.25%) (HRMS: found 
[M + NH41+, 380.1536. CigH3oN0 2 SSi2 requires 380.1536); Dmax(Nujol)/cm-i 1423 
and 1114 (Si-Ph), 1310 and 1160 (SO2 ) and 1260, 844 and 752 [Si-(CH3 )s]; 
8h(200M Hz; C^HCh) 0.40 [18 H, s, 2 x Si(CH3 )3 ], 7.34-7.57 ( 6  H, m, 2 x 3-H,
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2 x 4 -H  and 2 x 5-H) and 7.79-7.86 (2 H, m, 2 x 6 -H); 0c(50.3 MHz; C^HCls)
1.14 [Si(CH3 )3 ], 128.96, 129.11, 131.65 and 136.74 (Ar-CH), 140.08 (Ar-CSi) and
146.80 (Ar-CSOz); m/z (Cl) 380 (100, [M + NH4 ]+) and 347 (42, [M + NH4  -NH3 
- CH41+).
4,6-^w(Trimethylsilyl)-dibenzothiophene-5,5-dioxide, 135
T M S _  T M S
Method 1
To a stirred solution of sulfone 132 ( 1 . 4 5  g, 4  mmol) in THF ( 1 0 0  cm^), cooled to - 4 0  °C, 
was added dropwise w-BuLi ( 2 .1  mol dm-  ^ in hexanes; 4  cm^; 8 . 4  mmol). The resultant 
red solution was allowed to warm to - 3 0  °C over 3 0  min before it was cooled to - 7 0  °C. 
Tri-n-butyl borate ( 1 . 2  cm^; 4 . 4  mmol) was then added dropwise and the solution was 
allowed to warm to room temperature over 1 6  h. Saturated aqueous ammonium chloride 
( 5 0  cm^) was added, the layers were separated and the aqueous phase was extracted further 
with ether ( 3  x 5 0  cm^). The combined organic extracts were dried and evaporated to leave 
a pale yellow solid which was purified by flash column chromatography (eluant petrol- 
ethyl acetate 3 0 : 1 )  to give pure sulfone  135 as a white solid ( 4 3 0  mg, 3 0 % ) ,  
mp 1 3 9 - 1 3 9 . 5  °C (from ethyl acetate-cyclohexane) (Found: C, 5 9 . 7 ;  H, 7 . 0 .  
C i8 H 2 4 0 2 SSi2 requires C, 5 9 . 9 5 ;  H, 6 . 7 % )  (HRMS: found [M + H]+, 3 6 1 . 1 1 0 6 .  
CigH2 5 0 2 SSi2 requires 3 6 1 . 1 1 1 4 ) ;  'ümax(Nujol)/cm-i 1 1 6 0  (SO2) and 1 2 5 4 ,  8 4 4  and 7 6 5  
[Si-(CH3 )3 l; 5 h ( 2 0 0  MHz; C^HClg) 0 . 5 4  [ 1 8  H, s, 2  x Si(CH3 )3 ], 7 . 4 7 - 7 . 5 5  ( 2  H, m, 
Ar-H), 7 . 6 4  ( 2  H, dd, J  7 . 4  and 1 .2 ,  Ar-H) and 7 . 7 2  ( 2  H, dd, J  7 . 5  and 1 ,3 ,  Ar-H); 
8 c ( 5 0 . 3  MHz; C^HClg) 0 . 2 0  [Si(CH3 )3 ], 1 2 1 . 5 6 ,  1 3 2 . 2 3  and 1 3 6 . 4 4  (Ar-CH) and 
1 3 1 . 1 3 ,  1 3 7 . 1 3  and 1 4 2 . 6 5  (Ar-C quaternary); m/z (Cl) 3 6 1  (33%, [M + H]+) and 
3 4 5  ( 1 0 0 ,  [M + H - CH3 ]+).
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Method 2
This preparation was identical in manner to method 1 above, but 
diwopropoxyphenylborane (950 mm^; 833 mg, 4 mmol) was used as the electrophile. 
Pure sulfone 135 was isolated as a white solid (600 mg, 42%) which had physical 
properties identical to those described in method 1 above.
Dihenzothiophene-5,5-dioxide, 136
Method 1
A stirred solution of sulfone 135 (76 mg, 210 p,mol) in THF (10 cm^) was treated with 
TBAF (1 mol dm"  ^in THF; 1 cm^; 1 mmol). After 2 h, saturated aqueous brine (10 cm^) 
was added, the layers were separated and the aqueous phase was extracted further with 
ether (2 x 10 cm^). The combined organic extracts were dried and evaporated to leave 
crude dibenzothiophene-5,5-dioxide 136 (53 mg, quant, recovery). Pure 136 was 
prepared by method 2  below.
Method 2
To a stirred solution of sulfone 132 (1.45 g, 4 mmol) in THF (80 cm^), cooled to -40 °C, 
was added dropwise n-BuLi (2.3 mol dm-^ in hexanes; 3.55 cm^; 8.2 mmol). The 
resultant red solution was allowed to warm to -30 °C over a further 30 min. Boron 
trifluoride etherate (540 mm^; 605 mg, 4.2 mmol) was added dropwise and the solution 
was allowed to warm additionally over 3 h to room temperature. TBAF (1 mol dm-  ^ in 
THF; 8.2 cm^; 8.2 mmol) was added and the solution stirred for 16 h. Saturated aqueous 
brine (30 cm^) was added, the layers were separated and the aqueous phase was extracted
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further with ether (3 x 30 cm^). The combined organic extracts were dried and evaporated 
to leave a crude solid which was purified by flash column chromatography (eluant petrol- 
ethyl acetate 3:1) to give pure dibenzothiophene-5,5-dioxide 132 as a white solid (300 mg, 
31%), mp 230-232 °C (lit.,29i 233-237 °C); i)max(Nujol)/cm-i 1166 (SO2); 8h[200 MHz; 
(C% 3)2SO] 7.64-7.72 (2 H, m, Ar-H), 7.80-7.88 (2 H, m, Ar-H), 8.01 (2 H, d, 7 7.1, 
Ar-H) and 8.24 (2 H, d, J  7.7, Ar-H); ôc[50.3 MHz; (C2 H 3 )2 S0 ] 122.25, 122.99, 
131.22 and 134.84 (Ar-CH) and 131.07 and 137.16 (Ar-C quaternary); m/z (Cl) 
217 (100%, [M + H]+) and 186 (35).
2-Phenylthiobenzene boronic acid, 140
HO
To a stirred solution of 2-(bromophenylthio)benzene 154 (3.1 g, 11.7 mmol) in THF 
(100 cm3), cooled to -70 °C, was added dropwise w-BuLi (2.4 mol dm-^ in hexanes;
6.0 cm^; 14.4 mmol). The resultant solution was stirred for 30 min. Triwopropyl borate 
(3.4 cm^; 2.77 g, 14.4 mmol) was added dropwise and the solution was stirred for a 
further 30 min at -70 °C before it was allowed to warm to room temperature over 1 h. 
Saturated aqueous ammonium chloride (50 cm^) was added, the layers were separated and 
the aqueous phase was extracted further with ether (3 x 50 cm^). The combined organic 
extracts were dried and evaporated to leave a pale yellow solid which was purified by flash 
column chromatography (eluant hexane-ethyl acetate 4:1) to give boronic acid 140 as a 
white solid (2.16 g, 80%), mp 163-165 °C (from ethyl acetate-cyclohexane) 
(Found: C, 62.95; H, 4.6; M+, 230.0581. C12H 11BO2S requires C, 62.64; H, 4.82%; 
M+, 230.0573); i)max(Nujol)/cm-i 3304 (OH) and 1085 (BO); 5 h [ 3 0 0  MHz; (C2H3)2 S0 ] 
7.14-7.17 (1 H, m, Ar-H), 7.22-7.35 ( 6  H, m, Ar-H), 7.44-7.47 (1 H, m, Ar-H) and 
8.15 (2 H, br s, OH); 6c[75.4 MHz; (C2 H 3 )2 SO] 126.90, 127.06, 129.57, 129.77, 
130.60, 131.95 and 133.32 (Ar-CH), 136.97 and 137.52 (Ar-CS) and
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1 4 1 . 6 4  (br, Ar-CB); Ô b [ 9 6 . 3  MHz; (CH3 )2 C O -(C % 3 )2 CO, 3 : 1 ]  3 0 . 5 0 ;  m/z (Cl) 
2 3 1  ( 1 0 0 % ,  [M + H]+), 2 1 3  { 6 ,  [(2M - 2 H2 O + H)/2]+} and 1 8 7  ( 1 4 ,  [PI12S + H]+).
2-Phenyloxybenzene boronic acid, 141
This was prepared in a manner identical to the boronic acid 140 and employed 
2-brom ophenyloxybenzene 155 ( 1 . 6 9  g, 6 . 7 8  mmol) in THF ( 8 0  cm^), 
«-BuLi ( 2 . 4  mol dm'^ in hexanes; 3 . 3 5  cm^; 8 . 4  mmol), triw<2propyl borate ( 2 . 0  cm^;
1 .6  g; 8 . 4  mmol) and saturated aqueous ammonium chloride ( 4 0  cm^). After the layers 
were separated and the aqueous phase extracted further with ether ( 3  x 5 0  cm^), the 
combined organic extracts were dried and evaporated to leave a pale yellow solid. 
Purification by flash column chromatography (eluant hexane-ethyl acetate 5 :1  - 2 : 1 )  
afforded boronic acid 141 as a white solid ( 1 . 2 9  g, 8 4 % ) ,  mp 1 2 8 - 1 3 1  °C (lit.,230 \ 1 4  
(ethyl acetate-cyclohexane) (Found: C, 6 7 . 6 5 ;  H, 5 . 1 5 .  Calc, for C12H 11BO3 : C, 6 7 . 3 5 ;  
H, 5 . 2 % )  (HRMS: found [M + H]+, 2 1 5 . 0 8 7 5 .  Calc, for C1 2H 1 2BO 3 : 2 1 5 . 0 8 8 0 ) ;  
'V )m ax(N ujo l)/cm -l 3 5 0 2  and 3 3 2 8  (OH), 1 0 7 2  (BO) and 1 2 2 9  (ether); 0 h [ 3 0 0  MHz; 
(C % 3 )2 SO] 6 . 7 4 - 6 . 7 8  (1  H, m, Ar-H), 6 . 9 3 - 6 . 9 8  (2 H, m, Ar-H), 7 . 0 4 - 7 . 1 2  (2 H, m, 
Ar-H), 7 . 3 0 - 7 . 3 6  ( 3  H, m, Ar-H), 7 . 5 8  (1  H, dd, J 7 . 4  and 1 .7 ,  Ar-H) and 7 . 8 8  (2 H, br 
s, OH); 6 c [ 7 5 . 4  MHz; (C % 3 )2SO] 1 1 8 . 3 2 ,  1 1 9 . 1 2 ,  1 2 3 . 4 8 ,  1 2 3 . 5 4 ,  1 3 0 . 3 1 ,  1 3 1 . 5 2  and 
1 3 5 . 6 2  (Ar-CH), 1 2 7 . 3 8  (br, Ar-CB) and 1 5 7 . 8 1  and 1 6 0 . 4 8  (Ar-CO); 0 b [ 9 6 . 3  MHz; 
(C H 3 ) 2 C 0 - ( C 2 H 3 ) 2 C0 , 3 : 1 ]  3 0 . 1 2 ;  m /z  (Cl) 2 1 5  ( 1 0 0 % ,  [M + H]+), 
1 9 7  { 1 9 ,  [(2M - 2 H2O + H)/2]+} and 1 7 1  ( 1 2 ,  [PhgO + H]+).
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2-(2'-BromophenyIthio)pyridine, 145
A mixture of 2-bromopyridine (1.63 g, 10 mmol), 2-bromophenol (1.42 cm^; 1.95 g, 
10 mmol) and sodium hydrogen-carbonate (1 g, 12 mmol) in DMF (20 cm^) was heated at 
130 °C for 2 h, after which time evolution of carbon dioxide had ceased. The solvent was 
distilled off under reduced pressure and the residue was mixed with ethyl acetate (60 cm^) 
and water (20 cm^). The layers were separated and the organic phase was washed further 
with water (2 x 20 cm^), dried and evaporated. The resultant oil was purified by flash 
column chromatography (eluant petrol-ethyl acetate 20:1 - 3:1) to afford sulfide 145 as a 
clear oil (1.43 g, 54%) (Found: C, 49.7; H, 3.25; N, 5.2. CiiHgBrNS requires C, 49.65; 
H, 3.05; N, 5.25%) (HRMS: found [M + H]+, 265.9648. CnHgBrNS requires 
265.9639); 5 h ( 2 0 0  MHz; C^HClg) 6.92 (1 H, d, J  8.1, Ar-H), 7.10-7.07 (1 H, m, Ar-H), 
7.20-7.39 (2 H, m, Ar-H), 7.46-7.54 (1 H, m, Ar-H), 7.62-7.73 (2 H, m, Ar-H) and 
8.45 (1 H, d, J  4.0, 6-H); 0c(50.3 MHz; C^HCb) 119.08 (Ar-CBr), 129.41 and
132.80 (Ar-C-2 and Ar-C-1'), 149 (Ar-C-6 ) and 120.35, 122.03, 128.23, 130.36, 
133.75, 136.40 and 136.80 (other Ar-CH); m/z (Cl) 267 and 269 (15%, [M + H]+), 
266 and 268 (100, M+) and 186 (15%, [M - HBr]+).
2-(TrimethyIsilyl)thiophenol, 146
TMS
SH
To a solution of TMEDA (16 cm^; 12.2 g, 105 mmol) and «-BuLi (2.2 mol dm-^ in 
hexanes; 50 cm^; 110 mmol) in cyclohexane (120 cm^), cooled to 0 °C, was added 
dropwise a solution of thiophenol (5.3 cm^; 5.51 g, 50 mmol) in cyclohexane (10 cm^). 
The solution was then stirred at room temperature for 24 h. To the resultant off-white
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suspension was added chlorotrimethylsilane (1 6 .2  cm^; 13.58  g, 125 mmol) and the 
mixture stirred for a further 16 h to afford a lilac-coloured suspension. Water was added 
(4 0  cm3), the organic solvent was removed under reduced pressure. The residue was 
mixed with ether (3 5 0  cm^), washed with hydrochloric acid (5% v/v; 3 x 130 cm^) and 
water (2 x 7 0  cm^) then dried and evaporated to leave the crude intermediate silylsulfide 
149 as a pungent oily yellow liquid. The crude liquid was dissolved in methanol 
(1 0 0  cm3) and then heated under reflux for 9.5  h. The solution was evaporated and the 
resultant oil purified by Kiigelrohr distillation (oven temperature 130 °C; 1 mm Hg) 
( lit .,278 55  0 .1  mm Hg) to afford a clear pungent oil (8 .5 8  g, 94% );
'V)max(thin film)/cm-i 2 5 6 9  (SH), 1 4 2 2  and 1 1 2 6  (Si-Ph) and 1 2 5 1 ,  841 and 7 4 4  
[Si-(CH 3 ) 3 ]; 5 h ( 2 0 0  MHz; C2 HCI3 ) 0 .4 5  [9 H, s, Si(CH3 )3 ], 3 .5 6  (1 H, s, SH),
7 .1 9 -7 .3 7  (3 H , m, 4 -H , 5 -H  and 6-H ) and 7 .4 7 -7 .5 2  (1 H , m, 3-H); 0 c ( 5 0 .3  MHz; 
C 2H C I 3) - 0 .4 5  [Si(CH3 ) 3 ], 1 2 5 .1 9 ,  1 2 9 .6 1 ,  1 3 1 .4 8  and 1 3 5 .0 8  (Ar-CH),
1 3 7 .1 4  (Ar-CS) and 139 .53  (Ar-CSi); m/z (El) 182 (20% , M+), 167 (1 0 0 ,  [M - CH3]+) 
and 151 (9 5 ,  [M - CH3 - CH4 ]+).
2-[2’-(Trimethylsilyl)phenylthio]pyridine, 147 and 2-(Fhenylthio)pyndine, 
148
TMS
V  A'.
147 148
Method 1
A stirred suspension of 2-bromopyridine (1.61 g, 10 mmol), thiophenol 146 (1.82 g, 
10 mmol) and sodium hydrogen-carbonate (1 g, 12 mmol) in DMF (20 cm^) was heated at 
100 °C for 1 h. The solvent was evaporated and the residue mixed with ethyl acetate 
(50 cm^) and water (20 cm^). The layers were separated and the organic phase was 
washed with more water (4 x 50 cm^). The organic phase was dried and evaporated to
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afford an oil which was purified by flash column chromatography (eluant petrol-ethyl 
acetate 12:1) to give less polar 147 (310 mg, 12%) and more polar 148 (1.15 g, 62%), 
both as clear oils.
Less polar 147 (Found: C, 64.85; H, 6.85; N, 5,35; M+, 259.0857. C nH nN S S i 
requires C, 64.8; H, 6.6; N, 5.4%; M+, 259.0851); Dmax(lhin film)/cm'* 1417 and 1122 
(Si-Ph) and 1249, 841 and 756 [Si-(CH3 )3 ]; 5 h ( 2 0 0  MHz; C2 HCI3 ) 0.30 [9 H, s, 
Si(CH3 )3], 6.64 (1 H, d, J  7.8, Ar-H), 6.92-6.98 (1 H, m, Ar-H), 7.35-7.46 (3 H, m, 
Ar-H), 7.58-7.67 (2 H, m, Ar-H) and 8.41 (1 H, d, J  4.0, 6-H); 0c(50.3 MHz; C2HCI3) 
-0.07 [Si(CH3 )3 ], 119.32, 120.48, 128.60, 130.35, 135.85, 136.52, 137.34 and
149.28 (Ar-CH), 136.66 and 146.69 (Ar-C-1 ' and Ar-C-2’) and 163.08 (Ar-C-1); 
m/z (El) 259 (1%, M+), 244 (35, [M - CH3 ]+) and 186 {100, [M - Si(CH3)3]+}.
More polar 148; 0h(200 MHz; C2 HCI3 ) 6.87 (1 H, dd, 7 8.1 and 1.1, Ar-H), 6.94-6.98 
(1 H, m, Ar-H), 7.39-7.48 (4 H, m, Ar-H), 7.57-7.62 (2 H, m, Ar-H) and 8.42 
(1 H, d, 7 3.9, 6-H); 0c(50.3 MHz; C2HCI3 ) 119.77, 121.19, 128.99, 129.53, 134.83,
136.60 and 149.45 (Ar-CH), 130.89 (Ar-C-F) and 161.41 (Ar-C-1); m/z (El) 
186 (100%, M+).
Method 2
To a stirred suspension of sodium hydride (60% dispersion in mineral oil; 
684 mg, 17.1 mmol) in 1,4-dioxane (35 cm^) was added a solution of thiophenol 146 
(2.835 g, 15.55 mmol) in 1,4-dioxane (35 cm^). After 20 min, evolution of hydrogen had 
ceased and a solution of 2-bromopyridine (2.39 g, 15 mmol) in 1,4-dioxane (35 cm^) was 
added dropwise and the mixture heated under reflux for 48 h. The mixture was cooled to 
0 °C and saturated aqueous ammonium chloride (50 cm^) was added. The layers were 
separated and the aqueous phase was extracted further with ether (3 x 100 cm^). The 
combined organic extracts were dried and evaporated to leave an oil which was purified by
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flash column chromatography (eluant petrol-ethyl acetate 12:1) to give pure sulfide 147 a 
clear oil (2 .01  g, 52% ), which had physical properties identical to those described in 
method 1 above.
l , l ' “Thio6w[2-(trimethylsilyI)benzene], 150
TMS TMS
To a stirred solution of sulfide 99 (1 .3 8  g, 4  mmol) in THF (5 0  cm^), cooled to -7 0  °C, 
was added dropwise n-BuLi (2 .5  mol dm-  ^in hexanes; 3 .6  cm^; 9 mmol) and the resultant 
solution stirred for 3 0  min. Chlorotrimethylsilane (1 mol dm'^ in THF; 9 cm^; 9 mmol) 
was added dropwise and the solution allowed to warm to 2 5  °C over 1 h. Saturated 
aqueous ammonium chloride (20 cm^) was added, the layers were separated and the 
aqueous phase was extracted further with ether (3 x 5 0  cm^). The combined organic 
extracts were dried and evaporated to leave a pale yellow oil which was purified first by 
flash column chromatography (eluant petrol) and then by Kiigelrohr distillation (oven 
temperature 140  °C; 0 .4  mm Hg) to give sulfide 150 as a clear oil which solidified on 
standing (8 0 0  mg, 61% ), mp 4 5 - 4 5 .5  °C (Found: C, 6 5 .5 5 ;  H, 8 .15 ;  M+, 3 3 0 .1 3 0 1 .  
CigH2 6 SSi2  requires C, 65 .4 ;  H, 7.95% ; M+, 3 3 0 .1 2 9 4 );  i )m ax(N u jo l) /cm -i 1422  and 
1110  (Si-Ph) and 1249, 8 4 0  and 7 4 6  [Si-(CH])3 ]; ô h ( 2 0 0  MHz; C^HClg) 0.41 [18 H, s, 
2  X Si(CH3 )3 ], 7 .0 4 - 7 .0 9  (2  H, m, Ar-H), 7 .2 1 -7 .2 6  (4  H, m, Ar-H) and 7 .5 2 -7 .5 6  
(2  H, m, 2  X  6-H); 0 c ( 5 0 .3  MHz; C ^ H C ^ )  -0 .1 0  [Si(CH3)3], 1 2 5 .9 8 ,  130 .0 1 ,  1 3 1 .7 4  
and 1 3 4 .9 6  (Ar-CH), 1 4 1 .8 6  (Ar-CS) and 143.51 (Ar-CSi); m/z (Cl) 3 3 0  (55% , M+),  
315  (100 , [M - CH3]+) and 2 8 5  (26).
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i>w[2-(TrimethylsilyI)phenyl)disulfide, 151
TMS TMS
.S-S.
A stirred solution of thiophenol 146 (1 .8 2  g, 10 mmol) in methanol (25  cm^) was treated 
with a solution of sodium perborate tetrahydrate (3 .07 , 2 0  mmol) in water (10  cm^) at 
25  °C. Aliquot 3 3 6  {ca. 100 mg) was added and the solution stirred for 1 h. The solution 
was extracted with pentane (5 x 2 0  cm^) and the combined organic extracts were dried and 
evaporated to leave a pale yellow oil. Purification first by flash column chromatography 
(eluant petrol) and then by Kiigelrohr distillation (oven temperature 160 °C; 0.3  mm Hg) 
afforded disulfide 151 as a yellow oil (1 .3 2  g, 7 3 % ) (Found: C, 5 9 .5 5 ;  H, 7 .5 .  
C i8 H 2 6 S 2 Si2 requires C, 5 9 .6 ;  H, 7 .2 5 % ) (HRMS: found [M + H]+, 3 6 3 .1 1 0 2 .  
C i8H2 7 S2 Si2  requires 3 6 3 .1 0 9 3 ) ;  t»max(Nujol)/cm-i 1420, 1125  and 1103 (Si-Ph) and 
1250 , 8 4 0  and 7 4 8  [Si-(CH3 )3]; 5 h ( 2 0 0  MHz; C2HCI3 ) 0.41 [18 H, s, 2  x Si(CH3 )3 ],
7 .2 0 -7 .3 7  (4  H, m, Ar-H), 7 .4 6 -7 .5 7  (2 H, m, Ar-H) and 7 .6 1 - 7 .6 6  (2  H, m, Ar-H); 
6c(50.3 MHz; C2 HCI3) 0 .2  [Si(CH3)3], 1 2 6 .5 5 ,  128 .83 ,  1 3 0 .0 0  and 1 3 4 .6 9  (Ar-CH) 
and 1 4 0 .1 5  and 1 4 3 .5 9  (Ar-C quaternary); m/z (Cl) 36 3  (1 0 0 ,  [M + H]+), 3 4 7  (60 ,  
[M + H - CH31+) 3 1 7  (15 , [M + H - CH4  - 2 CH3]+), 2 7 5  {2 0 ,  [M + H - Si(CH3)4 ]+}, 
2 5 9  {35 , [M + H - CH4- Si(CH3)4 ]+} and 167 {31 , [M + H - (CH3 )3Si-CôH4SCH3]+}.
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2-Amînoethyl [2-(phenylsulfonyl)phenyl](methyl) borinate, 152
H3C6B NHg
To a stirred solution of diphenyl sulfone (1 .6 8 8  g, 7.5  mmol) in THF (60  cm^), cooled to 
-3 0  °C, was added dropwise n-BuLi (2 .5  mol dm-3 in hexanes; 3 .25  cm^; 8 .1 2  mmol), 
The resultant suspension was stirred for 3 0  min. Diwopropoxymethylborane (1 .5  cm^; 
1.14 g, 8 mmol) was then added dropwise and the suspension was stirred for an additional 
1 h at -3 0  °C before it was allowed to warm to room temperature over 1 h. Saturated 
aqueous ammonium chloride (3 0  cm^) was added, the layers were separated and the 
aqueous phase was extracted further with ether (3 x 5 0  cm^). The combined organic 
extracts were dried and evaporated to leave a pale yellow oil which was immediately 
purified by flash column chromatography (eluant petrol-ethyl acetate 3:1) to give borinic 
acid 142 as a clear oil (1 .65  g, 85%). Because of the instability of the borinic acid, it was 
immediately dissolved in ether (1 0  cm^), cooled to 0  °C and treated with ethanolamine 
(2  cm3). This caused the precipitation of a white solid and a viscous yellow oil. The solid 
was filtered off and washed with water ( 2 0 0  cm^) and recrystallised from ethyl acetate- 
cyclohexane to give ethanolamine ester 152 as white needles ( 8 1 0  mg, 36% ),  
mp 1 5 4 -1 5 8  (Found: C, 59.7; H, 5 .85 ;  N, 4 .5 5 .  CigHigBNOgS requires C, 59.4;  
H, 6 .0 ;  N, 4 .6 % ) (HRMS: found [M + H]+, 2 6 0 .0 9 1 3 .  C1 3 H 1 5 BN O 2 S requires 
2 6 0 .0 9 1 7 ) ;  i)max(Nujol)/cm-i 3 3 2 0  (NH2), 1321, 1150  and 1137 (SO2) and 1086 (CO); 
8 h [ 3 0 0  MHz; (0 ^ 3) 2 8 0 ; 8 0  °C] -0 .2 4  (3 H, s, CH3), 2 .8 0  (2  H, t, J 6.3 ,  CH2NH 2), 
3 .6 4  (2  H, t, 7  6 .3 ,  CH2 OB), 5 .6 3  (2  H, br s, NH2 ), 7 .2 3 - 7 .2 8  (1 H, m, Ar-H), 
7 .3 9 - 7 .4 4  (1 H, m, Ar-H), 7 .5 1 -7 .6 8  (4  H, m, Ar-H), 7 .7 7 -7 .8 1  (2  H, m, Ar-H) and 
7 .8 9 -7 .9 7  (1 H, m, Ar-H); 0 c [7 5 .4  MHz; (C2H3)2S0 ] 8 .5 0  (br, CH3), 4 1 .6 2  (CH2NH2 ), 
61.95 (CH2 OB), 126 .25 ,  127 .27 , 129 .35 ,  129 .80 , 131 .83 , 1 3 3 .0 4  and 13 4 .7 4  (Ar-CH),
1 4 3 .1 5  and 1 4 3 .3 7  [Ar-(CS0 2 )] and 1 5 4 .6 4  (br, Ar-CB); 0 b [ 9 6 . 3  MHz;
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(CH3)2 C0 -(C2H3 )2C0 , 3:1] 6.09; m/z (Cl) 546 {37%, [2M + H - NH2 (CH2)2 0 H]+}, 
344 (100), 304 (70, [M + H]+), 243 {12, [M + H - NH2 (CH 2 )2 ÛH - H2 0 ]+} and 
102 (45).
2-(Bromophenylthio)benzene, 154
Br
To stirred molten 2  bromoaniline (6 .88  g, 4 0  mmol) was added sulfuric acid (18 mol dm- ;^ 
5 g, 5 0  mmol) in water (75  cm^). The mixture was heated to 60  °C to effect complete 
dissolution of the amine. The solution was then cooled to 0  °C, vigorously stirred and 
treated with ice (25 g) then dropwise with a solution of sodium nitrite (3 g, 4 2 .2  mmol) in 
water (25 cm^), maintaining the temperature at 0-3  °C. After confirmation of the presence 
of excess nitrous acid (starch-iodide paper), the bright yellow suspension was neutralised 
to pH 4  with sodium acetate (2 .5  g, 3 0  mmol). The suspension was transferred to a 
dropping funnel and added dropwise to a stirred, ice-cold mixture of thiophenol (4 .5 4  g, 
4 0  mmol), NaOH (4 .8 2  g, 120.5  mmol) and copper powder (3 g, 4 7 .1 4  mmol) in water 
(25 cm^). After the addition of the diazonium salt was complete, the solution was heated to 
9 0  °C for 1 h. The solution was then cooled to room temperature, extracted with ether 
(4  X  100 cm^) and the combined organic extracts washed with brine (5 0  cm^), dried and 
evaporated to leave a brown oil. Purification by flash column chromatography (eluant 
petrol-ethyl acetate 100:0.5) and then by Kiigelrohr distillation (oven temp. 120 °C; 10 mm 
Hg) afforded sulfide 281 as a pale yellow oil (4 .98  g, 48% ) which did not crystallise upon 
standing (lit.,28i mp 3 4 -3 5  °C); 8 h ( 2 0 0  MHz; C2HCI3) 6.93  (1 H, dd, 7 7 .7  and 1.8, 
Ar-H), 7 .0 0 -7 .0 8  (1 H, m, Ar-H), 7 .1 2 -7 .2 0  (1 H, m, Ar-H), 7 .3 7 -  7 .5 0  (5 H, m, Ar-H) 
and 7 .5 7  (1 H, dd, 7  7 .8  and 1.4, 3’-H); 8 c ( 5 0 .3  MHz; C2 HCI3 ) 122.96 (Ar-CBr), 
127 .19 ,  127 .77 , 128 .44 ,  129 .61 ,  129 .67 ,  1 32 .97  and 133 .48  (Ar-CH) 132.78  (Ar-C-1) 
and 1 3 8 .7 4  (Ar-CF); m/z (Cl) 3 6 5  and 3 6 7  (100% , [M + H]+), 2 1 8  (2 0 )  and 
1 8 5 ( 1 5 ,  [ M + H  - HBr]+).
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2-Bromophenyl)oxybenzene, 155
To a stirred mixture of 2-phenoxyaniline (5.15 g, 27.5 mmol) and aqueous HBr (48%; 
10 cm3), cooled to 0-5 °C, was added dropwise a solution of sodium nitrite (1.95 g, 
27.5 mmol) in water (5 cm^). After confirmation of the presence of excess nitrous acid 
(starch-iodide paper), the solution was added to a boiling solution of aqueous HBr 
(48%; 4 cm^) that contained cuprous bromide (4.4 g, 30.14 mmol) and heated under 
reflux for 30 min. The resultant black solution was extracted with ether (5 x 50 cm^) and 
the combined green organic extracts were dried and evaporated to leave a black solid which 
was purified by flash column chromatography (eluant petrol-ethyl acetate 1 0 0 :1 ) to afford 
ether 155 as a white solid (4.82 g, 73%), mp 42.5-44.5 °C (lit.,283 4 3 .5 .4 4 . 5  °C); 
'Umax(Nujol)/cm-i 1236 (ether); Ôh ( 2 0 0  MHz; C2HCI3 ) 6.96-7.41 ( 8  H, m, Ar-H) and 
7.62-7.69 (1 H, m, 3'-H); 5c(50.3 MHz; C2HCI3 ) 114.87 (Ar-CBr), 118.07, 120.56, 
123.35, 124.94, 128.62, 129.75 and 133.78 (Ar-CH) and 153.61 and 156.81 (Ar-CO); 
m/z (Cl) 249 and 251 (100%, [M + H]+) and 169 (8 , [M + H - HBr]+).
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2-Aminoethyl [2-(phenylthio)phenyl] (methyl) borinate, 156
NHaH3C
To a stirred solution of 2-(bromophenylthio)benzene 154 (1.40 g, 5.3 mmol) in THF 
(50 cm^), cooled to -70 °C, was added dropwise «-BuLi (2.5 mol dm-^ in hexanes; 
2 .3  cm^;  5.75 mmol). The resultant solution was stirred for 30 min. 
Dii^opropoxymethylborane (1 cm^; 0.76 g, 5.3 mmol) was added dropwise and the 
solution stirred for a further 30 min at -70 °C before it was allowed to warm to room 
temperature over 1 h. Saturated aqueous ammonium chloride (30 cm^) was added, the 
layers were separated and the aqueous phase was extracted further with ether (3 x 30 cm^). 
The combined organic extracts were dried and concentrated to ca. 30 cm^ and ethanolamine 
(1 cm^) was added. The mixture was left for 2 days during which time the volume of the 
solution reduced to ca. 5 cm^. The resultant pale yellow crystals were recrystallised twice 
from ethyl acetate-cyclohexane to give pure ethanolamine ester 156 as pale yellow crystals 
(843 mg, 59%), mp 150.5-151.5 (Found: C, 6 6 .6 ; H, 7.0; N, 5.2. CigHigBNOS 
requires C, 66.45; H, 6.7; N, 5.15%) (HRMS: found [M + H]+, 272.1271. 
C 1 5H 19BNOS requires 272.1280); l)max(Nujol)/cm 1 3301 (NH2 ) and 1071 (CO); 
0h[300MHz; (C2 H3 )2 S0 ; 60 °C] -0.15 (3 H, s, CH3 ), 2.77 (2 H, apparent quintet, 
C7 f2 NH 2 ), 3.68 (2 H, t, J  6.3, CH2 OB), 5.58 (2 H, br s, NH2 ), 6.99-7.30 ( 8  H, m, 
Ar-H) and 7.58 (1 H, d, J  7.2, Ar-H); 0c[75.4 MHz; (C2H3 )2SO] 7.87 (br, CH3), 41.84 
(CH 2 NH 2 ), 62.14 (CH2 OB), 126.11, 126.38, 126.63, 129.28, 130.34, 131.89 and
132.61 (Ar-CH), 137.21 and 138.40 (Ar-CS) and 155.88 (br, Ar-CB); Ôb[96.3 MHz; 
(CH3 )2 C0 -(C2H3 )2 C0 , 3:1] 6.24; m/z (Cl) 272 (18%, [M + H]+), 229 (100, [M + H 
- CH2 =CHNH2 l+) and 227 (13, [Ph2S + H]+).
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2-Am inoethyl [2-(phenyIoxy)phenyl](methyI) borinate, 157 and 2- 
Phenoxyphenol, 153
HO
157 153
Method 1
To a stirred solution of diphenyl ether (850 mg, 5 mmol) in THF (50 cm^), cooled to 
-70 °C, was added dropwise f-BuLi (1.5 mol dm-  ^ in pentanes; 7 cm^; 10.5 mmol). The 
resultant solution was allowed to warm to room temperature over 30 min, then cooled to 
-50 °C. Diwopropoxymethylborane (920 mm^; 720 mg, 5 mmol) was added dropwise and 
the solution stirred for a further 2 h. Saturated aqueous ammonium chloride (30 cm^) was 
added, the layers were separated and the aqueous phase was extracted further with ether 
(3 X  50 cm^). The combined organic extracts were dried and evaporated to leave a pale 
yellow solid which was purified by flash column chromatography (eluant petrol-ethyl 
acetate 15:1) to give returned start material (340 mg, 40%), borinic acid 144 (70 mg, 7%), 
2-phenoxyphenol 153 (150 mg, 16%) and borinic acid 83 (330 mg, 33%).
Borinic acid 144, an oil, had an Rp identical to intermediate 144 prepared as part of the 
synthesis of ethanolamine ester 157 below; 5h[300 MHz; (C2H3)2S0 ] 0.6 (3 H, s, CH3), 
6.86-6.94 (3 H, m, Ar-H), 7.05-7.22 (2 H, m, Ar-H), 7.32-7.48 (3 H, m, Ar-H), 
7.71 (1 H, d, J  7.3, Ar-H) and 9.70 (1 H, s, OH).
2-Phenoxyphenol 153, mp 105-106 °C (from acetone) (lit.,2^2 104.5-106 °C) (HRMS: 
found M+, 186.0688. Calc, for C12H 10O2 : 186.0681); 'Omax(Nujol)/cm-  ^ 3412 (OH) and 
1240 (ether); 0h[300 MHz; (C2H3)2 S0 ] 6.77-6.84 (3 H, m, Ar-H), 6.92-7.05 (4 H, m,
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Ar-H), 7.26-7.31 (2 H, m, Ar-H) and 9.49 (1 H, s, OH); ôc[75.4 MHz; (C2 H3 )2 S0 ] 
116.70, 117.90, 120.24, 122.44, 122.56, 126.05 and 130.15 (Ar-CH) and 143.06, 
150.06 and 158.64 (Ar-C quaternary); m/z (CI) 243 (33%, [M + C4 H 8 + H]+) and 
187 (100, [M + H]+).
Borinic acid 83 had physical properties identical to those described earlier.
Method 2
Ethanolamine ester 157 was better prepared in a manner similar to ethanolamine ester 156 
and employed 2-bromophenyloxybenzene 155 (2.41 g, 10 mmol) in THF (80 cm^), 
n-BuLi (2.5 mol dm“3 in hexanes; 4.5 cm^; 11.25 mmol), diwopropoxymethylborane 
(2.15 cm^; 1.63 g, 11.3 mmol) and saturated aqueous ammonium chloride (40 cm^). 
After the layers were separated, the aqueous phase was extracted further with ether 
(3 X 50 cm^). The combined organic extracts containing crude borinic acid 144 were 
dried and concentrated to ca. 50 cm^ and a mixture of ethanolamine (3 cm^) and methanol 
(3 cm3) was added. The mixture was left for 2 days during which time the volume of the 
solution reduced to ca. 5 cm^. The resultant large white crystals precipitated were filtered 
off, washed with water ( 2 0 0  cm^) and dried under reduced pressure in a desiccator over 
phosphorus pentoxide for 3 days to give pure ethanolamine ester 157 (2.13 g, 82%), 
mp 180.5-181.5 '’C (Found; C, 70.8; H, 7.3; N, 5.45. C15H 18BNO2 requires C, 70.6; 
H, 7.1; N, 5.5%) (HRMS: found [M + H]+, 256.1513. C1 5 H 1 9 B N O 2 requires 
256.1509]; Dmax(Nujol)/cm-i 3332 (NH2 ), 1226 (ether) and 1064 (CO); 0h[300 MHz; 
(C2 H 3)2 SO; 60 °C] -0.24 (3 H, s, CH3), 2.75 (2 H, apparent quintet, CH2NH2 ), 3.65 
(2 H, t, J  6.3, CH2 OB), 5.43 (2 H, br s, NH2 ), 6.56 (1 H, dd, J  1.0 and 8.0, Ar-H), 
6.88-7.04 (5 H, m, Ar-H), 7.27-7.33 (2 H, m, Ar-H) and 7.45 (1 H, dd, J  2.0 and 7.2, 
Ar-H); 0c[75.4 MHz; (C % 3 )2 SO] 7.74 (br, CH3 ), 41.46 (CH2 NH2 ), 62.33 (CH2 OB), 
117.10, 118.98, 122.55, 122.66, 126.74, 129.93 and 133.33 (Ar-CH), 143.76 (br,
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Ar-CB) and 158.24 and 159.54 (Ar-CO); 0b [96.3 MHz; (CH3 )2 CO -(C% 3)2 CO, 3:1] 
5.89; m/z (ES+) 295 (15%, [M + K]+), 276 (10, [M + Na]+) and 255 (100, M+).
HIV-1 PR in vitro assay
The assay was based upon the hydrolytic cleavage of the decapeptide 
Lys-Ala-Arg-Val-Nle*(N0 2 )Phe-Glu-Ala-Nle-Gly-NH2 which leads to a reduction in the 
absorbence at 300 nm. The peptide was stored as a 10 mg cm"  ^ solution in water and 
2-5 mm^ of this solution was added to 1 cm^ of assay buffer (100 mmol dm-  ^ NaOAc, 
200 mmol dm'3 NaCl, 1 mmol dm-^ dithiothreitol at pH 5.6). The compounds to be 
tested were made up as 1 0  mmol dm-3 stock solutions in methanol and were used at 
concentrations over the range 1-100 pmol dm-3. Methanol was added to a final 
concentration of 2 % in the assay mixture and the solution was allowed to thermally 
equilibrate to 37 °C before the reaction was initiated by the addition of 15 mm^ of enzyme 
solution. (The enzyme was stored as a 993 mmol dm-  ^solution in 10 mmol dm-  ^NaOAc 
containing 0.05% 2-mercaptoethanol, 1 mmol dm'^ EDTA, 20% glycerol and 5% ethylene 
glycol).
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A p p e n d ix  i  
C r y s t a l l o g r a p h ic  d a t a
Crystallographic Data for Compound 117
C2 4 H 1 6B 2 OS2 , M = 406.13, orthorhombic, space group Pbca (#61), a = 13,44(1), 
b = 23.36(1), c = 12.71(1) k , V  = 3990(4) Â^, Z = 8 , % =  1.352 g cm ,^ T = 293 K. 
2958 unique reflections were collected on a Rigaku AFC7S diffractometer employing 
Mo-Ka radiation {X = 0.71069 Â) of which 1197 [7 > 30(7)] were used for refinement. 
Convergence at R{F) = 5.0%, R'^{F) = 3.6% for 262 variables. The structures of 117 and 
also 122, 128, 131, 140 and 141 were solved using SIR92 and were refined using
TEXSAN.293
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Table A l l:  Bond Lengths (A) for 117
atom atom distance atom atom distance
S(l) C(6) 1.714(7) S(l) 0(7) 1.745(8)
S(2) C(14) 1.735(8) S(2) 0(20) 1.737(8)
0(1) B(l) 1.353(9) 0(1) B(2) 1.337(9)
C(l) C(2) 1.41(1) C(l) 0(6) 1.419(9)
C(l) B(l) 1.50(1) C(2) 0(3) 1.37(1)
C(3) C(4) 1.378(10) C(4) 0(5) 1.367(10)
C(5) C(6) 1.378(9) C(7) 0(8) 1.374(9)
C(7) C(12) 1.431(9) C(8) 0(9) 1.40(1)
C(9) C(10) 1.38(1) 0(10) 0(11) 1.33(1)
C(ll) C(12) 1.42(1) 0(12) B(l) 1.52(1)
C(13) C(14) 1.422(9) 0(13) 0(18) 1.40(1)
C(13) B(2) 1.53(1) 0(14) 0(15) 1.36(1)
C(15) C(16) 1.35(1) 0(16) 0(17) 1.39(1)
C(17) C(18) 1.35(1) 0(19) 0(20) 1.392(9)
C(19) C(24) 1.38(1) 0(19) B(2) 1.54(1)
C(20) C(21) 1.39(1) 0(21) C(22) 1.33(1)
C(22) C(23) 1.37(2) 0(23) 0(24) 1.36(2)
C(2) H(6) 0.95 0(3) H(9) 0.95
C(4) H(5) 0.95 0(5) H(2) 0.95
C(8) H(l) 0.95 0(9) H(7) 0.95
C(10) H(15) 0.95 0(11) H(4) 0.95
C(15) H(3) 0.95 0(16) H(8) 0.95
C(17) H(16) 0.95 0(18) H(14) 0.95
C(21) H(13) 0.95 0(22) H(ll) 0.95
C(23) H(10) 0.95 0(24) H(12) 0.95
Table A1.2: Bond Angles (°) for 117
atom atom atom distance atom atom atom distance
C(6) S(l) C(7) 107.1(4) 0(14) S(2) C(20) 107.0(5)
B(l) 0(1) B(2) 169.2(9) 0(2) 0(1) 0(6) 115.7(8)
C(2) C(l) B(l) 123.4(8) 0(6) 0(1) B(l) 120.9(8)
C(l) C(2) C(3) 123.7(8) 0(2) 0(3) C(4) 118.9(9)
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C(3) 0(4) 0(5) 119.7(9) 0(4) 0(5) 0(6) 122.3(8)
S(l) 0(6) 0(1) 124.9(7) S(l) 0(6) 0(5) 115.4(7)
C(l) 0(6) 0(5) 119.7(7) S(l) 0(7) 0(8) 116.1(7)
S(l) 0(7) C(12) 122.7(7) 0(8) 0(7) 0(12) 121.2(8)
C(7) 0(8) 0(9) 120.9(8) 0(8) 0(9) 0(10) 117.9(10)
C(9) 0(10) 0(11) 121(1) 0(10) 0(11) 0(12) 123.2(9)
C(7) 0(12) 0(11) 114.8(8) 0(7) 0(12) B(l) 121.5(8)
C(ll) 0(12) B(l) 123.7(8) 0(14) 0(13) 0(18) 114.7(8)
C(14) 0(13) B(2) 121.1(8) 0(18) 0(13) B(2) 124.1(9)
S(2) 0(14) 0(13) 124.0(7) S(2) 0(14) 0(15) 114.5(8)
C(13) 0(14) 0(15) 121.5(8) 0(14) 0(15) 0(16) 121(1)
C(15) 0(16) 0(17) 119(1) 0(16) 0(17) 0(18) 119(1)
0(13) 0(18) 0(17) 123(1) 0(20) 0(19) 0(24) 117.0(9)
C(20) 0(19) B(2) 121.6(9) 0(24) 0(19) B(2) 121.4(10)
S(2) 0(20) 0(19) 124.4(8) S(2) 0(20) 0(21) 115.1(9)
0(19) 0(20) 0(21) 120.5(9) 0(20) 0(21) 0(22) 119(1)
0(21) 0(22) 0(23) 122(1) 0(22) C(23) 0(24) 118(1)
0(19) 0(24) 0(23) 122(1) 0(1) B(l) 0(1) 118.9(8)
0(1) B(l) 0(12) 118.3(8) 0(1) B(l) 0(12) 122.9(7)
0(1) B(2) 0(13) 120.0(9) 0(1) B(2) 0(19) 118.3(9)
0(13) B(2) 0(19) 121.7(8)
0(1) 0(2) H(6) 118.2 0(3) 0(2) H(6) 118.2
0(2) 0(3) H(9) 120.6 0(4) 0(3) H(9) 120.6
C(3 0(4) H(5) 120.1 0(5) 0(4) H(5) 120.1
0(4) 0(5) H(2) 118.9 0(6) 0(5) H(2) 118.9
0(7) 0(8) H(l) 119.5 0(9) 0(8) H(l) 119.5
0(8) 0(9) H(7) 121.0 0(10) 0(9) H(7) 121.0
0(9) 0(10) H(15) 119.1 0(11) 0(10) H(15) 119.1
0(10) 0(11) H(4) 118.4 0(12) 0(11) H(4) 118.4
0(14) 0(15) H(3) 119.4 0(16) 0(15) H(3) 119.3
0(15) 0(16) H(8) 120.1 0(17) 0(16) H(8) 120.0
0(16) 0(17) H(16) 120.4 0(18) 0(17) H(16) 120.4
0(13) 0(18) H(14) 118.3 0(17) 0(18) H(14) 118.3
0(20) 0(21) H(13) 120.2 0(22) 0(21) H(13) 120.1
0(21) C(22) H(ll) 119.0 0(23) C(22) H(ll) 118.9
0(22) 0(23) H(10) 120.9 C(24) 0(23) H(10) 120.9
0(19) C(24) H(12) 118.8 C(23) 0(24) H(12) 118.7
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Crystallographic Data for Compound 122
C4
'C5
C13
C2C6
C8
C9
,CIO
02 '
01
eu
C 12
C 13H 1 4BNO 2 S, M = 259.13, monoclinic, space group P2i/c (#14), a ~ 10,672(6), 
b = 8.915(4), c = 13.695(5) Â, |3 = 99.77(4) °, V = 1284(1) Â^, Z = 4, D e = 
1.340 g cm-3, T = 293 K. 2432 unique reflections were collected on a Rigaku AFC7S 
diffractometer employing Mo-Ka radiation {X ~ 0.71069 Â) of which 1683 [/ > 3a(/)] 
were used for refinement. Convergence at R{F) = 3.7%, Rw(F7 = 2.8% for 163 variables.
Table A1.3: Bond Lengths (A) for 122
atom atom distance atom atom distance
S(l) 0(1) 1.460(2) S(l) 0(2) 1.449(2)
S(l) 0(1) 1.762(3) S(l) 0(7) 1.757(2)
N(l) B(l) 1.642(3) 0(1) 0(2) 1.390(3)
C(l) 0(6) 1.387(3) 0(2) 0(3) 1.400(3)
C(2) B(l) 1.640(4) 0(3) 0(4) 1.385(4)
C(4) 0(5) 1.371(4) 0(5) 0(6) 1.375(4)
C(7) 0(8) 1.393(3) 0(7) 0(12) 1.392(3)
C(8) 0(9) 1.397(3) 0(8) B(l) 1.628(4)
C(9) 0(10) 1.379(4) 0(10) 0(11) 1.372(4)
C(ll) 0(12) 1.382(4) 0(13) B(l) 1.607(4)
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N(l) H(12) 0.95 N(l) H(13) 0.95
N(l) H(14) 0.95 0(3) H(3) 0.95
C(4) H(4) 0.95 0(5) H(2) 0.95
C(6) H(l) 0.95 0(9) H(7) 0.95
C(10) H(6) 0.95 0(11) H(8) 0.95
C(12) H(5) 0.95 0(13) H(9) 0.95
C(13) H(10) 0.95 0(13) H(ll) 0.95
Table A1.4: Bond Angles (°) for 122
atom atom atom distance atom atom atom distance
0(1) S(l) 0(2) 115.7(1) 0(1) S(l) 0(1) 107.3(1)
0(1) S(l) 0(7) 107.3(1) 0(2) S(l) 0(1) 110.9(1)
0(2) S(l) 0(7) 110.4(1) 0(1) S(l) 0(7) 104.5(1)
S(l) 0(1) 0(2) 116.8(2) S(l) 0(1) 0(6) 118.2(2)
C(2) 0(1) 0(6) 124.9(2) 0(1) 0(2) 0(3) 114.0(2)
C(1) 0(2) B(l) 122.8(2) 0(3) 0(2) B(l) 123.1(2)
0(2) 0(3) 0(4) 122.4(3) 0(3) 0(4) 0(5) 120.8(3)
0(4) 0(5) 0(6) 119.5(3) 0(1) 0(6) 0(5) 118.3(3)
S(l) 0(7) 0(8) 117.0(2) S(l) 0(7) 0(12) 117.6(2)
0(8) 0(8) 0(12) 125.5(2) 0(7) 0(8) 0(9) 114.0(2)
0(7) 0(9) B(l) 123.3(2) 0(9) 0(8) B(l) 122.7(2)
0(8) 0(11) 0(10) 122.4(3) 0(9) 0(10) 0(11) 121.1(3)
0(10) 0(1) 0(12) 119.8(3) 0(7) 0(12) 0(11) 117.4(3)
N(l) B(l) 0(2) 105.9(2) N(l) B(l) 0(8) 106.9(2)
N(l) B(l) 0(13) 107.1(2) 0(2) B(l) 0(8) 110.6(2)
0(2) B(l) 0(13) 112.7(2) 0(8) B(l) 0(13) 113.1(2)
B(l) N(l) H(12) 109.4 B(l) N(l) H(13) 109.3
B(l) N(l) H(14) 109.3 H(12) N(l) H(13) 109.6
H(12) N(l) H(14) 109.6 H(13) N(l) H(14) 109.5
0(2) 0(3) H(3) 118.8 0(4) 0(3) H(3) 118.8
0(3) 0(4) H(4) 119.6 0(5) 0(4) H(4) 119.6
0(4) 0(5) H(2) 120.3 0(6) 0(5) H(2) 120.2
0(1) 0(6) H(l) 120.9 0(5) 0(6) H(l) 120.8
0(8) 0(9) H(7) 118.8 0(10) 0(9) H(7) 118.8
0(9) 0(10) H(6) 119.5 0(11) 0(10) H(6) 119.4
0(10) 0(11) H(8) 120.2 0(12) 0(11) H(8) 120.0
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C(7) C(12) H(5) 121.2 C(ll) C(I2) H(5) 121.3
BCD C(13) H(9) 109.2 B(l) C(13) H(10) 109.3
k- B(l) C(13) H(ll) 109.3 H(9) C(13) H(10) 109.6
H(9) C(I3) H(ll) 109.7 H(10) C(13) H(ll) 109.8
Crystallographic Data for Compound 128
C ilCIO
02oi
C12C9
C8 C2
C3NI
B1
C6
03
C4C13 C5
C 13H 1 4BNO 3 S, M = 275.13, monoclinic, space group C2/c (#15), a = 23.615(4), 
b = 8.665(5), c = 13.643(5) Â, P = 108.09(2) °, V = 2653(1) Z = 8 , D c = 
1.377 g cm*3, T = 293 K. 2509 unique reflections were collected on a Rigaku AFC7S 
diffractometer employing Mo-Ka radiation (1 = 0.71069 Â) of which 1941 [/>  3a(/)] 
were used for refinement. Convergence at R{F) -  7.5%, R^{F) = 8.4% for 177 variables.
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Table A1.5: Bond Lengths (A) for 128
atom atom distance atom atom distance
S(l)
S(l)
0(3)
C(l)
C(2)
C(4)
C(6)
C(7)
C(8)
C(10)
C(13)
0 (1)
C(l)
N (l)
C(2)
C(3)
0(5)
B (l)
0 (12)
0(9)
0 (11)
B(l)
1.463(4)
1.770(5)
1.436(6)
1.409(7)
1.387(8)
1.368(8)
1.648(8)
1.398(7)
1.393(9)
1.385(8)
1.585(8)
S(l)
S(l)
N (l)
0 (1)
0(3)
0(5)
0(7)
0(7)
0(9)
0 (11)
0(2
0 (12)
B(l)
0(6)
0(4)
0(6)
0 (8)
B (l)
0 (10)
0 (12)
1.448(4)
1.751(5)
1.630(7)
1.381(7)
1.368(9)
1.402(7)
1.396(7)
1.622(8)
1.363(9)
1.392(8)
0(3) H(14) 1.12(9) N(l) H(12) 0.95
N(l) H(13) 0.95 0(2) H(l) 0.95
0(3) H(2) 0.95 0(4) H(3) 0.95
0(5) H(4) 0.95 0(8) H(5) 0.95
0(9) H(6) 0.95 0(10) H(7) 0.95
0(11) H(8) 0.95 0(13) H(9) 0.95
0(13) H(10) 0.95 0(13) H(ll) 0.95
ble A1.6: Bond Angles (°) for 128
atom atom atom distance atom atom atom distance
0(1) S(l) 0(2) 115.0(2) 0(1) S(l) 0(1) 107.1(2)
0(1) S(l) 0(12) 107.8(2) 0(2) S(1) 0(1) 110.5(2)
0(2) S(l) 0(12) 110.8(3) 0(1) S(1) 0(12) 105.1(3)
0(3) N(l) B(l) 112.9(4) S(l) 0(1) 0(2) 116.1(4)
S(l) 0(1) 0(6) 117.5(4) 0(2) 0(1) 0(6) 126.1)
0(1) 0(2) 0(3) 115.5(5) 0(2) 0(3) 0(4) 120.6(6)
0(3) 0(4) 0(5) 121.6(6) 0(4) 0(5) 0(6) 121.9(6)
0(1) 0(6) 0(5) 114.2(5) 0(1) 0(6) B(l) 123.4(5)
0(5) 0(6) B(l) 122.3(5) 0(8) 0(7) 0(12) 114.6(5)
0(8) 0(7) B(l) 121.8(5) 0(12) 0(7) B(l) 123.6(5)
0(7) 0(8) 0(9) 122.0(6) 0(8) 0(9) 0(10) 120.8(6)
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0(9) 0(10) 0(11) 120.2(6) 0(10) 0(11) 0(12) 117.6(6)
S(l) 0(12) 0(7) 117.5(4) S(l) 0(12) 0(11) 117.5(4)
0(7) 0(12) 0(11) 124.8(5) N(l) B(l) 0(6) 105.3(4)
N(l) B(l) 0(7) 103.1(4) N(l) B(l) 0(13) 107.8(4)
0(6) B(l) 0(7) 110.9(4) 0(6) B(l) 0(13) 114.2(5)
0(7) B(l) 0(13) 114.3(5)
N(l) 0(3) H(14) 125(4) 0(3) N(l) H(12) 108.5
0(3) N(l) H(13) 108.8 B(l) N(l) H(12) 108.5
B(l) N(l) H(13) 108.6 H(12) N(l) H(13) 109.5
0(1) 0(2) H(l) 122.2 0(3) 0(2) H(l) 122.3
0(2) 0(3) H(2) 120.0 0(4) 0(3) H(2) 119.4
0(3) 0(4) H(3) 119.6 0(5) 0(4) H(3) 118.9
0(4) 0(5) H(4) 119.3 0(6) 0(5) H(4) 118.9
0(7) 0(8) H(5) 119.1 0(9) 0(8) H(5) 118.9
0(8) 0(9) H(6) 120.1 0(10) 0(9) H(6) 119.1 .
0(9) 0(10) H(7) 120.0 0(11) 0(10) H(7) 119.8
0(10) 0(11) H(8) 121.2 0(12) 0(11) H(8) 121.2
B(l) 0(13) H(9) 109.5 B(l) 0(13) H(10) 109.1
B(l) 0(13) H(ll) 109.2 H(9) 0(13) H(10) 109.8
H(9) 0(13) H(ll) 109.7 H(10) 0(13) H(ll) 109.4
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Crystallographic Data for Compound 131
D
C 1 8H 1 5BO 3 S, M = 322.18, monoclinic, space group C2/c (#15), a = 24.055(8), 
6  = 7.957(4), c = 18.218(9) À, P = 104.33(3) = 3378(2) Â^, Z = 8 , D c =
1.267 g cm-3, T = 293 K. 3203 unique reflections were collected on a Rigaku AFC7S 
diffractometer employing Mo-Ka radiation (k = 0.71069 Â) of which 1442 [/>  3a(/)] 
were used for refinement. Convergence at R(F) = 4.5%, RwiF) = 3.5% for 208 vaiiables.
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Table A1.7: Bond Lengths (A) for 131
atom atom distance atom atom distance
S(l)
S(l)
0(3)
C(l)
0(3)
0(5)
0(7)
0(9)
0 (11)
0(13)
0(13)
0(15)
0(17)
0 (1)
0 (1)
B(l)
0 (6)
0(4)
0(6)
0 (12)
0 (10)
0 (12)
0(14)
B(l)
0(16)
0(18)
1.434(3)
1.776(4)
1,363(5)
1.376(6)
1.355(9)
1.389(7)
1.387(5)
1.378(6)
1.400(5)
1.395(5)
1.543(6)
1.367(7)
1.372(6)
S(l)
S(l)
0 (1)
0 (2)
0(4)
0(7)
0 (8)
0 (10)
0 (12)
0(13)
0(14)
0(16)
0(2)
0(7)
0 (2)
0(3)
0(5)
0(8)
0(9)
0 (11)
B(l)
0(18)
0(15)
0(17)
1.444(3)
1.765(4)
1.348(6)
1.374(7)
1.354(9)
1.388(5)
1.367(5)
1.377(5)
1.579(6)
1.387(6)
1.375(6)
1.379(7)
0(3) H(15) 0.96 0(2) H(l) 0.95
0(3) H(2) 0.94 0(4) H(3) 0.95
0(5) H(4) 0.96 0(6) H(5) 0.96
0(8) H(6) 0.95 0(9) H(7) 0.95
0(10) H(8) 0.95 0(11) H(9) 0.95
0(14) H(10) 0.94 0(15) H(ll) 0.95
0(16) H(12) 0.95 0(17) H(13) 0.95
0(18) H(14) 0.95
ble A1.8: Bond Angles C) for 131
atom atom atom distance atom atom atom distance
0(1) S(l) 0(2) 120.0(2) 0(1) S(l) 0(1) 106.9(2)
0(1) S(1) 0(7) 109.1(2) 0(2) S(l) 0(1) 107.0(2)
0(2) S(l) 0(7) 106.7(2) 0(1) S(l) 0(7) 106.4(2)
S(l) 0(1) 0(2) 119.7(4) S(l) 0(1) 0(6) 118.2(4)
0(2) 0(1) 0(6) 122.1(4) 0(1) 0(2) 0(3) 119.9(6)
0(2) 0(3) 0(4) 119.1(7) 0(3) 0(4) 0(5) 121.3(7)
0(4) 0(5) 0(6) 120.5(7) 0(1) 0(6) 0(5) 117.1(5)
S(l) 0(7) 0(8) 118.2(3) S(l) 0(7) C(12) 117.9(3)
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C(8) 0(7) 0(12) 123.9(4) 0(7) 0(8) 0(9) 119.3(4)
0(8) 0(9) 0(10) 119.1(4) 0(9) 0(10) 0(11) 120.8(4)k 0(10) 0(11) 0(12) 122.3(4) 0(7) 0(12) 0(11) 114.6(4)
0(7) 0(12) B(l) 126.1(4) 0(11) 0(12) B(l) 119.2(4)
0(14) 0(13) 0(18) 116.2(4) 0(14) 0(13) B(l) 121.2(4)
0(18) 0(13) B(l) 122.5(4) 0(13) 0(14) 0(15) 121.9(5) ^A. 0(14) 0(15) 0(16) 120.4(5) 0(15) 0(16) 0(17) 119.1(5)
0(16) 0(17) 0(18) 120.2(5) 0(13) 0(18) 0(17) 122.1(5)
0(3) B(l) 0(12) 120.5(4) 0(3) B(l) 0(13) 116.7(4)
0(12) B(l) 0(13) 121.6(4)
B(l) 0(3) H(15) 117.5 0(1) 0(2) H(l) 120.2
0(3) 0(2) H(l) 119.9 0(2) 0(3) H(2) 121.8
0(4) 0(3) H(2) 119.1 0(3) 0(4) H(3) 121.4
0(5) 0(4) H(3) 117.3 0(4) 0(5) H(4) 121.0
0(6) 0(5) H(4) 118.4 0(1) 0(6) H(5) 121.0
0(5) 0(6) H(5) 121.9 0(7) 0(8) H(6) 120.6
0(9) 0(8) H(6) 120.2 0(8) 0(9) H(7) 120.4
0(10) 0(9) H(7) 120.5 0(9) 0(10) H(8) 119.5
0(11) 0(10) H(8) 119.8 0(10) 0(11) H(9) 118.8
0(12) 0(11) H(9) 118.9 0(13) 0(14) H(10) 119.5
0(15) 0(14) H(10) 118.6 0(14) 0(15) H(ll) 120.0
0(16) 0(15) H(ll) 119.6 0(15) 0(16) H(12) 120.4
0(17) 0(16) H(12) 120.5 0(16) 0(17) H(13) 119.9
0(18) 0(17) H(13) 119.8 0(13) 0(18) H(14) 119.1
0(17) 0(18) H(14) 118.7
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Crystallographic Data for Compound 140
C4 C3
C5 C2
C6 Cl
C7 C8
01
C12 C9
CIO
c i l
02
C 1 2H 1 1BO 2 S, M -  230.09, monoclinic, space group P2i/c (#14), a = 5.129(6), 
b = 19.777(7), c = 11.337(6) Â, |3 = 98.74(7) = 1136(1) Z = 4, D c =
1.345 g cm-3, T = 293 K. 1738 unique reflections were collected on a Rigaku AFC7S 
diffractometer employing Mo-Ka radiation (K = 0.71069 Â) of which 1234 [/ > 3a(/)] 
were used for refinement. Convergence at R{F) -  11.9%, Ry^{F) ~ 15.2% for 144 
variables.
Table A1.9: Bond Lengths (Â) for 140
atom atom distance atom atom distanc
S(l) C(l) 1.77(1) S(l) C(7) 1.80(1)
0(1) B(l) 1.35(2) 0(2) B(l) 1.35(2)
C(l) C(2) 1.36(2) C(l) C(6) 1.38(2)
C(2) C(3) 1.35(2) C(3) C(4) 1.36(2)
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C(4) 0(5) 1.36(2) 0(5) 0(6) 1.37(2)
C(7) 0(8) 1.39(2) 0(7) 0(12) 1.38(2)
C(8) 0(9) 1.36(2) 0(9) 0(10) 1.36(2)
C(10) 0(11) 1.38(2) 0(11) 0(12) 1.38(2)
C(12) B(l) 1.60(2)
C(2) H(l) 0.95 0(3) H(2) 0.95
C(4) H(3) 0.95 0(5) H(4) 0.95
C(6) H(5) 0.96 0(8) H(6) 0.95
C(9) H(7) 0.94 0(10) H(8) 0.95
C(ll) H(9) 0.95
ible Al.lO: Bond Angles (°) for 140
atom atom atom distance atom atom atom distance
C(l) S(l) 0(7) 99.7(6) S(l) 0(1) 0(2) 120(1)
S(l) 0(1) C(6) 121(1) 0(2) 0(1) 0(6) 117(1)
C(1) 0(2) C(3) 121(1) 0(2) 0(3) C(4) 120(1)
C(3) 0(4) 0(5) 119(1) 0(4) 0(5) C(6) 119(1)
C(l) 0(6) 0(5) 120(1) S(l) 0(7) C(8) 116(1)
S(l) 0(7) 0(12) 122(1) 0(8) 0(7) C(12) 121(1)
C(7) 0(8) C(9) 120(1) 0(8) 0(9) C(10) 119(1)
C(9) 0(10) C(ll) 119(1) 0(10) 0(11) C(12) 122(1)
C(7) 0(12) C(ll) 116(1) 0(7) 0(12) B(l) 126(1)
C(ll) 0(12) B(l) 117(1) 0(1) B(l) 0(2) 118(1)
0(1) B(l) 0(12) 124(1) 0(2) B(l) C(12) 116(1)
C(l) 0(2) H(l) 119.0 0(3) 0(2) H(l) 119.4
0(2) 0(3) H(2) 119.8 0(4) 0(3) H(2) 120.1
0(3) 0(4) H(3) 120.1 0(5) 0(4) H(3) 120.0
0(4) 0(5) H(4) 120.4 0(6) 0(5) H(4) 119.7
0(1) 0(6) H(5) 119.5 0(5) 0(6) H(5) 119.9
0(7) 0(8) H(6) 119.7 0(9) 0(8) H(6) 120.0
0(8) 0(9) H(7) 120.4 0(10) 0(9) H(7) 119.8
0(9) 0(10) H(8) 120.4 0(11) 0(10) H(8) 119.9
0(10) 0(11) H(9) 119.2 0(12) 0(11) H(9) 118.2
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Crystallographic Data for Compound 141
C4 C5
01C6
C3 Cl
03 B1 02
C2
C7
C9
C12
CIO
Cil
C 1 2 H 1 1 B O 3 , M = 214.03, monoclinic, space group P2\!c (#14), a = 5.33(1), 
è = 7.639(7), c = 26.44(1) Â, p = 90.4(1) °V= 1077(2) Â3,Z = 4, 7?c= 1.319 g cm-3, 
T = 293 K. 1652 unique reflections were collected on a Rigaku AFC7S diffractometer 
employing Mo-Ka radiation (X = 0.71069 Â) of which 1127 [/ > 3a(/)] were used for 
refinement. Convergence at R{F) = 3.2%, R^{F) = 2.5% for 154 variables.
Table A l . l l :  Bond Lengths (A) for 141
atom atom distance atom atom distance
0(1) B(l) 1.367(4) 0(2) B(l) 1.355(4)
0(3) C(l) 1.385(2) 0(3) 0(7) 1.402(3)
C(l) C(2) 1.386(3) 0(1) 0(6) 1.379(3)
C(2) C(3) 1.382(3) 0(3) 0(4) 1.376(4)
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C(4)
C(7)
C(8)
C(9)
C(ll)
C(5)
C(8)
C(9)
C(10)
C(12)
1.381(4)
1.384(3)
1.396(3)
1.382(3)
1.381(3)
0(5)
0(7)
0 (8)
0 (10)
0(6)
0 (12)
B(l)
0 (11)
1.370(3)
1.379(3)
1.567(3)
1.382(3)
0(1) H(10) 0.79(2) 0(2) H(ll) 0.85(2)
0(2) H(l) 0.95 0(3) H(2) 0.95
0(4) H(3) 0.95 0(5) H(4) 0.95
0(6) H(5) 0.95 0(9) H(6) 0.95
0(10) H(7) 0.95 0(11) H(8) 0.95
0(12) H(9) 0.95
Table A1.12: Bond Angles C)  for 141
atom atom atom distance atom atom atom distance
0(1) 0(3) 0(7) 118.6(2) 0(3) 0(1) 0(2) 123.6(2)
0(3) 0(1) 0(6) 115.3(2) 0(2) 0(1) 0(6) 121.1(2)
0(1) 0(2) C(3) 118.3(2) 0(2) 0(3) 0(4) 121.1(2)
0(3) 0(4) C(5) 119.4(2) 0(4) 0(5) 0(6) 120.6(2)
0(1) 0(6) C(5) 119.5(2) 0(3) 0(7) 0(8) 118.8(2)
0(3) 0(7) C(12) 117.8(2) 0(8) 0(7) 0(12) 123.3(2)
0(7) 0(8) C(9) 116.1(2) 0(7) 0(8) B(l) 123.2(2)
0(9) 0(8) B(l) 120.7(2) 0(8) 0(9) 0(10) 122.1(2)
0(9) 0(10) C(ll) 119.5(2) 0(10) 0(11) 0(12) 120.1(2)
0(7) 0(12) C(ll) 118.8(2) 0(1) B(l) 0(2) 118.3(2)
0(1) B(l) C(8) 123.3(2) 0(2) B(l) 0(8) 118.4(2)
B(l) 0(1) H(10) 118(2) B(l) 0(2) H(ll) 115(1)
0(1) 0(2) H(l) 120.9 0(3) 0(2) H(l) 120.8
0(2) 0(3) H(2) 119.5 0(4) 0(3) H(2) 119.4
0(3) 0(4) H(3) 120.3 0(5) 0(4) H(3) 120.3
0(4) 0(5) H(4) 119.7 0(6) 0(5) H(4) 119.8
0(1) 0(6) H(5) 120.2 0(5) 0(6) H(5) 120.2
0(8) 0(9) H(6) 119.0 0(10) 0(9) H(6) 118.9
0(9) 0(10) H(7) 120.3 0(11) 0(10) H(7) 120.2
0(10) 0(11) H(8) 119.9 0(12) 0(11) H(8) 120.0
0(7) 0(12) H(9) 120.6 0(11) 0(12) H(9) 120.6
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Compound Assay Result Compound Assay Result
62
OH 
S>
63 Ph
Insoluble
IC5o = 40llMt
140
141
HO OH
. 0 .I I  I I
OH HO OH
Inactive*
Inactive*
:
65 Ph Ph Insoluble
OH
O-
66 Ph Ph Insoluble
OH
122
128
T y
HgC NHa
iT yXH3G NHgOH
131Ph, Ph
OH
Inactive* 152
NHaOH
Inactive*117 156
Inactive*109 157
OH
Inactive*
108
B -O H
Key to symbols (*, t  and $) overleaf
180
Inactive*
Inactive*
Inactive*
Inactive*
Inactive*
Inactive*
Key to symbols (*, t  and $)
* Insoluble compounds are those which precipitate from the buffer solution at
concentrations below which inhibition is not observed. Meaningful analyses could, 
therefore, not be achieved.
t  IC50 values were determined for those compounds that were found to inhibit HIV- 1
PR (see Chapter 3). Different quantities of inhibitor (corresponding to 0 - 100 jxM) 
were added to a buffered solution of a peptide substrate which absorbed strongly at 
300 nm. After thermal equilibration, HIV-1 PR was added and the initial rates 
calculated. This was achieved by monitoring the rate of the decrease in absorbance 
at 300 nm. Performing this procedure in duplicate over a range of concentrations 
allowed graphs of initial rates v concentrations of inhibitor to be plotted. From these 
IC5 0  values were derived.
$ Those compounds indicated as being inactive against the enzyme were tested at
concentrations of up to 200 |xM. However, no decrease in the initial rate of 
cleavage of the substrate was observed.
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